OPTIONS X
for the Control of INFLUENZA

28 AUGUST–1 SEPTEMBER 2019 SUNTEC SINGAPORE

PROGRAMME

BREAKTHROUGH INFLUENZA VACCINES
TAKE LARGE DOSES OF INNOVATION

Protecting people from the ever-changing threat of influenza takes unwavering commitment. That's why we're dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We're with you.

ON THE **FRONT LINE**™

Seqirus
A CSL COMPANY

CONTENT

OPTIONS X SUPPORTERS	----------	4
OPTIONS X EXHIBITORS & COMMITTEES	----------	5
AWARD INFORMATION	----------	6
WELCOME MESSAGES	----------	7
SCHEDULE AT A GLANCE	----------	10
CONFERENCE INFORMATION	----------	11
SOCIAL PROGRAMME	----------	14
ABOUT SINGAPORE	----------	15
SUNTEC FLOORPLAN	----------	16
SCIENTIFIC COMMUNICATIONS	----------	17
PROGRAMME	----------	19
SPEAKERS	----------	31
SPONSORED SYMPOSIA	----------	39
ORAL PRESENTATION LISTINGS	----------	42
POSTER PRESENTATION LISTINGS	----------	51
POSTER DISPLAY LISTINGS	----------	54
SPONSOR AND EXHIBITOR LISTINGS	----------	80
EXHIBITION FLOORPLAN	----------	83
NOTE	----------	84

ABSTRACTS

OPTIONS X SUPPORTERS

We would like to thank the following organisations for their support of OPTIONS X:

TRAVEL FELLOWSHIP AWARD

Bill & Melinda Gates foundation

PLATINUM LEVEL

Sanofi Pasteur

Roche

Seqirus
A CSL COMPANY

GOLD LEVEL

gsk

BRONZE LEVEL

The influenzer Initiative | Sabin

Viroclinics biosciences

Janssen Infectious Diseases & Vaccines

OPTIONS X PARTNER

National Centre for Infectious Diseases

Supported by	Held in	Managed by	Official Service Provider	Supporting Airline
Singapore Exhibition & Convention Bureau	Singapore Passion Made Possible	ace:daytons direct	MyRepublic	Singapore Airlines

OPTIONS X EXHIBITORS

OPTIONS X COMMITTEES

International Organising Committee

Vernon Lee – Chair
Ministry of Health
Singapore

Lance Jennings
ISIRV Chair
Canterbury Laboratories
New Zealand

Ximena Aguilera
University of Desarollo
Chile

Rebecca Cox
University of Bergen
Norway

Jean-Michel Heraud
Institut Pasteur
Madagascar

Daniel B. Jernigan
Centers for Disease Control and Prevention,USA

Hitoshi Oshitani
Graduate School of Medicine
Tohoku University, Japan

Nahoko Shindo
World Health Organisation
Switzerland

Kanta Subbarao
WHO Influenza Collaborating Centre
Australia

Hassan Zaraket
American University of Beirut
Lebanon

Scientific Committee

Paul Anantharajah Tambyah - Chair
National University Hospital
Singapore

Mark Chen
Saw Swee Hock School of Public Health
Singapore

Vincent Chow
National University of Singapore
Singapore

Cheryl Cohen
National Institute for Communicable Diseases
South Africa

Alex Cook
Saw Swee Hock School of Public Health
Singapore

Ben Cowling
The University of Hong Kong
Hong Kong

Jeffery Cutter
Ministry of Health
Singapore

Yi Guan
University of Hong Kong
Hong Kong

Frederick Hayden
University of Virginia
USA

Aeron Hurt
University of Melbourne
Australia

Nelson Lee
University of Alberta
Canada

Raymond Lin
National Centre for Infectious Diseases
Singapore

Sebastian Maurer-Stroh
Agency for Science, Technology and Research
Singapore

Peter Openshaw
Imperial College London
UK

Yuelong Shu
Chinese Center for Disease Control and Prevention
China

Gavin Smith
Duke-NUS School of Medicine
Singapore

Leo Yee Sin
National Centre for Infectious Diseases
Singapore

Mark Tompkins
University of Georgia
USA

Timothy Uyeki
Centers for Disease Control and Prevention
USA

AWARD INFORMATION

TRAVEL FELLOWSHIP AWARD

BILL & MELINDA GATES *foundation*

The Options X for the Control of Influenza conference is pleased to announce that the Bill & Melinda Gates Foundation has supported fellows from economically disadvantaged areas to attend the Options X Conference.

Sukanta Chowdhury Bangladesh	**Saurabh Bhargava** India	**Bimalesh Kumar Jha** Nepal
Md. Habibulla Fahad Bangladesh	**Anitha Jagadesh** India	**Subeksha Shrestha** Nepal
Rubaiyea Farrukee Bangladesh	**Rakesh Kumar** India	**Bishnu Prasad Upadhyay** Nepal
S M Murshid Hasan Bangladesh	**Nilanshu Manocha** India	**Chinonyerem Nkemakolam Chinyere** Nigeria
Md. Zakiul Hassan Bangladesh	**Shruti Mishra** India	**Dennis Kabantiyok** Nigeria
Ariful Islam Bangladesh	**Sanjesh Saini** India	**George Okoli** Nigeria
Mahbubur Rahman Bangladesh	**Agustiningsih Agustiningsih** Indonesia	**Khristine Joy Constantino Antigua** Philippines
Binay Thapa Bhutan	**Arindita Niatazya Novianti** Indonesia	**Rukshan Ahamed Mohamed Rafeek** Sri Lanka
Seng Heng Cambodia	**Vivi Setiawaty** Indonesia	**Ya Jankey Jagne** The Gambia
Hazem Hamza Ewess Egypt	**David Collins Owuor** Kenya	**Hind Bouguerra** Tunisia
Adamu Tayachew Mekonnen Ethiopia	**Galina Landgraf** Kyrgyzstan	**Iaryna Iosyk** Ukraine
Augustina Kwakyewaa Arjarquah Ghana	**Verohasina Joelinotahina Rabarison** Madagascar	**Liudmyla Leibenko** Ukraine
Mani Bhargava India	**Norosoa Harline Razanajatovo** Madagascar	**Cong Khanh Nguyen** Vietnam

Welcome Message from the Chair, Organising Committee, Options X

Welcome to Singapore and to the 10th Edition of Options for the Control of Influenza (Options X) 2019.

Options is the premier global meeting on influenza that brings together researchers, clinicians, policy makers, and public health practitioners to address the impact of influenza. As we all know, seasonal influenza results in substantial burden of disease and mortality, while the threat posed by pandemic influenza looms large.

Despite the awareness of this threat and the years of research on influenza-related topics, substantial gaps still remain in our understanding of influenza disease burden and epidemiology, its host-pathogen interactions, how to rapidly diagnose it in the field, optimal clinical management, the development of a universal vaccine, and pandemic preparedness and response, among other issues. Many of these issues have been highlighted in various global influenza research agenda.

This five-day meeting, organised by the International Society of Influenza and other Respiratory Viruses, aim to address these research and knowledge gaps through the sharing of recent advances in virology and pathogenesis, clinical sciences, diagnostics, vaccines, public health, and understanding of co-infections with other respiratory pathogens. For the first time, we are also introducing a policy makers' track to provide easy-to-understand summaries of key issues for decision making and to accelerate translation of research into policy; and a Chinese research session devoted to the latest research from China.

Options X provides the unique opportunity for like-minded individuals to network and to explore future collaborations. I wish to thank the Organising Committee, the Scientific Committee, and the sponsors for giving their time and resources to make Options X a success. I hope that through our collective efforts we can effectively combat influenza, and I wish you a successful conference.

I also hope that all of you will have sufficient time to explore this vibrant city, which has much to offer first time and repeat visitors. We hope that you will enjoy the uniquely Singaporean hospitality and experience!

Vernon Lee
Chair of the Organising Committee
Options X

Welcome Message from the Chair, ISIRV

It is an honour to welcome you to the 10th Edition of Options for the Control of Influenza (Options X) 2019, which builds on the success of previous meetings in the Options series. It is the International Society for Influenza and other Respiratory Virus Diseases' (ISIRV) premier event and remains the largest international conference exclusively dedicated to influenza prevention, control and treatment, including seasonal influenza and pandemic preparedness. The conference brings together academic scientists, researchers, healthcare professionals and public health specialists to share their experiences and research results on all aspects of influenza.

It also provides an interdisciplinary platform with global reach, for the discussion of the most recent innovations, advances and concerns. ISIRV is very focused on fostering the exchange of scientific knowledge and practice and has introduced a Chinese focused stream. It is hoped that science policy focus of this stream, dedicated to public health officials will address the pressing issues in the wider Asian region.

At this Conference, ISIRV recognises its membership in several ways; firstly, by bestowing prestigious awards, "the ISIRV Lifetime Achievement Award" recognising the long and productive career of a member in the field of respiratory infectious diseases and their service to isirv, and providing the "Geoffrey Schild Travel Award" to an imminent Plenary Speaker. And secondly, by supporting promising young scientists and scientists from poor resourced countries, by providing 38 travel and accommodation grants.

On behalf of ISIRV, I would like to thank everyone who has contributed to the preparation of this conference, with special thanks to the Conference Chairs, A/Prof Vernon Lee and his Organising Committee; and Prof Paul Tambyah and his Scientific Committee. The Committees have developed an exciting scientific program which will cover all aspects of influenza, the disease, its treatment and control. Finally, I wish to acknowledge our sponsoring partners for their support of this internationally important conference.

Lance C Jennings
Chair, ISIRV

Welcome Message from the Scientific Committee Chair, Options X

Dear all,

On behalf of the scientific committee, it gives me great pleasure to welcome you to OPTIONS X in Singapore. I would first like to begin by thanking the track chairs and all the reviewers, moderators, presenters and submitters who have contributed to making this yet again, the leading scientific meeting on influenza globally. The track chairs in particular have done a stellar job in planning the program, reviewing abstracts, judging for the awards and overall making the scientific content of this meeting second to none.

As you all know, influenza remains at the forefront of global public health with fears of another deadly pandemic of a novel strain of influenza keeping policy makers, public health professionals, scientists and clinicians on our toes constantly. Fortunately, thanks to the work of many of the people at this conference, influenza is one of the few respiratory viral infections with licensed therapeutics available as well as a wide range of vaccine choices. At the same time, while there are concerns about the emergence of resistance to antivirals there is renewed hope that a universal influenza vaccine may become a reality sooner rather than later. Rapid advances are also being made in the fields of virology, pathogenesis and public health.

The International Society for Influenza and other Respiratory Viruses (ISIRV) is the leading scientific society in the field and Singapore is proud to be the first Southeast Asian host for the OPTIONS meeting. While East and Southeast Asia have been viewed as the epicenters for future influenza pandemics, the region is also the focus of a growing scientific community eager to contribute to global public health and the advancement of the science.

We do hope that you get some time either before or after the conference to enjoy the sights, sounds and perhaps most famously the tastes of Singapore, a truly unique experience.

Paul Ananth Tambyah
Chair of Scientific Committee
Options X

SCHEDULE AT A GLANCE

WEDNESDAY I 28 AUGUST 2019		
9:00am – 1:00pm	Special Session : Latest Research from China	Room 331
3:00pm – 3:45pm	Official Opening Ceremony	Hall 406CX
3:02pm – 3:07pm	Welcome Address from the Chair, Options X	
3:07pm – 3:13pm	Welcome Address from the Chair, ISIRV	
3:13pm – 3:25pm	Opening Address by Guest-of-Honour	
3:35pm – 3:45pm	Award Presentation	
3:45pm – 4:15pm	Tea Break	Exhibition Hall 405EX
4:15pm – 5:45pm	Opening Keynote	Hall 406CX
5:45pm – 8:00pm	Opening Reception/Dinner	Exhibition Hall 405EX
6:30pm – 8:00pm	Clinical Sciences and Co-Infection Poster Session + Poster Reception	Exhibition Hall 405EX
6:30pm – 8:00pm	Shortlisted Poster Presentations for Poster Awards	Exhibition Hall 405EX

THURSDAY I 29 AUGUST 2019		
8:30am – 10:00am	Plenary Talks: Vaccines	Hall 406CX
10:00am – 10:30am	Tea Break	Exhibition Hall 405EX
10:30am – 12:00pm	Session 1	Hall 406CX, 405B, 406D
12:00pm – 1:30pm	Sponsored Lunch Symposium (Sanofi Pasteur)	Hall 406CX
12:00pm – 2:30pm	Lunch	Exhibition Hall 405EX
1:30pm – 2:30pm	ISIRV Annual General Meeting	Hall 406D
2:30pm – 4:00pm	Session 2	Hall 406CX, 405B, 406D
4:00pm – 4:30pm	Tea Break	Exhibition Hall 405EX
4:30pm – 6:00pm	Session 3	Hall 406CX, 405B, 406D
6:00pm – 7:30pm	Sponsored Evening Symposium (Hoffmann-Roche)	Hall 406CX
6:00pm – 8:00pm	ISIRV Epidemiology Group Session	Hall 406D

FRIDAY I 30 AUGUST 2019		
8:30am – 10:00am	Plenary Talks: PISA & Virology	Hall 406CX
10:00am – 10:30am	Tea Break	Exhibition Hall 405EX
10:30am – 12:30pm	Session 4	Hall 406CX, 405B, 406D
12:30pm – 2:00pm	Sponsored Lunch Symposium (Seqirus)	Hall 406CX
12:30pm – 2:00pm	Lunch	Exhibition Hall 405EX
2:00pm – 4:00pm	Session 5	Hall 406CX, 405B, 406D
4:00pm – 4:30pm	Tea Break	Exhibition Hall 405EX
4:30pm – 6:00pm	Session 6	Hall 406CX, 405B, 406D
6:00pm – 7:30pm	Virology and Pathogenesis Poster Session + Poster Reception	Exhibition Hall 405EX
6:10pm – 7:30pm	Shortlisted Poster Presentations for Poster Awards	Exhibition Hall 405EX

SATURDAY I 31 AUGUST 2019		
8:30am – 10:00am	Plenary Talks: WHO Vision and Approaches	Hall 406CX
10:00am – 10:30am	Tea Break	Exhibition Hall 405EX
10:30am – 12:30pm	Session 7	Hall 406CX, 405B, 406D
12:30pm – 2:00pm	Sponsored Lunch Symposium (GSK)	Hall 406CX
12:30pm – 2:00pm	Lunch	Exhibition Hall 405EX
2:00pm – 3:30pm	Session 8	Hall 406CX, 405B, 406D
3:30pm – 4:00pm	Tea Break	Exhibition Hall 405EX
4:00pm – 5:30pm	Session 9	Hall 406CX, 405B, 406D
5:30pm – 7:00pm	Public Health Poster Session + Poster Reception	Exhibition Hall 405EX
5:30pm – 7:00pm	Shortlisted Poster Presentations for Poster Awards	Exhibition Hall 405EX
7:30pm – 10:30pm	Gala Dinner at the Flower Field Hall, Gardens by the Bay (Ticketed Event)	Off-site Event

SUNDAY I 1 SEPTEMBER 2019		
8:30am – 10:30am	Session 10	Hall 406CX, 405B, 406D
10:30am – 11:00am	Tea Break	Hall 405EX
11:00am – 1:00pm	Session 11	Hall 406CX, 405B, 406D
1:00pm – 1:30pm	Lunch	Hall 405EX
1:30pm – 3:00pm	Closing Plenary Talks	Hall 406CX
3:00pm – 3:30pm	Closing Ceremony / Presentation of Best Oral & Poster Awards	Hall 406CX

Note: All Halls are located on Level 4 and Rooms are on Level 3, Suntec Singapore

CONFERENCE INFORMATION

CONFERENCE VENUE

Suntec Singapore Convention & Exhibition Centre
(Suntec Singapore)
1 Raffles Boulevard, Suntec City, Singapore 039593
Tel: (65) 6 337 2888

ACCESSIBILITY

Suntec Singapore, the official Conference Venue for the Options X, is specially designed for the comfort of all guests. Each level is easily accessible with wheelchair-friendly elevators. The public areas have been built with wide corridors to ensure adequate space for wheelchairs and other mobility equipment.

CONFERENCE SECRETARIAT ROOM

(Level 3, Room 334)

Operating Hours:

Day	Date	Time
Tuesday	27 August 2019	3:00pm – 7:00pm
Wednesday	28 August 2019	8:00am – 8:00pm
Thursday - Friday	29 - 30 August 2019	7:00am – 8:00pm
Saturday	31 August 2019	7:00am – 6:00pm
Sunday	1 September 2019	7:00am – 3:00pm

REGISTRATION & BAG COLLECTION COUNTER

All delegates may collect their Conference satchels, programme handbook and name badge at the Registration Counter, Concourse 4, Level 3.

Operating Hours:

Day	Date	Time
Tuesday	27 August 2019	3:00pm – 6:00pm
Wednesday - Thursday	28 – 29 August 2019	7:00am – 8:00pm
Friday - Saturday	30 – 31 August 2019	7:00am – 5:00pm
Sunday	1 Sept 2019	7:00am – 11:00am

BADGES

Please note that delegates are required to wear their Conference name badges at all times at Suntec Singapore. Access to all venues will be monitored. Name badges are not transferable. The organiser reserves the right to request for proof of identity.
Should you lose your badge, please proceed to the Registration Counter at Concourse 4, Level 3 Suntec Singapore for a replacement badge. Each replacement badge will cost SGD 50.00 + GST.
A badge recycling box is available at the registration counter.

BADGE SCANNING PRIVACY POLICY

- You understand that by allowing your contact details to be captured during the Conference (by an exhibitor, sponsor or at a lunch or evening symposium, you are giving consent to share your personal data with the sponsors and exhibitors, allowing them to contact you about their products or services, and any information collected by them may be shared outside of Singapore for the same purposes.
- The Conference Organisers, Conference Management Company and their partners will not be held responsible should the information collected be misused for other purposes by the sponsors and exhibitors.

EXHIBITION

The Exhibition will be located in Hall 405EX, Level 4.

Operating Hours:

Day	Date	Time
Wednesday	28 August 2019	2:30pm – 7:30pm
Thursday – Friday	29 – 30 August 2019	8:00am – 7:30pm
Saturday	31 August 2019	8:00am – 7:00pm

CATERING

Tea / coffee and lunch for delegate, will be served in the Exhibition Hall 405EX and sponsored lunch and evening symposia (at Hall 406 CX) at the times specified in the scientific programme.

PLENARY TALKS

All Plenary talks will be live streamed into Conference Hall 405B on Level 4.

ROOM CAPACITIES

We make every effort to ensure the room size is appropriate for the session, based on the information provided to us by delegates when they registered for the Conference.
We regret we cannot guarantee availability in any particular session, although we do our best to avoid any disappointment. We apologise in advance if you are not able to attend a session because a room is full. With this in mind, we encourage you to arrive promptly at your chosen session to ensure you have a seat.

INDUSTRY-SPONSORED SYMPOSIA

Symposia organised by the industry will take place in Hall 406 CX, Level 4 as follows:

Descriptions	Day	Date	Time
Sanofi Pasteur Lunch Symposium	Thursday	29 August 2019	12:00pm – 1:30pm
Hoffmann La-Roche Evening Symposium	Thursday	29 August 2019	6:00pm – 7:30pm
Seqirus Lunch Symposium	Friday	30 August 2019	12:30pm – 2:00pm
GSK Lunch Symposium	Saturday	31 August 2019	12:30pm – 2:00pm

SPECIAL EVENTS

Opening Ceremony

Venue	: Hall 406 CX, Level 4, Suntec Singapore
Day/ Date/ Time	: Wednesday, 28 August 2019, 2:45pm – 3:45pm
Guest-of-Honour	:Dr. Lam Pin Min Senior Minister of State, Ministry of Health and Ministry of Transport, Singapore
Dress Code	: Business Suit

Opening Dinner

Venue	: Exhibition Hall 405 EX, Level 4
Day/ Date/ Time	: Wednesday, 28 August 2019, 5:45pm onwards

Poster Sessions + Poster Reception

Venue	: Exhibition Hall 405EX, Level 4
Day/ Date/ Time	: Wednesday, 28 August 2019, 6:30pm – 8:00pm
	: Friday, 30 August 2019, 6:00pm – 7:30pm
	: Saturday, 31 August 2019, 5:30pm – 7:00pm

Shortlisted Poster Presentations for Poster Awards

Venue	: Exhibition Hall 405EX, Level 4
Day/ Date/ Time	: Wednesday, 28 August 2019, 6:30pm – 8:00pm
	: Friday, 30 August 2019, 6:10pm – 7:30pm
	: Saturday, 31 August 2019, 5:30pm – 7:00pm

Download Options X Mobile App

Step 1:

SCAN QR CODE TO DOWNLOAD Options X MOBILE APPLICATION

OR
Visit the App Store or Google Play and search for "**Options X** " to download the mobile application

The same email address & password* **OptionsX2019 *are required to login the app*

Download on the App Store | Google play

Step 2:

Scan **QR code on your name badge** or Log in with **your registered email**.

In case you have forgotten your password, please reset your password by clicking* *"Forgot Password"*** *and check your registered email for new password.*

Step 3:

Select **"Options X"**

During installation, please allow MICEapps to access your location and turn* ***"ON" *your* ***Bluetooth*** *to receive nearby notification/ broadcast announcements.*

Visit us at the Registration Counter
Concourse 4, Level 3,
Suntec Singapore Convention and Exhibition Centre

WIFI

High-speed high-density dedicated Conference WiFi is available throughout the Convention Centre.

INTERNET SSID : Options X
SSID Password : OptionsX2019

MOBILE APPLICATION

Options X has designed a mobile application that includes all programme information and abstracts. Easily access sessions, speakers, exhibitors and organiser messages.

How to Download

iOS App Store

1. On your device, open the App Store app
2. Search for Options X 2019 App
3. Download and Open
4. To login, key in the following
   User ID : "**your email address**" as registered for the conference.
   Login password : **OptionsX2019**
5. Then "click" on the green arrow on right bottom corner of your mobile phone
6. Click on the "save" button.

Android Google Play

1. On your device, open the Google Play
2. Search for Options X 2019 App
3. Download and Open
4. To login, key in the following
   User ID : "**your email address**" as registered for the conference.
   Login password : **OptionsX2019**
5. Then "click" on the green arrow on right bottom corner of your mobile phone
6. Click on the "save" button.

MOBILE PHONES

Delegates are requested to turn their mobile phones or devices to silent when entering sessions.

SOCIAL MEDIA

Join the conversation using the hashtag **#OptionsX19.** You can simultaneously post to both social media and Mobile App. Link your account in the settings on the Mobile App and then click on the social media item icon.

CERTIFICATE OF ATTENDANCE

After event, you will receive an email with a link to an online evaluation form (please check your junk box if you do not receive it). Once you have submitted the form, you will receive your certificate of attendance.

CME ACCREDITATION

The Options X is recognised by the Singapore Medical Council as a Continuing Medical Education programme (CME). All fully and conditionally registered Doctors in Singapore can sign up for their CME Points.

To sign-up for CME points on each day of participation, you are required to manually sign in and out at the Bag Collection Counter as follows:

- Morning Session : By 12:30pm
- Afternoon Session : By 5:00pm

PHOTOGRAPHY

Please be aware that a photographer has been commissioned by the ISIRV to take photographs at this event.

These photographs may be included in the ISIRV's educational, promotional, corporate publications and on its website. They may also be circulated in the media and made available to interested parties.

If you do not wish to be included in any shots or footage, please advise the photographer.

ACCOMMODATION

If you have any queries with your accommodation (booked through Conference Secretariat & Housing Bureau), kindly proceed to the Exhibition Management Counter located outside the Exhibition Hall 405EX.

EMERGENCY NUMBERS

No	Organisation	Contact Number
1	Police	999 (toll-free)
2	Ambulance & Fire Brigade	995 (toll-free)
3	ER Ambulance	+65 6222 2995
4	Non-Emergency Ambulance	1777
5	Civic Ambulance	+65 6333 3000
6	STB Tourist Line (24-hr automated tourist information system)	1800 7360 2600 (toll-free in Singapore only)

GST/TAX REFUNDS ON DEPARTURE

As a tourist in Singapore, if you make any purchase of more than SGD 100 (including GST) at participating shops, you may claim a refund on the 7% Goods and Services Tax (GST) paid on your purchases.

You are entitled up to 3 same-day receipts/invoices from shops bearing the same GST registration number to meet this minimum purchase amount of SGD 100. To know whether a shop is participating in the Tourist Refund Scheme (TRS), look for a "Tax Free" shopping logo or sign displayed at the shop. You can also check with the retailer whether your purchases are eligible for GST refund.

INDEMNITY/INSURANCE

The Conference Organisers have taken reasonable care in making arrangements for the Conference, Exhibition, and Social Programme. Neither the Organising Body, the Local Core Organising Committee, the Conference Management Company, nor its sponsors or committee members assume any responsibility, contractual or delictual for any loss, injury or damage to persons or belongings, or additional expenses incurred as a result of delays or changes in air, rail, sea, road or other services, strikes, sicknesses, weather, or for any acts or omissions by any persons, or for any unforeseen changes to the programme including cancellation of the Conference due to force majeure or any related events or activities. All participants are accordingly advised to make their own arrangements for adequate insurance cover including personal health and travel insurance.

LANGUAGE

The official language of the Conference is English. There will be no simultaneous interpretation.

LOST AND FOUND

For information on any lost and found property, please check with the Options X Exhibition Management Counter, located outside the Exhibition Hall 405 EX, Level 4.

MESSAGE / HELP DESK

Messages may be left and picked up at the Exhibition Management Counter, located outside the Exhibition Hall 405 EX, Level 4.

PARKING

Parking is available at Suntec Singapore.

Car Park Rates

Monday to Friday	
7:00am – 5:00pm	SGD2.20 Per Hour
From 5:00pm (Per Entry)	SGD2.80 per entry till 7:00am the next day
Saturday/ Sunday/ Public Holiday	
7:00am – 5:00pm	SGD1.10 Per Hour
From 5:00pm (Per Entry)	SGD2.80 per entry till 7:00am the next day

SMOKING

The Suntec Singapore Convention & Exhibition Centre is a non-smoking venue. There are designated smoking areas outside the building.

PRAYER ROOM

A prayer room will be provided for delegates of any faith at the Exhibition Hall 405 EX.

NURSING ROOM

Suntec Singapore has a nursing room located on Level 3 beside the concierge, it has a sink with running water, chairs, baby changing area and power points in the room.

DISCLAIMER

The information and content provided in this letter is intended purely as a guideline and service for participants and visitors to Options X. The information may change at any time and without notice. The event and organisers accept no responsibility or liability whatsoever related to this publication.

SOCIAL PROGRAMME

Gala Dinner, Gardens by the Bay

Ticketed Off-site Event

Join us for an enchanting evening at the Gardens by the Bay.

Date	: Saturday, 31 August 2019
Venue	: Flower Field Hall, Gardens by the Bay
Address	: 18 Marina Gardens Drive, Singapore 018953
Dress Code	: Smart Casual

Hours	**Programme-at-a-Glance**
7:30pm – 8:00pm	Registration & Cocktail Reception
8:00pm - 10:30pm	Dinner (Jazz Band Performance)
9:00pm - 10:45pm	Private viewing of the Flower Dome

Gardens by the Bay, Flower Field Hall and Flower Dome

Enjoy the Singapore culinary experience with accompanying local Jazz Band at the Flower Field Hall. Nestled within the Flower Dome at the Gardens by the Bay, Flower Field Hall provides a picturesque setting that will engage and captivate you with a sensorial experience.

Offering a stunning backdrop of perpetual spring with full views of the splendid Flower Dome and a spectacular panorama of the Marina Bay skyline, this spacious indoor space will wow you with its unforgettable vistas and experiences.Specially programmed LED mood lights also add to the enchanting setting, changing into the different colours of the rainbow.

Places are limited and entry is by ticket only.

Type	**Fee**
Options X Attendee	SGD100
Guest	SGD200

Ticket includes dinner, drinks and entertainment.

TRANSPORTATION SHUTTLE TIMES:

Shuttle transport is available to all guests with an Options X Gala Dinner ticket from outside Suntec Singapore (Level 1, Drop-off Point).

Shuttle coach services will run at the following times:

1. **From Suntec Singapore (Level 1, Drop-off Point) to Gala Dinner @ Gardens by the Bay**
   Time: 6:30pm / 6:45pm / 7:00pm / 7:15pm / 7:30pm
2. **From Gala Dinner @ Gardens by the Bay to Pan Pacific Singapore Hotel**
   Time: 10:15pm / 10:30pm / 10:45pm

Note: Shuttle coaches will depart promptly at the stipulated times.

ABOUT SINGAPORE

From a humble fishing village, Singapore has grown to become a prosperous cosmopolitan nation with four major races, namely Chinese, Malay, Indian and Eurasian. With abundant greenery and world-class attractions like the beautiful Botanical Gardens, the futuristic Gardens by the Bay and the Jewel Changi Airport, Singapore truly is a Garden City. Yet it is our distinct historical neighbourhoods that make Singapore a unique destination, where you can enjoy discovering our cultural, religious and culinary diversity, all within a stone's throw of the city centre.

Conference Location: Suntec Singapore
Only 20 minutes from Changi International Airport, Suntec Singapore is conveniently located in the Central Business District and just minutes from the city's entertainment and cultural attractions and the Marina Bay area. Suntec Singapore offers direct access to more than 5,200 hotel rooms, 1,000 retail outlets, 300 restaurants, 6 museums and Esplanade - Theatres on the Bay and more.

Attractions near to Suntec Singapore

Arts & Culture

- Asian Civilisations Museum (1.7 km)
- MINT Museum of Toys (0.5 km)
- National Gallery Singapore (1.1 km)
- National Museum of Singapore (1.1 km)
- Parkview Museum (1 km)
- Peranakan Museum (1.5 km)
- Red Dot Design Museum (1.8 km)
- Singapore Art Museum (4.1km)
- Singapore City Gallery (2.5 km)
- Singapore Philatelic Museum (1.3 km)
- The Art Science Museum (1.5 km)

Shopping

- Bugis Junction (1.1km)
- Bugis Street Market (1.1 km)
- Marina Bay Link Mall (1.9km)
- Marina Square (0.5km)
- Millenia Walk (0.3 km)
- Raffles City (0.6km)
- Shoppes at Marina Bay Sands (1.3km)
- Suntec City Mall (0.2 km)

Recreation

- Esplanade – Theatres on the Bay (0.5km)
- Gardens by the Bay (1.3 km)
- Marina Bay Sands Hotel (1.6 km)
- Marina Bay Light Shows (1.6km)
- Scooters and Explore
- Ride the Singapore Flyer (1km)
- Stroll the City by Night
- The Merlion of Singapore (1km)
- Walk the Helix Bridge (1 km)
- Watch the Sunset Over The City

SUNTEC FLOORPLAN

LEVEL 3



334 Conference Secretariat Room (27 Aug – 1 Sept)

335 Speakers' Preview Room (27 Aug – 1 Sept)

Registration / Mobile Apps / Bag Collection Counter

LEVEL 4



Exhibition Management Counter
Information / Lost & Found Counter

Official Contractor / Freight Forwarder

406CX Plenary & Breakout Room 1
- Virology & Pathogenesis

405B Breakout Room 2
- Public Health : Day 1 – 5
- Policy (31 Aug 2019)

406D Breakout Room 3
- Clinical Sciences

405EX Exhibition Hall
Tea Break Area

405EX
- Poster Display Area
- Shortlisted Poster Presentations for Poster Awards (on Stage)

SCIENTIFIC COMMUNICATIONS

SPEAKERS' PREVIEW ROOM

Room 335, Level 3

Registration of Speakers and Chairpersons will be at the Speakers' Preview Room.

Speakers and Oral Presenters:

- Please proceed to the speakers' Preview Room to collect your Conference pass the day prior to your scheduled presentation.
- Please ensure that all amendments are completed in the speakers' preview room at least 4-hours before the start of your session.
- If you are giving a video only presentations (as specified on the programme), please bring a link with you to download the video.
- Changes to your slides can be done in the Speakers' Preview Room, at the following timings:

Operating Hours:

Day	Date	Time
Tuesday	27 August 2019	3:00pm – 7:00pm
Wednesday	28 August 2019	8:00am – 8:00pm
Thursday	29 August 2019	7:00am – 8:00pm
Friday - Saturday	30 – 31 August 2019	7:00am – 6:00pm
Sunday	1 Sept 2019	7:00am – 3:00pm

- Please note that all rooms are fitted with computer projection facilities only. No overhead projector facilities are available.
- Speakers should report to the room of their presentation at least 20 minutes before the start of the session to meet the session chairpersons, and familiarise themselves with the audio-visual equipment and venue layout.
- A preview monitor will be provided and placed on the floor in front of the stage. A wireless remote laser pointer and slide progressor that will enable you to either advance or return to your previous slide(s). The forward and return keys will be clearly indicated on the remote.
- No PPT foot notes will be visible during your presentation from the preview monitor.
- Speakers are required to strictly adhere to the allocated presentation time allowance.
- PLEASE NOTE: Session chairs will be instructed to stop your presentation when you exceed your allocated time.
- All speakers must declare their interests in the second slide of their presentation.
- If you have no declarations of interest, please state 'declaration of interests – none'.

The following audio-visual equipment will be provided for the presentations: microphones, laser pointers, LCD projectors, Laptop (Notebook loaded with Window10 / Microsoft Office 2016 or equivalent).
Software Application: Adobe Reader, QuickTime, Media Player, Flash Player, VLC Player

Session Chairpersons

- Proceed to the Speakers' Preview Room to collect the bios of the presenting speakers in your session at least 1 hour before the start of your session.
- Be at the venue of your session at least 20 minutes before the session starting time. The room manager will introduce the presenting speakers to you.

Oral and/or Poster Presentation Judges

- Proceed to the Speakers' Preview Room to collect the scoring sheets at least 30 mins before the start of your session.
- Report to the venue of your session at least 20 minutes before the start of the session to meet the session chairpersons.

Format & Audio-Visual Information

- All PowerPoint presentations or videos must be in the 16:9 ratio format.
- If you have embedded videos in your presentation please also bring them separately so that if there is a problem, the technician in the speakers' preview room can assist with this.
- If you have prepared your presentation on a Mac, please allow a bit of extra time to make sure it runs correctly on the conference systems. In some cases you may be required to use your own Mac and should carry your converter cables and adaptors with you for this purpose.

ORAL PRESENTATION

Each presenter is allowed a maximum of 10 minutes for oral presentation followed by 2 minutes for questions & answers. All presenters should familiarise themselves with the date, time and venue of their sessions, and arrive at the correct venue at least 20 minutes before the start of the session.

Please refer to Pages **42** to **50** for details.

POSTER DISPLAY

Posters will be put on display at the Exhibition Hall 405EX. Each poster board will be individually marked with the Abstract ID number. A full directory of the Abstract ID Numbers will also be displayed at the Poster Area. Mounting supplies will be provided at the poster area.

Wednesday, 28 August 2019 :
Poster Session 1 – Clinical Sciences & Co-Infection

Time	: 6:30pm – 8:00pm
Setup	: Day of Display, 28 August 2019 from 8:00am - 10:00am
Teardown	: Day after Display, 29 August 2019 from 4:00pm - 5:30pm

SCIENTIFIC COMMUNICATIONS

Friday, 30 August 2019 :
Poster Session 2 – Virology & Pathogenesis

Time	: 6:00pm – 7:30pm
Setup	: Eve of Poster Display, 29 August 2019, from 6:00pm – 7:30pm
Teardown	: Day of Poster Display from 7:45pm – 8:45pm or Next morning, 31 August 2019, from 7:15am – 8:15am

Saturday, 31 August 2019 :
Poster Session 3 – Public Health

Time	: 5:30pm – 7:00pm
Setup	: Day of Display from 8:30am – 10:00am
Teardown	: Evening of Display from 7:45pm – 8:45pm

Please refer to pages **54** to **79** for details

All posters not taken down at the stipulated dates and times will be taken down and disposed off. The Conference Management Company will not be responsible for any misplaced or lost posters

SHORTLISTED POSTER PRESENTATIONS FOR POSTER AWARDS

Poster Presentations will be held on the stage located at the Exhibition Hall 405EX.

In addition to putting up your posters based on the schedules stated above (Poster Display), poster presenters will also be required to do the following:

- Each presenter needs to bring either a powerpoint version of the poster or powerpoint slides (maximum of 4 slides) for the presentation.
- All presenters should familiarise themselves with the date, time and venue of their sessions, and arrive at the correct venue at least 20 minutes before the start of the session

Schedule for Poster Presentation:

- **Wednesday, 28 August 2019 : Clinical Sciences & Co-Infection**
  Time : 6:30pm – 8:00pm
  Each presenter will be given a total of 5 mins
  (3 mins for presentation and 2 mins for Q&A).

- **Friday, 30 August 2019 : Virology & Pathogenesis**
  Time : 6:10pm – 7:30pm
  Each presenter will be given a total of 5 mins
  (3 mins for presentation and 2 mins for Q&A)

- **Saturday, 31 August 2019 : Public Health**
  Time : 5:30pm – 7:00pm
  Each presenter will be given a total of 3 mins of presentation

Order of presentations : refer to Page **51** to **53** for details.

THE SABIN-ASPEN
VACCINE SCIENCE
& POLICY GROUP
SABIN VACCINE INSTITUTE | THE ASPEN INSTITUTE

PICK UP YOUR COPY OF
THE REPORT AT BOOTH B1

A group of **internationally recognized, cross-disciplinary experts** developed a set of "big ideas" to ignite a movement toward successful development of a universal influenza vaccine (UIV).

The report provides **bold, actionable recommendations** designed to spur momentum toward transformative breakthroughs and overcome obstacles in research and development, policy and industry.

DOWNLOAD AND READ
THE REPORT AT INFLUENZER.ORG

SABIN VACCINE INSTITUTE | FLU LAB

@theinfluenzers

Day 1: 28/8/2019 Wednesday

Latest Research from China / Level 3, Room 331 /

Session Chair: **John Tam** */The Hong Kong Polytechnic University, Hong Kong/*

09.00am **Opening Remarks**
Liang Xiao Feng */Chinese Preventive Medicine Association ,China/*

09.15am **Part 1: Animal and Zoonotic Influenza in China**

The Avian Influenza Control in China
Chengjun Li */Chinese Academy of Agricultural Sciences ,China/*

Human Infections with Zoonotic Influenza Virus in China
Dayan Wang */Chinese National Influenza Center,China/*

Human Infections with Novel Influenza Viruses and Pandemic Preparedness in China
Lei Zhou */Chinese Center for Disease Control and Prevention ,China/*

Seasonal Influenza Vaccine Policy Development and Implementation in China
Luzhao Feng */Chinese Center for Disease Control and Prevention ,China/*

11.15am **Tea Break / Level 3, Room 331 /**

11.30am - 1.00pm **Part 2: Pharmaceutical Research in China (with a Focus on Chinese Medicine)**

Adjuvant Use of Traditional Chinese Medicine in Influenza and Pneumonia
Bin Cao */China-Japan Friendship Hospital,China/*

Repress Antiviral Genes STAT1/2 in Avian Influenza Infection
Chengyu Jiang */Peking Union Medical College,China/*

Prediction of Zoonotic Influenza Virus Transmission and Clinical Severity Using Biomarkers
Yuelong Shu */Sun Yat-sen University, China/*

Official Opening Ceremony / Level 4, Hall 406CX /

3.00pm **Vernon Lee** */Chair, Options X/*
Lance Jennings */Chair, ISIRV/*
Lam Pin Min */Senior Minister of State, Ministry of Health and Ministry of Transport, Singapore/*

Presentation of ISIRV Awards

ISIRV Lifetime Achievement Award:
Frederick Hayden */University of Virginia School of Medicine, USA/*

Geoffrey Schild Lecture:
Barney Graham */National Institute of Allergy and Infectious Disease, USA/*

ISIRV Wiley Young Investigator Award:
Khristine Joy Antigua */Chungbuk National University, Republic of Korea/*

3.45pm **Tea Break / Exhibition Hall 405EX /**

Opening Keynote / Level 4, Hall 406CX /

Session Chair: **Vernon Lee** */Ministry of Health, Singapore/*

4.15pm **Pandemic and Seasonal Influenza: The Known Unknowns**
Malik Peiris */University of Hong Kong, Hong Kong/*

A Bird's Eye View of Influenza Research
Kanta Subbarao */Peter Doherty Institute for Infection and Immunity, Australia/*

The Geoffrey Schild Lecture: Design Options for Universal Influenza Vaccines
Barney Graham */National Institute of Allergy and Infectious Disease, USA/*

6.00pm **Opening Reception / Dinner / Exhibition Hall 405EX /**

6.30pm -8.00pm **Clinical Sciences and Co-Infection Poster Session + Poster Reception / Exhibition Hall 405EX /**

6.30pm -8.00pm **Shortlisted Poster Presentations for Poster Awards / Exhibition Hall 405EX /**

Day 2: 29/8/2019 Thursday

Plenary Talks: Vaccines / Level 4, Hall 406CX /

Session Chair: **Mark Tompkins** */University of Georgia, USA/*

8.30am **Challenges in Influenza Prevention and Control**
Dan Jernigan */Centers for Disease Control and Prevention (CDC), USA/*

Global Coordination Activities on Universal Vaccines and Priorities
Martin Friede */World Health Organisation, Switzerland/*

10.00am **Tea Break / Exhibition Hall 405EX /**

Day 2: 29/8/2019 Thursday

Session 1

	/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /
	Virology & Pathogenesis		**Clinical Sciences**		**Public Health**
	Virus Pathogenesis & Transmission **Session Chairs:** **Jessica Belser** */Centers for Disease Control and Prevention, USA/* **Sander Herfst** */Erasmus MC, The Netherlands/*		**Clinical (I)** **Session Chairs:** **Maria Zambon** */Public Health England, UK/* **Dale Fisher** */National University Hospital, Singapore/*		**Vaccine Efficacy/Effectiveness (I)** **Session Chairs:** **Sheena Sullivan** */WHO Collaborating Centre for Reference and Research on Influenza, Australia/* **Esther Kissling** */Epiconcept, France/*
10.30am	**Influenza Transmission in Experimental and Field Settings** **Hui-Ling Yen** */University of Hong Kong, Hong Kong/*	10.30am	**Rapid Molecular Point of Care Tests: Strategies for Use** **Maria Zambon** */Public Health England, UK/*	10.30am	**Do Influenza Vaccines Attenuate the Severity of Breakthrough Infections?** **Mark Thompson** */Centers for Disease Control and Prevention, USA/*
10.50am	**Pathogenesis and Transmission of Emerging Influenza Viruses** **Sander Herfst** */Erasmus MC, The Netherlands/*	10.50am	**Shifting the Diagnostic Paradigm from Pathogen to Host** **Ann Falsey** */University of Rochester, USA/*	10.50am	**Impact on Cardiovascular Outcomes** **Jeff Kwong** */ICES, Canada/*
11.10am	**Implications of Incomplete Viral Genomes for Influenza A Virus Fitness** **Anice Lowen** */Emory, USA/*	11.10am	**Innovation in Pandemic Influenza Response** **Rick Bright** */U.S. Department of Health and Human Services, USA/*	11.10am	Variations in seasonal influenza vaccine effectiveness due to biological characteristics: A systematic review and META-analysis of test-negative design studies **(Abstract No 10311)** **George Okoli** */University of Manitoba, Canada/*
11.30am	Autophagy-mediated restriction of avian influenza virus replication in mammalian cells **(Abstract No 10440)** **Siwen Liu** */The University of Hong Kong, Hong Kong/*	11.30am	The impact of syndromic molecular point-of-care testing for respiratory viruses in adults presenting to hospital with exacerbation of airways disease: Further analysis form a randomised controlled trial **(Abstract No 10563)** **Nathan Brendish** */University Hospital Southampton NHS Foundation Trust, UK/*	11.22am	Vaccine effectiveness against influenza hospitalization in the 2018-2019 season: comparison between cell-based and egg-based influenza vaccines **(Abstract No 10395)** **Hung Fu Tseng** */Kasier Permanente Southern California, USA/*
11.42am	Haemagglutinin mutation and higher neuraminidase activity enhanced the adaption of H5N6 avian influenza viruses to mammalian hosts **(Abstract No 10855)** **Honglei Sun** */China Agricultural University,China/*	11.42am	Evaluation of the Febridx host response point-of-care test to differentiate viral from bacterial aetiology in adults hospitalised with acute respiratory illness during Influenza season **(Abstract No 10565)** **Nathan Brendish** */University Hospital Southampton NHS Foundation Trust, UK/*	11.34am	Influenza vaccine effectiveness against laboratory-confirmed influenza mortality in older adults **(Abstract No 10881)** **Jeff Kwong** */ICES, Canada/*
11.54am	Assessment of zoonotic transmission of swine influenza A viruses from pigs to naïve or vaccinated ferrets **(Abstract No 10945)** **Ian Brown** */Animal and Plant Health Agency, UK/*			11.46am	Relative vaccine effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study **(Abstract No 10499)** **Robertus van Aalst** */Sanofi Pasteur, USA/*
12.00pm	**Lunch / Exhibition Hall 405EX /**				
12.00pm	**Sponsored Lunch Symposium (Sanofi Pasteur) / Level 4, Hall 406CX /** **Beyond Acute Respiratory Disease: How to Demonstrate the Full Public Health Impact of Influenza and its Prevention**				
1.30pm	**ISIRV Annual General Meeting / Level 4, Hall 406D /**				

Day 2: 29/8/2019 Thursday

Session 2

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Co-Infection		**Clinical Sciences**		**Public Health**	
Co-infection **Session Chairs:** **Keith Klugman** */Bill & Melinda Gates Foundation, USA/* **Nahoko Shindo** */World Health Organization, Switzerland/*		**Clinical (II)** **Session Chairs:** **Norio Sugaya** */Keiyu Hospital, Japan/* **Frederick Hayden** */University of Virginia School of Medicine, USA/*		**Vaccine Efficacy/Effectiveness (II)** **Session Chairs:** **Mark Thompson** */Centers for Disease Control and Prevention , USA/* **Sarah Cobey** */University of Chicago, USA/*	
2.30pm	**The Potential of Vaccines to Address Antimicrobial Resistance** **Padmini Srikantiah** */Bill & Melinda Gates Foundation, USA/*	2.30pm	**Neuraminidase Inhibitors: In Pursuit of Laboratory Correlates of Clinically Relevant Resistance** **Larisa Gubareva** */Centers for Disease Control and Prevention, USA/*	2.30pm	**Explaining Differences in Vaccine Effectiveness and Virus Circulation in the Southern Hemisphere, 2019** **Sheena Sullivan** */WHO Collaborating Centre for Reference and Research on Influenza, Australia/*
2.50pm	**Bacterial Interactions: The Role of Influenza in the Epidemiology of Pneumonia** **Pej Rohani** */University of Georgia, USA/*	2.50pm	**Antiviral Resistance [Polymerase Inhibitors]** **Aeron Hurt** */Peter Doherty Institute, Australia/*	2.50pm	**Immune Responses to Repeated Vaccination** **Annette Fox** */Doherty Institute, Australia/*
3.10pm	**Management of Co-infection in Emerging Influenza– Insights from the WHO New Standard Influenza Clinical Management Guidance** **Nahoko Shindo** */World Health Organization, Switzerland/*	3.10pm	**Clinical Studies on Immunopathogenesis** **Jake Dunning** */Public Health England, UK/*	3.10pm	**Variable Effects of Annually Repeated Influenza Vaccination: Evidence, Mechanisms, and Implications** **Danuta Skowronski** */British Columbia Centre for Disease Control, Canada/*
3.30pm	Epidemiology of influenza-associated community-acquired pneumonia admissions: A 7-year retrospective cohort study in Singapore **(Abstract No 10912)** **Win Mar Kyaw** */Tan Tock Seng Hospital, Singapore/*	3.30pm	Rapid molecular testing for influenza in children improves patient management in acute care setting **(Abstract No 10877)** **Rangaraj Selvarangan** */Childrens Mercy Hospital, USA/*	3.30pm	Birth cohort-specific vaccine effectiveness against influenza A(H1N1)PDM09 in seasons with different A(H1N1) PDM09 virus vaccine components, I-MOVE multicentre primary care study, Europe, 2013/14 TO 2018/19 **(Abstract No 11047)** **Esther Kissling** */Epiconcept, France/*
3.42pm	Evaluating the window of susceptibility to secondary bacterial infections post-influenza infection in ferrets **(Abstract No 10904)** **Edin Mifsud** */Peter Doherty Institute, Australia/*	3.42pm	Seasonal and other influenza viruses with reduced susceptibility to Baloxavir and Pimodivir **(Abstract No 10750)** **Larisa Gubareva** */Centers for Disease Control and Prevention, USA/*	3.42pm	Viral genomic variation and vaccine effectiveness across consecutive influenza A(H3N2) epidemics in Canada, 2016-17 and 2017-18 **(Abstract No 10983)** **Danuta Skowronski** */British Columbia Centre for Disease Control, Canada/*
4.00pm	**Tea Break / Exhibition Hall 405EX /**				

Session 3

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Influenza Glycobiology **Session Chairs:** **Sarah Londrigan** */The University of Melbourne, Peter Doherty Institute, Australia/* **Robert de Vries** */Utrecht Institute for Pharmaceutical Sciences, The Netherlands/*		**Clinical (III)** **Session Chairs:** **Andrew Pavia** */University of Utah, USA/* **David Lye** */National Centre for Infectious Diseases, Singapore/*		**Surveillance & Forecasting** **Session Chairs:** **Alex Cook** */National University of Singapore, Singapore/* **Jeff Kwong** */ICES Canada/*	
4.30pm	**Evolution of Virus-Glycan Interactions** **Andrew Thompson** */Scripps Research Institute, USA/*	4.30pm	**Inhibiting Viral Polymerase in Treating Influenza: Clinical Updates** **Nelson Lee** */University of Alberta, Canada/*	4.30pm	**Forecasting Seasonal Influenza Activity** **Jeff Shaman** */Columbia University, USA/*
4.50pm	**N-Glycolylneuraminic Acid as a Receptor for Influenza A Viruses** **Robert de Vries** */Utrecht Institute for Pharmaceutical Sciences, The Netherlands/*	4.50pm	**Polyclonal and Monoclonal Antibodies for the Treatment of Influenza** **John Beigel** */National Institute of Allergy and Infectious Diseases, USA/*	4.50pm	**Building a Forecasting Capability for Australian Public Health** **Robert Moss** */The University of Melbourne, Australia/*
5.10pm	**Defining Correlates of Immunity against Influenza Using Systems Serology** **Galit Alter** */Ragon Institute of MGH, MIT and Harvard, USA/*	5.10pm	**Management of Antiviral Resistance: Lessons from the Transplant Population** **Mike Ison** */Northwestern University,USA/*	5.10pm	**Forecasting Virus Strains** **Trevor Bedford** */Fred Hutchinson Cancer Research Center, USA/*

Day 2: 29/8/2019 Thursday

Session 3

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Influenza Glycobiology		**Clinical (III)**		**Surveillance & Forecasting**	
5.30pm	Influenza A virus surface proteins are organized to help penetrate host mucus **(Abstract No 11089)** **Michael Vahey** */Washington University in St. Louis, USA/*	5.30pm	Emergence of viruses with reduced susceptibility to Baloxavir Marboxil: Impact on clinical and virologic outcomes in patients with influenza at high risk of complications (Capstone-2) **(Abstract No 10753)** **Simon Portsmouth** */Shionogi Inc., USA/*	5.30pm	Globalization complicated emergence and spread of H3N2 seasonal influenza A viruses **(Abstract No 11184)** **Xiu-Feng (Henry) Wan** */University of Missouri-Columbia, USA/*
5.42pm	Seasonal H1N1 and antigenically drifted H3N2 influenza viruses that have limited binding to sialic acid bind to phosphorylated high mannose glycans from the human lung **(Abstract No 10964)** **Lauren Byrd-Leotis** */Harvard Medical School, USA/*	5.42pm	Neuraminidase-targeted hapten immunotherapy to treat influenza **(Abstract No 10900)** **Xin Liu** */Purdue University , USA/*	5.42pm	FluSight: Six seasons of forecasting influenza in the United States, 2013–14 to 2018–19 **(Abstract No 10347)** **Matthew Biggerstaff** */Centers for Disease Control and Prevention , USA/*
6.00pm -7.30pm	**Sponsored Evening Symposium (Hoffmann La-Roche)/ Level 4, Hall 406CX / Can We Stop Flu Going Viral?**				
6.00pm -8.00pm	**ISIRV Epidemiology Group Session / Level 4, Hall 406D /**				

Day 3: 30/8/2019 Friday

Plenary Talks: PISA & Virology / Level 4, Hall 406CX /

Session Chair: **Ben Cowling** */University of Hong Kong, Hong Kong/*

8.30am **Combination Influenza Therapy: Concept to Clinical Reality**
Frederick Hayden */University of Virginia School of Medicine, USA/*

Challenges in Influenza
Yoshihiro Kawaoka */University of Wisconsin-Madison, USA and University of Tokyo, Japan/*

10.00am **Tea Break / Exhibition Hall 405EX /**

Session 4

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
NextGen/Universal Vaccines **Session Chairs:** **Diane Post** */National Institutes of Health,USA/* **Kanta Subbarao** */Peter Doherty Institute for Infection and Immunity, Australia/*		**Clinical (IV)** **Session Chairs:** **Jake Dunning** */Public Health England, UK/* **Nelson Lee** */University of Alberta, Canada/*		**Optimising Vaccine Strategies (I)** **Session Chairs:** **Alicia Fry** */Centers for Disease Control and Prevention, USA/* **George Okoli** */University of Manitoba, Canada/*	
10.30am	**The Influenza Virus Neuraminidase as a Vaccine Target** **Florian Krammer** */Icahn School of Medicine at Mount Sinai, USA/*	10.30am	**Adjuvant Therapy for Severe Influenza Infection** **Ivan Hung** */University of Hong Kong, Hong Kong/*	10.30am	**Strategies to Enhance Local Protective Influenza-Specific Immunity in the Respiratory Tract** **Andrea Sant** */University of Rochester Medical Center, USA/*
10.50am	**Next-generation Broadly Reactive Influenza Vaccines** **Ted Ross** */University of Georgia, USA/*	10.50am	**Adjuvant Use of Corticostroids in Influenza and Pneumonia** **Cao Bin** */China-Japan Friendship Hospital, China/*	10.50am	**Comparative Immunogenicity of Enhanced Influenza Vaccines in Older Adults in Hong Kong: A Randomized Controlled Trial (PIVOT)** **Ben Cowling** */University of Hong Kong, Hong Kong/*
11.10am	**T Cell Vaccines Against Influenza** **Sarah Gilbert** */University of Oxford, UK/*	11.10am	**Potential Host Targeted Therapies in Influenza** Andrés Pizzorno */Centre International de Recherche en Infectiologie, France/*	11.10am	Serologic response to sequential influenza vaccination in older adults from a randomized trial **(Abstract No 10390)** **Huong McLean** */Marshfield Clinic Research Institute, USA/*
11.30am	Characterising human memory B cells with cross- lineage recognition of the influenza B hemagglutinin following seasonal immunisation **(Abstract No 11170)** **Adam Wheatley** */University of Melbourne, Australia/*	11.30am	Development of a new class of broad spectrum influenza PB2 inhibitors **(Abstract No 11025)** **Sam Lee** */Cocrystal Pharma Inc., USA/*	11.22am	Prior infection enhances the magnitude and breadth of anti-H3N2 antibody responses to influenza vaccination and reduces the risk of subsequent A/H3N2 virus infection **(Abstract No 11171)** **Maria Auladell** */Peter Doherty Institute for Infection and Immunity, Australia/*

Day 3: 30/8/2019 Friday

Session 4

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
NextGen/Universal Vaccines		**Clinical (IV)**		**Optimising Vaccine Strategies (I)**	
11.42am	Intranasal M2SR (M2-deficient single replication) influenza vaccine induced protection against challenge with a substantially drifted H3N2 virus in a phase 2 study **(Abstract No 11110)** **Joseph Eiden** */FluGen, USA/*	11.42am	Intravenous Peramivir in emergency department high-risk patients with influenza: A multicenter randomized controlled study **(Abstract No 11127)** **Yu-Hsiang Hsieh** */Johns Hopkins University School of Medicine, USA/*	11.34am	Does strain change influence vaccine effectiveness against influenza A (H3N2)? **(Abstract No 10609)** **Huong McLean** *Marshfield Clinic Research Institute, USA/*
11.54am	A human broadly cross-reactive anti-neuraminidase antibody protects against different subtypes of influenza A and B viruses in the mouse model **(Abstract No 10535)** **Daniel Stadlbauer** */Icahn School of Medicine at Mount Sinai, USA/*	11.54am	Human-to-human transmission of influenza A(H3N2) viruses exhibiting reduced susceptibility to Baloxavir due to a PA I38T substitution in Japan **(Abstract No 10475)** **Emi Takashita** */National Institute of Infectious Diseases, Japan /*	11.46am	Repeat vaccination reduces antibody affinity maturation irrespective of influenza vaccine platform in humans **(Abstract No 10561)** **Surender Khurana** */Center for Biologics Evaluation and Research (CBER), FDA,USA/*
12.06pm	Pre-existing immunity to the conserved hemagglutinin stalk of influenza virus may drive selection for an escape mutant virus in humans **(Abstract No 10880)** **Jae-Keun Park** */National Institute of Health, USA/*	12.06pm	Pharmacokinetics of Favipiravir (T-705) in combination with Oseltamivir for treatment of critically ill patients with severe influenza **(Abstract No 11286)** **Yeming Wang** */Institute of Respiratory Medicine, Chinese Academy of Medical Science,China/*	12.58pm	Comparison of influenza antibody titers among women who were vaccinated in the 2nd and 3rd trimesters of pregnancies **(Abstract No 10385)** **Joshua A. Mott** */U.S. Centers for Disease Control and Prevention, Thailand/*
12.18pm	RNACTIVE©: A promising mRNA based influenza vaccine **(Abstract No 10980)** **Lidia Oostvogels** */CureVacAG, Germany/*	12.18pm	A randomized controlled trial on the effect of fever suppression by antipyretics on influenza **(Abstract No 11217)** **Dennis Kai Ming Ip** */The University of Hong Kong, Hong Kong/*	12.10pm	Heterologous prime-boost using AS03 adjuvanted A(H5N1) pandemic stockpiled influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost **(Abstract No 10375)** **Min Levine** */Centers for Disease Control and Prevention,USA/*
12.30pm	Immunogenicity of chimeric hemagglutinin-based universal influenza virus vaccine candidates: interim results of a randomized, placebo-controlled, phase 1 clinical trial **(Abstract No 11735)** **Florian Krammer** */Icahn School of Medicine at Mount Sinai, USA/*				
12.30pm	**Lunch / Exhibition Hall 405EX /**				
12.30pm - 2.00pm	**Sponsored Lunch Symposium (Seqirus) / Level 4, Hall 406CX / Raising Defenses: Strengthening Influenza Protection**				

Session 5

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Immune Response to Infection **Session Chairs:** **Nicole La Gruta** */Monash University, Australia/* **Andrea Sant** */University of Rochester Medical Center, USA/*		**Special Populations – Clinical Aspects** **Session Chairs:** **Ann Falsey** */University of Rochester, USA/* **Paul Tambyah** */National University of Singapore, Singapore/*		**Optimising Vaccine Strategies (II)** **Session Chairs:** **Barbara Rath** */Vienna Vaccine Safety Initiative,USA/* **Abu Muhammad Zubair Akhtar** */ icddr, b, Bangladesh/*	
2.00pm	**Human CD8+ T cell Cross-reactivity Across Influenza A, B and C Viruses** **Katherine Kedzierska** */University of Melbourne, Australia/*	2.00pm	**Impact of Influenza Vaccination during Pregnancy on the Mother, Fetus, and Infant** **Marta Nunes** */University of the Witwatersrand, South Africa/*	2.00pm	**Efficacy of Live-attenuated Vaccines** **Martin Friede** */World Health Organization, Switzerland/*
2.20pm	**How the Host Response Determines Disease Outcome After Influenza Virus Infection** **Paul Thomas** */St. Jude Children's Research Hospital, USA/*	2.20pm	**Influenza and Older Adults: Frailty, Function and Healthy Ageing** **Melissa Andrew** */Dalhousie University and Canadian Centre for Vaccinology, Canada/*	2.20pm	**Influenza Vaccination of Children – What Have We Learnt?** **Richard Pebody** */Public Health England,UK/*

Day 3: 30/8/2019 Friday

Session 5

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Immune Response to Infection		**Special Populations – Clinical Aspects**		**Optimising Vaccine Strategies (II)**	
2.40pm	**The Pandemic Matrix Gene Enhances Innate Immune Responses During Infection** **Mark Tompkins** */University of Georgia , USA/*	2.40pm	**Influenza in Children: Challenges and Unanswered Questions** **Andrew Pavia** */University of Utah, USA/*	2.40pm	The United Kingdom's childhood influenza vaccination programme: Review of uptake and vaccine effectiveness over the first six seasons **(Abstract No 10811)** **George Kassianos** */Royal College of General Practitioners, UK/*
3.00pm	Annotation and recovery of ferret-specific immunoglobulin sequences **(Abstract No 10528)** **Julius Wong** */University of Melbourne, Australia/*	3.00pm	Lower cognition among toddlers who experience acute respiratory illnesses in Panama and El Salvador **(Abstract No 11345)** **Eduardo Azziz-Baumgartner** */ Centers for Disease Control and Prevention , USA/*	2.52pm	Impact of the introduction of the paediatric live attenuated influenza vaccine (LAIV) programme: An inter-country comparison across the United Kingdom and the Republic of Ireland **(Abstract No 11195)** **Mary Anissa Sinnathamby** */Public Health England, UK/*
3.12pm	Broadened cross-reactive immunity in ferrets after repeated influenza A/H3 exposures **(Abstract No 10490)** **Hang Xie** */Center for Biologics Evaluation and Research, US Food and Drug Administration, USA/*	3.12pm	Long-Term Care/Nursing Home admission following hospitalization with influenza and acute respiratory illness: The role of social vulnerability. A report from the Canadian Serious Outcomes Surveillance Network. **(Abstract No 11300)** **Melissa K Andrew** */Dalhousie University, Canada/*	3.04pm	First trimester seasonal influenza vaccination and major congenital malformations: A 2010-2016 UK retrospective cohort study **(Abstract No 10913)** **Punam Mangtani** */London School of Hygiene and Tropical Medicine, UK/*
3.24pm	Molecular and functional dissection of the influenza virus-specific CD8+ T-cell receptor repertoire during aging **(Abstract No 10471)** **Carolien van de Sandt** */The University of Melbourne at The Peter Doherty Institute, Australia/*	3.24pm	Effect of treatment with neuraminidase inhibitors on the risk of in-hospital death among influenza patients reported from EU countries, 2010–2019 **(Abstract No 10712)** **Cornelia Adlhoch** */European Centre for Disease Prevention and Control, Sweden/*	3.16pm	Viral shedding in recipients of live attenuated influenza vaccine in the 2016/17 and 2017/18 influenza seasons in the United Kingdom **(Abstract No 10749)** **David Jackson** */Public Health England, UK/*
3.36pm	Innate-like signatures of influenza-specific CD8+ resident memory T cell responses in the human lung **(Abstract No 11035)** **Suzanna Paterson** */Imperial College, UK/*	3.36pm	Impact of antiviral therapy on short- and long-term outcomes of patients with Copd following influenza infection **(Abstract No 11163)** **Christopher Wallick** */Genentech, USA/*	3.28pm	Cost-effective analysis for influenza vaccination coverage and timing in tropical and subtropical climate settings: a modelling study **(Abstract No 10376)** **Mu Yue** */National University of Singapore, Singapore/*
3.48pm	Subdominance and diminished TFH elicitation constrain humoral immunity against the influenza Ha-stem **(Abstract No 11216)** **Hyon-Xhi Tan** */Peter Doherty Institute for Infection and Immunity at the University of Melbourne, Australia/*	3.48pm	Treating influenza with antivirals is associated with a decreased burden of complications and health resource utilization in high risk patients **(Abstract No 11161)** **Christopher Wallick** */Genentech, USA/*	3.40pm	Costs and effects of childhood influenza vaccination in The Netherlands: Important risk of undesirable effects**(Abstract No 10332)** **Pieter de Boer** */National Institute for Public Health and the Environment, The Netherlands/*
4.00pm	**Tea Break / Exhibition Hall 405EX /**				

Session 6

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Cellular and Molecular Virology		**Avian and Zoonotic Influenza**		**Infection Severity**	
Session Chairs: **Wendy Barclay** */Imperial College London, UK/* **David Wentworth** */Centers for Disease Control and Prevention, USA/*		**Session Chairs:** **Leo Yee Sin** */National Institute for Infectious Diseases, Singapore/* **Andrew Bowman** */The Ohio State University, USA/*		**Session Chairs:** **Richard Pebody** */Public Health England,UK/* **Hasina Joelinotahina Rabarison** */Institut Pasteur de Madagascar, Madagascar/*	
4.30pm	**Next Generation Orally Efficacious Influenza Drug Candidate with High Genetic Resistance Barrier** **Richard Plemper** */Georgia State University, USA/*	4.30pm	**Lessons and Experience of Clinical Diagnosis and Treatment on Avian Influenza Cases in Guangzhou, China** **Zhong Nanshan** */The First Affiliated Hospital of Guangzhou Medical University, China/*	4.30pm	**Pandemic Severity Assessment** **Carrie Reed** */Centers for Disease Control and Prevention, USA/*

Day 3: 30/8/2019 Friday

Session 6

	/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
	Virology & Pathogenesis	**Clinical Sciences**	**Public Health**
	Cellular and Molecular Virology	**Avian and Zoonotic Influenza**	**Infection Severity**
4.50pm	**Structural Snapshots of Actively Transcribing Influenza Polymerase** **Stephen Cusack** */European Molecular Biology Laboratory in Grenoble, France/*	**Zoonotic Transmission of Influenza A Viruses at Agricultural Fairs** **Andrew S Bowman** */The Ohio State University,USA/*	**Disease Severity in Influenza and Other Respiratory Viral Infections** **Barbara Rath** */Vienna Vaccine Safety Initiative, USA/*
5.10pm	**The Interplay Between Influenza and Cellular Sphingolipids** **Hassan Zaraket** */American University of Beirut, Lebanon/*	**Clinical Features of Influenza A(H5N1) Infection and Other NA Subtypes** **David Hui** */The Chinese University of Hong Kong, Hong Kong/*	**The FLU CATs Study - Validation of Triage Tools for Use Across a National Healthcare System during Surge in Healthcare Demand Due to Pandemic Influenza** **Calum Semple** */University of Liverpool, UK/*
5.30pm	Dissecting the mechanism of signaling-induced nuclear export of influenza virus vRNPs **(Abstract No 11313)** **Stephan Ludwig** */University of Muenster, Germany/*	Incidence and seroprevalence of avian influenza viruses among Egyptian backyard poultry growers: Results from a prospective cohort study **(Abstract No 10853)** **Ghazi Kayali** */Human Link, Lebanon/*	Burden and severity of influenza-like illness in Australia: 10 years of flutracking online surveillance **(Abstract No 11254)** **Craig Dalton** */University of Newcastle, Australia/*
5.42pm	Differential regulation of Post-Translational Modification (PTM) status of influenza A viral Ribonucleoproteins (RNPs) during different stages of the viral life cycle **(Abstract No 10698)** **Lin Zhu** */Hong Kong Baptist University, Hong Kong/*	Clinical evaluation of adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic A(H7N9) influenza virus **(Abstract No 10966)** **Ruben O. Donis** */BARDA, USA/*	Estimating the influenza disease pyramid in Singapore **(Abstract No 10547)** **Rachael Pung** */Ministry of Health, Singapore/*
6.00pm -7.30pm	**Virology and Pathogenesis Poster Session + Poster Reception / Level 4, Exhibition Hall 405EX /**		
6.10pm -7.30pm	**Shortlisted Poster Presentations for Poster Awards**		

Day 4: 31/8/2019 Saturday

Plenary Talks: WHO Vision and Approaches / Level 4, Hall 406CX /

Session Chair: **Cheryl Cohen** */National Institute for Communicable Diseases, South Africa/*

8.30am

Global Influenza Strategy: Where We Want to Be in a Decade
Ann Moen */World Health Organization, Switzerland/*

Pandemic Influenza Preparedness – 10 Years After Pandemic H1N1 2009
Wenqing Zhang */World Health Organization, Switzerland/*

Measuring Influenza Severity: Where We Are and Where We Will Go
Katelijn Vandemaele */World Health Organization, Switzerland/*

10.00am **Tea Break / Exhibition Hall 405EX /**

Session 7

	/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
	Virology & Pathogenesis	**Clinical Sciences**	**Policy**
	Host-pathogen Interactions Session Chairs: Randy Albrecht */Icahn School of Medicine at Mount Sinai, USA/* Ryan Langlios */University of Minnesota, USA/*	**Influenza in the Tropics** Session Chair: Jean-Michel Heraud */Institut Pasteur de Madagascar, Madagascar/*	**Policy Perspectives for the Prevention and Control of Seasonal Influenza** Session Chair: Sheena Sullivan */WHO Collaborating Centre for Reference and Research on Influenza, Australia/*
10.30am	**Immunity to Influenza in Dirty Mice** **Ryan Langlios** */University of Minnesota, USA/*	**Influenza in the Tropics** **Lance Jennings** */University of Otago, New Zealand/*	**Effectiveness of Influenza Vaccination in Different Populations** **Brendan Flannery** */Centers for Disease Control and Prevention, USA/*
10.50am	**Obesity as a Risk Factor in Influenza Virus Infection** **Stacey Schultz-Cherry** */St. Jude Children's Research Hospital, USA/*	**"Seasonality" of Influenza in the Tropics Due to Waning of Protection** **Alex Cook** */National University of Singapore, Singapore/*	11.00am **Rational Policy for Neuraminidase Inhibitors** **Jonathan Nguyen Van Tam** */Department of Health and Social Care, UK/*

Day 4: 31/8/2019 Saturday

Session 7

	/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
	Virology & Pathogenesis	**Clinical Sciences**	**Policy**
	Host-pathogen Interactions	**Influenza in the Tropics**	**Policy Perspectives for the Prevention and Control of Seasonal Influenza** Session Chair: Joseph Bresee */Centers for Disease Control and Prevention, USA/*
11.10am	**ANP32 Proteins: Host Factors that Impact Influenza Virus Polymerase Activity and Host Range** **Wendy Barclay** */Imperial College London, UK/*	**Monitoring Influenza Activity and Burden in the Tropics** **Mark Chen** */National University of Singapore, Singapore/*	**Evolutions of National Influenza Immunization Program in the Republic of Korea** **Kong Insik** */Ministry of Health and Welfare, Republic of Korea/*
11.30am	Abstract No 10428: Spatial and temporal quantification of putative lung regenerating cells during early recovery from influenza pneumonia **Joe Ong** */National University of Singapore, Singapore/*	Resistance development in influenza A viruses infecting mallards exposed to low levels of Peramivir **(Abstract No 11211)** **Josef Järhult** */Uppsala University, Sweden/*	**Evidence Needed to Accelerate Influenza Vaccine Introduction into National Immunisation Programme in China** **Hongjie Yu** */Fudan University,China/*
11.42am	Obesity increases the cardiac complications of influenza virus infection (Abstract No 11138) **Kirsty Short** */University of Queensland, Australia/*	Live attenuated influenza vaccine induces early tonsillar follicular T helper cell responses correlating with durable systemic antibody responses (**Abstract No 10100**) **Sarah Larteley Lartey Jalloh** */University of Bergen, Norway/*	**Session Chair: Chong Chia Yin** */KK Women's and Children's Hospital, Singapore/*
11.54am	A history of obesity reduces the immune response to influenza virus in an NLRP3 dependent manner **(Abstract No 11112)** **Katina D. Hulme** */University of Queensland, Australia/*	Development of a universal Influenza A T cell-based vaccine **(Abstract No 11289)** **Elizabeth Eagling-Vose** */Vaccitech, UK/*	
12.06pm	Repeated seasonal influenza vaccination results in reduced protection against influenza A(H3N2) infection in ferrets compared to single vaccination **(Abstract No 10740)** **Ian York** */Centers for Disease Control and Prevention,USA/*	Prevention of influenza during mismatched seasons in older adults: a randomized efficacy study of an MF59-adjuvanted quadrivalent influenza vaccine **(Abstract No 11792)** **Jonathan Edelman** */Seqirus Inc, USA/*	12.00pm **Panel Discussion on Overcoming Challenges for Implementation of Prevention and Control of Seasonal Influenza** **Kong Insik** */Ministry of Health and Welfare, Republic of Korea/* **Hongjie Yu** */Fudan University, China/* **Seng Heng** */Ministry of Health, Cambodia/* **Chong Chee Kheong** */Ministry of Health, Malaysia/*
12.18pm	MHC class II proteins mediate cross-species entry of bat influenza viruses **(Abstract No 10591)** **Thiprampai Thamamongood** */University of Freiburg, Germany/*	Vaccination with 1/6th standard dose of a split inactivated influenza vaccine using a high-density micro-projection array patch induces comparable immune responses to conventional full-dose intramuscular injection; results from a phase I randomized controlled clinical trial **(Abstract No 11748)** **Angus Forster** */Vaxxas Pty Ltd, Australia/*	
12.30pm	**Lunch / Exhibition Hall 405EX /**		
12.30pm - 2.00pm	**Sponsored Lunch Symposium (GSK) / Level 4, Hall 406CX /** **Prevention of Paediatric Influenza: Why and How?**		

Session 8

	/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
	Virology & Pathogenesis	**Co-Infection**	**Policy**
	Viral Replication Session Chairs: **Victor Huber** */University of South Dakota, USA/* **Marciela DeGrace** */National Institute of Allergy and Infectious Diseases, USA/*	**Controlled Human Infection Model (CHIM) Challenge Studies** Session Chairs: **Peter Openshaw** */Imperial College London, UK/* **Chris Woods** */Duke University, USA/*	**Policy Perspectives for Pandemic Influenza Preparedness & Response** Session Chair: **Gabriel Leung** */The University of Hong Kong, Hong Kong/*
2.00pm	**How Antiviral Proteins can Stimulate Influenza Virus Replication** **Andrew Mehle** */University of Wisconsin Madison, USA/*	**Insight into Host-pathogen Interactions in the Upper Respiratory Tract from Live Attenuated Influenza Vaccine Studies in Children** **Thushan de Silva** */The Gambia @LSHTM, UK/*	**Non-pharmaceutical Public Health Measures for Mitigating the Risk and Impact of Epidemic and Pandemic Influenza** **Ben Cowling** */The University of Hong Kong, Hong Kong/*

Day 4: 31/8/2019 Saturday

/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
Virology & Pathogenesis	**Co-Infection**	**Policy**
Viral Replication	**Controlled Human Infection Model (CHIM) Challenge Studies**	**Policy Perspectives for Pandemic Influenza Preparedness & Response**
2.20pm **Visualizing Influenza Virus Assembly** **Seema Lakdawala** */University of Pittsburgh, USA/*	2.20pm **Mucosal Immunity in Pathogenesis and Protection Against Human Influenza Infection Challenge** **Chris Chiu** */Imperial College London,UK/*	2.30pm **Policy Considerations for Pandemic Preparedness and Response** **Vernon Lee** */Ministry of Health, Singapore/*
2.40pm **Mini viral RNAs: Consequences of RNA Structure for Genome Replication and Innate Immune Sensing** **David Bauer** */University of Oxford, UK/*	2.40pm **Harnessing the Host Response to Generate Biomarkers for Influenza and Other Respiratory Tract Infections** **Chris Woods** */Duke University,USA/*	**Session Chair: Ann Moen** */World Health Organization, Switzerland/*
		2.45pm **Policy Considerations for Pandemic Preparedness and Response Planning: Thailand's Experiences** **Supamit Chunsuttiwat** */Ministry of Public Health, Thailand/*
3.00pm New genomic approaches to understand the heterogeneity of viral replication in single cells **(Abstract No 10606)** **David Bacsik***/Fred Hutchinson Cancer Research Center, USA/*	3.00pm Correlates of protection for better, faster influenza vaccine development **(Abstract No 11082)** **Armen Donabedian** */US Health and Human Services, USA/*	3.00pm **Panel Discussion on Overcoming Challenges for Pandemic Preparedness Planning** **Vernon Lee** */Ministry of Health, Singapore/* **Supamit Chunsuttiwat** */Ministry of Public Health,Thailand/* **Seng Heng** */Ministry of Health, Cambodia/* **Chong Chee Kheong** */Ministry of Health, Malaysia/*
3.12pm ANP32 proteins from different mammalian species act as host range barriers and shape influenza polymerase adaptation **(Abstract No 10843)** **Thomas Peacock** */Imperial College London, UK/*	3.12pm Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human Influenza challenge model **(Abstract No 10943)** **Delphine Guyon-Gellin** */Osivax , France/* **Nicolas Noulin** */hVivo,UK/*	
3.30pm **Tea Break / Exhibition Hall 405EX /**		

Session 9

/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
Virology & Pathogenesis	**Clinical Sciences**	**Public Health**
Influenza Evolution & Human Ecology **Session Chairs:** **Richard Neher** */University of Basel, Switzerland/* **Nicola Lewis** */Royal Veterinary College, UK/*	**Critical Influenza Illness** **Session Chairs:** **David Hui** */The Chinese University of Hong Kong, Hong Kong/* **Tan Thuan Tong** */Singapore General Hospital, Singapore/*	**Disease Burden, Impact, and Severity** **Session Chairs:** **Cecile Viboud** */National Institutes of Health, USA/* **Mark Chen** */National University of Singapore, Singapore/*
4.00pm **Mapping Selection on Influenza Virus from Polyclonal Human Serum** **Jesse Bloom** */Fred Hutch Cancer Research Center,USA/*	4.00pm **REMAP-CAP: A Platform Trial to Advance Knowledge of Optimal Treatment for Critically Ill Patients with Influenza** **Steve Webb** */Royal Perth Hospital, Australia/*	4.00pm **Influenza Burden and Links to Policy - Building the Pyramid** **Cheryl Cohen** */National Institute for Communicable Diseases, South Africa/*
4.20pm **Influenza in the Age of Mammals** **Martha Nelson** */National Institutes of Health,USA/*	4.20pm **Neurological Complications Associated with Influenza** **Tim Uyeki** */Centers for Disease Control and Prevention, USA/*	4.20pm **Global Estimates of Influenza-associated Hospitalization from the InfluEnza BurdEn, Global Project (IcEBErG)** **Danielle Iuliano** */Centers for Disease Control and Prevention, USA/*
4.40pm **Evolution of Seasonal Influenza Viruses** **Colin Russell** */University of Amsterdam, The Netherlands/*	4.40pm **Cardiovascular Complications of Influenza** **William Fischer** */University of North Carolina, USA/*	4.40pm The burden of in-hospital and out-of-hospital deaths among patients hospitalized with influenza, FluSurv-NET, 2010–2016 **(Abstract No 11044)** **Shikha Garg** */Centers for Disease Control and Prevention, USA/*
5.00pm The evolutionary dynamics of influenza A and influenza B viruses in naturally infected human hosts **(Abstract No 10822)** **Adam Lauring** */University of Michigan, USA/*	5.00pm Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury induced by highly pathogenic avian influenza virus A/H5N1 **(Abstract No 11151)** **Resti Yudhawati Meliana** */Airlangga University/Dr. Soetomo Hospital, Indonesia/*	4.52pm Estimating the number of deaths due to Influenza — An alternative to regression-based estimates of excess influenza mortality **(Abstract No 10858)** **Melissa Rolfes** */Centers for Disease Control and Prevention, USA/*

Day 4: 31/8/2019 Saturday

Session 9

/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
Virology & Pathogenesis	**Clinical Sciences**	**Public Health**
Influenza Evolution & Human Ecology	**Critical Influenza Illness**	**Disease Burden, Impact, and Severity**
5.12pm Predicting evolutionary pathways to 'fit' oseltamivir resistant influenza viruses **(Abstract No 10995)** **Rubaiyea Farrukee** */University of Melbourne, Australia/*	5.12pm Baloxavir for the treatment of Influenza virus infection in hematopoietic stem cell transplant recipients who failed oseltamivir **(Abstract No 11309)** **Mirella Salvatore** */Weill Cornell Medicine, USA/*	5.04pm Community burden of influenza in a rural and an urban setting, South Africa, 2016-2017 **(Abstract No 10667)** **Cheryl Cohen** */NICD, South Africa/*
		5.16pm Under-detection of laboratory-confirmed influenza-associated hospitalizations among infants in a multi-country prospective study **(Abstract No 10362)** **Mark Thompson** */Centers for Disease Control and Prevention, USA,/*
5.30pm -7.00pm	**Public Health Poster Session + Poster Reception / Level 4, Exhibition Hall 405EX / Shortlisted Poster Presentations for Poster Awards**	
7.30pm - 10.45pm	**Gala Dinner at Flower Field Hall, Gardens by the Bay**	

Day 5: 1/9/2019 Sunday

Session 10

/ Level 4, Hall 406CX /	/ Level 4, Hall 406D /	/ Level 4, Hall 405B /
Virology & Pathogenesis	**Clinical Sciences**	**Public Health**
Non-Human Influenza Viruses **Session Chairs:** **David Swayne** */U.S. Department of Agriculture,USA/* **Andrew Bowman** */The Ohio State University,USA/*	**Non-pharmaceutical Interventions** **Session Chairs:** **Ben Cowling** */The University of Hong Kong, Hong Kong/* **Angela Chow** */Tan Tock Seng Hospital, Singapore/*	**Imprinting, Sero-epidemiology, Age Profile Differences** **Session Chairs:** **Annette Fox** */Doherty Institute, Australia/* **Robert Moss** */The University of Melbourne, Australia/*
8.30am **Ten Years after the 2009 "Swine Flu" Pandemic: A Perspective from a Veterinary Biomedical Researcher** **Kristien van Reeth** */Ghent University, Belgium/*	8.30am **Contagious Phenotypes of Influenza Virus Infection** **Donald Milton** */University of Maryland School of Public Health, USA/*	8.30am **Epidemiological Consequences of Immune Memory** **Sarah Cobey** */University of Chicago ,USA/*
8.50am **The Emergence, Epidemiology and Evolution of the H3N8 and H3N2 Canine Influenza Virus** **Colin Parrish** */Cornell University, USA/*	8.50am **Spread of Pandemic Influenza in US Communities in 1920 and 2009: What Changed in the Last Century?** **Simon Cauchemez** */Institut Pasteur, France/*	8.50am **Influenza in Context: Insights into Universal Vaccination against Influenza** **Patrick Wilson** */University of Chicago, USA/*
9.10am **Repeated Outbreaks of H5 Highly Pathogenic Avian Influenza in Wild Birds and Poultry in Europe between 2014 and 2019** **Thijs Kuiken** */Erasmus University Medical Centre, The Netherlands/*	9.10am Quantifying the effects of school closures on mitigation of influenza epidemics in Hong Kong **(Abstract No 10910)** **Sheikh Taslim Ali** */The University of Hong Kong, Hong Kong/*	9.10am **Using Serological Data to Reconstruct Historical Influenza Dynamics** **Adam Kucharski** */London School of Hygiene & Tropical Medicine, UK/*
9.30am Improving avian influenza surveillance through wetland sampling **(Abstract No 11198)** **Lauren Tindale** */University of British Columbia, Canada/*	9.22am Access to Telework, Paid Leave Benefits, and Work Attendance in Adults with Medically-Attended Acute (Abstract No 10466) Respiratory Illness (ARI) **Faruque Ahmed** */Centers for Disease Control and Prevention, USA/*	9.30am Effect of maternal pandemic vaccination on seroprevalence against influenza in children at birth and at 4 years **(Abstract No 11088)** **Anna Hayman Robertson** */Norwegian Institute of Public Health, Norway/*
9.42am Repeated crow (corvus spendens) mortality events linked to H5N1 influenza virus circulation in live bird markets, Bangladesh **(Abstract No11253)** **Ariful Islam** */EcoHealth Alliance, USA/*	9.34am A global, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of VIS410 in combination with OSELTAMIVIR versus OSELTAMIVIR alone in hospitalized adults with influenza A requiring oxygen **(Abstract No 11754)** **David Oldach** */Visterra Inc, USA/*	9.42am Risk factors and attack rates of seasonal influenza infection: Results of the SHIVERS Seroepidemiologic cohort study **(Abstract No 11349)** **Sue Huang** */Institute of Environmental Science and Research, New Zealand/*

Day 5: 1/9/2019 Sunday

Session 10

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Non-Human Influenza Viruses		**Non-pharmaceutical Interventions**		**Imprinting, Sero-epidemiology, Age Profile Differences**	
9.54am	Characterizing the functionality of the Wuhan Spiny Eel Influenza Virus surface Glycoproteins **(Abstract No.11794)** **Guha Asthagiri Arunkumar** */Icahn School of Medicine at Mount Sinai, USA/*	9.46am	Reduced susceptibility viruses to baloxavir marboxil: Prognosis factors of the emergence and impact on clinical and virologic outcomes in pediatric patients in Japan **(Abstract No 10812)** **Takeki Uehara** */Shionogi & Co., Ltd., Japan/*	9.54am	Serosolver: An open source tool to infer epidemiological and immunological dynamics from serological data **(Abstract No 11206)** **Steven Riley** */Imperial College, UK/*
10.06am	Low literacy program for safe slaughter of poultry in developing countries to reduce human infection with avian influenza virus **(Abstract No.10355)** **David Swayne** */U.S. Department of Agriculture,USA/*	9.58am	Single-dose Baloxavir is well tolerated and effective for treatment of influenza in otherwise healthy children aged 1 to <12 years: A randomized, double-blinded, active-controlled study (miniSTONE-2) (Abstract No 11756) **Jeffrey Baker** */Clinical Research Prime, USA/*	10.06am	Antibody response and influenza-like illness among healthcare workers after influenza vaccination **(Abstract No 11162)** **Vivian Leung** */Peter Doherty Institute for Infection and Immunity, Australia/*
10.18am	The bat influenza H17N10 can be neutralized by BNMABS and its NA facilitates viral egress **(Abstract No. 10108)** **Nigel Temperton** */University of Kent, UK/*	10.10am	Single-dose Baloxavir for the prevention of Influenza among household contacts: A randomized,double -blinded, placebo controlled post-exposure prophylaxis study (BLOCKSTONE) **(Abstract No 11718)** **Hideyuki Ikematsu** */Ricerca Clinica Co., Japan/*	10.18am	Hemagglutinin and neuraminidase antibodies are induced in an age- and subtype-dependent manner after influenza virus infection. **(Abstract No 11051)** **Sook-San Wong** */Guangzhou Medical University, China/*
10.30am	**Tea Break / Exhibition Hall 405EX /**				

Session 11

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Emerging Influenza Viruses **Session Chairs:** **Ghazi Kayali** */Human Link , Lebanon/* **Zeynep A Kocer** */IZMIR Biomedicine and Genome Center, Turkey/*		**Vaccines** **Session Chairs:** **Arnold Monto** */University of Michigan School of Public Health, USA/* **Louis Chai** */National University Hospital, Singapore/*		**Epidemiology and Transmission Dynamics** **Session Chairs:** **Adam Kucharski** */London School of Hygiene & Tropical Medicine, UK/* **Carrie Reed** */Centers for Disease Control and Prevention,USA,/*	
11.00am	**Fighting Influenza from a One Health Perspective** **Albert Osterhaus** */TiHO, Germany/*	11.00am	**Influenza Vaccination of the Immunocompromised** **Deepali Kumar** */University Health Network, Canada/*	11.00am	**Healthcare Outbreaks of Influenza** **Paul Tambyah** */National University of Singapore, Singapore/*
11.20am	**Emergence of Swine Influenza in Australia** Vijay Dhanasekaran */Monash University, Australia/*	11.20am	**On Waning and Boosting: Is There a Sweet Spot for Influenza Vaccination Strategies in the Tropics?** **Barnaby Young** */National Centre for Infectious Diseases, Singapore/*	11.20am	**Deep Sequencing and Mapping Chains of Transmission** **Sebastian Maurer Stroh** */A*STAR, Singapore/*
11.40am	**Emergence of Avian Influenza Viruses in Asia** **Maria Zhu** */The University of Hong Kong, Hong Kong/*	11.40am	Vaccine induced mucosal IgA contributes to protection against influenza infection in humans **(Abstract No 10324)** **Sean Tucker** */Vaxart, Inc., USA/*	11.40am	Preliminary estimates of the incidence of influenza-associated acute respiratory infection among adults aged >60 years in a multi-site community cohort in India **(Abstract No 10448)** **Rakesh Kumar** */All India Institute of Medical Sciences, India/*
12.00pm	**Reverse Genetic Analysis of Bat Influenza Viruses: A Journey Full of Surprises** **Martin Schwemmle** */University of Freiburg, Germany/*	11.52am	Towards an improved wild-type sequence based hemagglutination inhibition assay for the evaluation of influenza vaccines: challenges and new developments **(Abstract No 11083)** **Vivek Shinde** */Novavax, USA/*	11.52am	Influenza virus transmission from symptomatic and asymptomatic individuals in a rural and an urban setting, South Africa, 2016-2017 **(Abstract No 10352)** **Meredith McMorrow** */Centers for Disease Control and Prevention, South Africa/*

Day 5: 1/9/2019 Sunday

Session 11

/ Level 4, Hall 406CX /		/ Level 4, Hall 406D /		/ Level 4, Hall 405B /	
Virology & Pathogenesis		**Clinical Sciences**		**Public Health**	
Emerging Influenza Viruses		**Vaccines**		**Epidemiology and Transmission Dynamics**	
12.20pm	Few substitutions of H5 gene belonging to Clade 2.3.4 have altered the NA gene preferences of the virus other than N1 **(Abstract No 11179)** **Khristine Joy Antigua** */Chungbuk National University, Republic of Korea/*	12.04pm	First-in-man clinical trials of influenza vectored vaccines against tuberculosis with intranasal and sublinqual routes of administration **(Abstract No 10944)** **Marina Stukova** */Smorodintsev Research Institute of Influenza, Russian Federation/*	12.04pm	Impact of influenza antigenic evolution on disease dynamics in the United States **(Abstract No 10702)** **Amanda Perofsky** */Fogarty International Center, National Institutes of Health, USA/*
12.32pm	Comprehensive mapping of adaptation of the avian influenza polymerase protein PB2 to humans **(Abstract No 10649)** **Shirleen Soh** */Fred Hutchinson Cancer Research Center, USA/*	12.16pm	OVX836, A novel universal influenza A vaccine candidate: First results of a phase I clinical trial in humans **(Abstract No 10937)** **Alexandre Le Vert** */Osivax, France/*	12.16pm	Determinants of influenza transmission in households in rural North India **(Abstract No 10492)** **Aslesh Ottapura Prabhakaran** */US Centers for Disease Control and Prevention India Office, India/*
12.44pm	Mitigating pandemic risk with influenza A virus field surveillance: Mia (Mobile Influenza Analysis) **(Abstract No 10960)** **John R. Barnes** */Centers for Disease Control and Prevention, USA/*	12.28pm	Immune history to influenza is a novel correlate of protection of influenza vaccination **(Abstract No 11095)** **Tomer Hertz** */Ben-Gurion University of the Negev, Israel /*	12.28pm	Effect of host genetic polymorphism on transmission of influenza virus infection in a household setting **(Abstract No 11200)** **Dennis Kai Ming Ip** */The University of Hong Kong, Hong Kong/*
		12.40pm	Induction of broadly cross-reactive immune responses against A(H3N2) viruses: results of a phase 2 trial of a novel recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccine **(Abstract No 11073)** **Vivek Shinde** */Novavax, USA/*	12.40pm	The Epidemioloogical Signature of the influenza B/Victoria and B/Yamagata Lineages in the 21st Century **(Abstract No 11001)** **John Paget** */Nivel, The Netherlands/*
1.00pm	**Lunch / Exhibition Hall 405EX /**				

Closing Plenary Talks / Level 4, Hall 406CX /

Session Chair: **Paul Tambyah** */National University of Singapore, Singapore/*

1.30pm **Mitigating Against Geopolitical Determinants of Global Public Health and Envisioning Counterfactual Futures for Outbreak Preparedness and Response**
Gabriel Leung */University of Hong Kong, Hong Kong/*

The Future of Influenza Vaccines
Arnold Monto */University of Michigan School of Public Health, USA/*

Influenza Pandemic Preparedness: Progress Since 2009 and Remaining Gaps
Sylvie Briand */World Health Organization, Switzerland/*

3.00pm **Closing Ceremony**
Presentation of Best Oral and Poster Awards
Handover to Options XI

KEYNOTE & PLENARY SPEAKERS

Sylvie Claire BRIAND
Director
World Health Organization, Switzerland

Dr Briand, Director of the Infectious Hazards Management department (IHM) in the Health Emergencies Programme at the World Health Organization's (WHO) headquarters in Geneva, Switzerland. IHM develops global strategies to prevent and control epidemic-prone diseases under the International Health Regulations through global partnerships with a variety of research, strategic, financial and operational partners. IHM portfolio includes epidemic diseases such as cholera, yellow fever, meningitis, seasonal and pandemic influenza, Zika, MERs CoV, plague, smallpox and Ebola, as well as emerging infectious diseases.

Barney S GRAHAM
Deputy Director
National Institute of Allergy and Infectious Diseases, USA

Dr. Graham is Deputy Director of NIAID Vaccine Research Center and Chief, Viral Pathogenesis Laboratory. Undergraduate at Rice University, MD from University of Kansas School of Medicine, PhD in Microbiology & Immunology, Internal Medicine residency, chief residencies, and fellowship in Infectious Diseases from Vanderbilt University School of Medicine. He directs basic laboratory research on structural basis for antibody-mediated viral neutralization and basic mechanisms of T cell function and regulation. He also provides oversight for advanced development of candidate VRC vaccines and designs novel vaccine approaches for respiratory virus infections and emerging viral diseases including RSV, influenza, MERS, Nipah, and Zika.

Frederick Glen HAYDEN
Professor Emeritus
University of Virginia School of Medicine, USA

Dr. Hayden is Stuart S. Richardson Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine at the University of Virginia School of Medicine, Charlottesville, Virginia. He joined the faculty of the University of Virginia in 1978, became Richardson Professor in 1990, and transitioned to emeritus status in 2015. During 2006-2008 he served as medical officer in the Global Influenza Programme at the World Health Organization, Geneva and during 2008-2012 as influenza research coordinator at the Wellcome Trust, London. His principle research interests have focused on the development of antiviral agents for influenza and other respiratory viral infections. He has published over 400 peer-reviewed articles, chapters, and reviews, and co-edits the textbook Clinical Virology published by ASM Press.

Yoshihiro KAWAOKA
Professor
University of Wisconsin-Madison, USA
University of Tokyo, Japan

Dr. Yoshihiro Kawaoka was educated in Japan, receiving his DVM in 1978 and his PhD in 1983 from Hokkaido University. Dr. Kawaoka established the technique of reverse genetics, which allows the generation of 'designer' influenza viruses. This technology – coupled with his findings regarding the weakening of deadly influenza viruses – has been used to develop candidate bird flu virus vaccines. Dr. Kawaoka discovered what makes bird flu viruses so deadly and what makes bird flu jump from birds to humans. In recognition of his achievements, Dr. Kawaoka was awarded the Robert Koch Award in 2006; he received the Japan Academy Award in 2016 from the Emperor of Japan. In 2013, he was elected as a Foreign Associate of the United States National Academy of Sciences. In 2015, he received the UNESCO Carlos J. Finlay Prize for Microbiology.

Gabriel Matthew LEUNG
Dean
The University of Hong Kong, Hong Kong

Gabriel Leung is the fortieth Dean of Medicine (2013-), inaugural Helen and Francis Zimmer Professor in Population Health and holds the Chair of Public Health Medicine at the University of Hong Kong (HKU). He was Hong Kong's first Under Secretary for Food and Health (2008-11) and fifth Director of the Chief Executive's Office (2011-2) in government.

Leung is one of Asia's leading epidemiologists and global health exponents, having authored more than 450 scholarly papers with an h-index of 60 (Scopus). He is an elected member of the US National Academy of Medicine (NAM).

He was inaugural Chair (2010-4) of the Asia Pacific Observatory on Health Systems and Policies and continues to chair its Strategic and Technical Advisory Committee (2018-). Leung regularly advises national and international agencies including the World Health Organization, World Bank, Asian Development Bank, Boao Forum for Asia, Institut Pasteur, Japan Center for International Exchange and China Centers for Disease Control and Prevention. He is an Adjunct Professor of Peking Union Medical College and Adjunct Professorial Researcher of the China National Health Development Research Center.

Arnold S MONTO
Professor
University of Michigan School of Public Health, USA

Arnold S. Monto, MD is the Thomas Francis Jr. Professor at the University of Michigan School of Public Health. The focus of his work has been the epidemiology, prevention and treatment of acute infections in the individual and the community. He led the studies of respiratory infection in Tecumseh, MI, a landmark study of infection in the community, and is now updating these observations in Michigan households with children. Dr. Monto is has been involved in assessing the efficacy of various types of influenza vaccines in prophylaxis and antivirals in prophylaxis and therapy of influenza. He now heads observational studies of effectiveness of influenza vaccines in various settings. He is a past president of the American Epidemiological Society, the 2009 recipient of the Alexander Fleming Award of the Infectious Diseases Society of America for lifetime achievement and the 2012 recipient of the Charles Merieux award of the National Foundation for Infectious Diseases

KEYNOTE & PLENARY SPEAKERS

Malik PEIRIS
Professor Chair of Virology
The University of Hong Kong, Hong Kong

Professor Malik Peiris is a clinical and public health virologist with a particular interest in emerging virus disease using a "One Health" approach. His research encompasses the pathogenesis, transmission and ecology of human and animal influenza viruses. He provided understanding on the emergence and pathogenesis of the 2009 pandemic H1N1 virus and on avian influenza viruses H5N1, H9N2 and H7N9 and provided evidence-based options for control of avian viruses in poultry. In 2003, he discovered a novel coronavirus was the cause of SARS. Currently he is researching the recently emerged MERS coronavirus.

Kanta SUBBARAO
Director
Peter Doherty Institute for Infection and Immunity, Australia

Dr. Kanta Subbarao is the Director of the WHO Collaborating Centre for Reference and Research on Influenza and Professor, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity. She is a virologist and a physician with specialty training in paediatrics and paediatric infectious diseases. Her current research efforts are directed at understanding the biology and immune responses to influenza viruses and vaccines. She is a Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America. She serves on the Editorial Board of PLoS Pathogens and mBio.

Daniel Bruce JERNIGAN
Director
U.S. Centers for Disease Control and Prevention, USA

Daniel B. Jernigan, MD MPH is the Director of the Influenza Division in the National Center for Immunization and Respiratory Diseases at CDC where he is responsible for oversight and direction of over 300 staff executing a broad scientific program to improve the detection, prevention, treatment, and response to seasonal, novel, and pandemic influenza. The Influenza Division is responsible for national and global surveillance of influenza, serves as a World Health Organization Collaborating Center for the Surveillance, Epidemiology and Control of Influenza, and provides ongoing risk assessment of emerging influenza viruses to inform domestic and international responses.

Ann MOEN
Chief
World Health Organization,Switzerland

Ann Moen is Chief, Influenza Preparedness and Response at WHO. For 18 years she worked at US CDC to develop the Influenza Division's international capacity building program to support capacity for laboratory, surveillance and response in more than 50 countries. Prior experience includes working with Community and Migrant Health Centers in the US for the delivery of healthcare to the underserved and as a microbiologist at CDC in the BSL4 laboratory on Ebola, Lassa and other hemorrhagic fever pathogens. Her career started as a Peace Corps volunteer in rural Thailand at a District Hospital on laboratory diagnostics and quality control.

Michael RYAN
Executive Director
World Health Organization, Switzerland

Dr Mike Ryan has been at the forefront of managing acute risks to global health for nearly 25 years. He served as Assistant Director-General for Emergency Preparedness and Response in WHO's Health Emergencies Programme from 2017 to 2019.

Dr Ryan first joined WHO in 1996, with the newly established unit to respond to emerging and epidemic disease threats. He has worked in conflict affected countries and led many responses to high impact epidemics. He is a founding member of the Global Outbreak Alert and Response Network (GOARN), which has aided the response to hundreds of disease outbreaks around the world. He served as Coordinator of Epidemic Response (2000-2003), Operational Coordinator of WHO's response to the SARS outbreak (2003), and as WHO's Director of Global Alert and Response (2005-2011)

He was a Senior Advisor on Polio Eradication for the Global Polio Eradication Initiative from 2013 to 2017, deploying to countries in the Middle East.

He completed medical training at the National University of Ireland, Galway, a Master's in Public Health at University College Dublin, and specialist training in communicable disease control at the Health Protection Agency in London and the European Programme for Intervention Epidemiology Training.

Katelijn VANDEMAELE
World Health Organization, Switzerland

Dr Katelijn Vandemaele started her career as a General Practitioner in Belgium. She picked up interest for public health during the post-graduate courses in tropical medicine (Antwerp). In 1996 she joined the then newly created division of Emerging and Other communicable diseases (EMC) in WHO, Geneva led by Dr David Heymann. She worked for two years in Public Health in the Oxford Region (UK) and obtained a masters in public health at the University of Birmingham (UK). Since 2000, she has been working in several departments in WHO Geneva on emerging and re-emerging diseases, and involved in outbreaks of SARS, H5N1, H7N9, the pandemic 2009 and MERS CoV. In the past ten years, she has been focusing on epidemiology and surveillance of seasonal, zoonotic and pandemic influenza.

KEYNOTE & PLENARY SPEAKERS

Wenqing ZHANG
Head
World Health Organization, Switzerland

Heading the Global Influenza Programme of WHO in its headquarters in Geneva Switzerland since November 2012, Dr Zhang provides leadership and coordinates global activities on influenza surveillance, virus monitoring, detection of emerging novel viruses, risk assessment and evidence for policies, vaccine virus and pandemic preparedness including pandemic influenza vaccine response. From 2002 to 2012, Dr Zhang coordinated the WHO Global Influenza Surveillance and Response System (GISRS), building and functioning the global system of surveillance, preparedness and response. In response to 2009 A(H1N1) influenza pandemic, Dr Zhang directed the Laboratory Response and Capacity of WHO response. Before joining WHO, Dr Zhang worked for 9 years in the Chinese Academy of Preventive Medicine, Ministry of Health on tuberculosis, schistosomiasis and iodine deficiency disorder initiatives in collaboration with WHO, World Bank, UNICEF and UNIDO. MD by education with postgraduate training on system evaluation and epidemiology and a bachelor degree on biomedical engineering.

SESSION SPEAKERS

Galit ALTER
Professor
Medicine
Ragon Institute of MGH, MIT and Harvard, USA

Melisa Kathryn ANDREW
Associate Professor
Geriatric Medicine
Dalhousie University and Canadian Centre for Vaccinology, Canada

Wendy Sue BARCLAY
Professor
Infectious Disease
Imperial College London, UK

David L.V. BAUER
Sir William Dunn School of Pathology
University of Oxford, UK

Trevor BEDFORD
Associate Member
Vaccine and Infectious Disease Division
Fred Hutchinson Cancer Research Center, USA

John BEIGEL
Associate Director
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, USA

Jesse BLOOM
Associate Member Fred Hutch; Investigator HHMI
Basic Sciences
Fred Hutch Cancer Research Center, Howard Hughes Medical Institute, USA

Andrew Scott BOWMAN
Assistant Professor
Veterinary Preventive Medicine
The Ohio State University, USA

Rick A. BRIGHT, PhD
Deputy Assistant Secretary for Preparedness and Response
Director of the Biomedical Advanced Research and Development Authority (BARDA)
U.S. Department of Health and Human Services, USA

Bin CAO
Chief physician, Professor
Respiratory and Critical Care Department
China-Japan Friendship Hospital, China

Simon CAUCHEMEZ
Research Director
Mathematical Modelling of Infectious Diseases Unit
Institut Pasteur, France

Hualan CHEN
Director
Animal Influenza Laboratory,
Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China

Mark I-Cheng CHEN
Assistant Professor
Saw Swee Hock School of Public Health
National University of Singapore, Singapore

Christopher CHIU
Clinical Senior Lecturer
Infectious Diseases
Imperial College London, UK

SESSION SPEAKERS

Chee Kheong CHONG
Deputy Director
Public Health
Ministry of Health, Malaysia

Sarah COBEY
Associate Professor
Ecology & Evolution
University of Chicago, USA

Alex R COOK
Associate Professor
Saw Swee Hock School of Public Health
National University of Singapore, Singapore

Stephen CUSACK
Head
EMBL Grenoble
European Molecular Biology Laboratory, France

Robert DE VRIES
Principle Investigator
Chemical Biology
Utrecht Institute for Pharmaceutical Sciences,
The Netherlands

William Jake DUNNING
Consultant in Infectious Diseases
National Infection Service
Public Health England, UK

Luzhao FENG
Professor
Division of Infectious Diseases
Chinese Center for Disease Control and Prevention,China

Brendan FLANNERY
Epidemiologist
Influenza Division
Centers for Disease Control and Prevention,
Atlanta, USA

Martin FRIEDE
Co-ordinator for the Initiative for Vaccine Research
Immunization, Vaccines and Biologicals
World Health Organization, Switzerland

Supamit CHUNSUTTIWAT
Advisor
Disease Control
Ministry of Public Health, Thailand

Cheryl COHEN
Centre Head and Associate Professor
Centre for Respiratory Diseases and Meningitis (CRDM) and
Wits School of Public Health
National Institute for Communicable Diseases, a division of the National Health Laboratory Service and University of the Witwatersrand, South Africa

Benjamin John COWLING
Professor
School of Public Health
The University of Hong Kong, Hong Kong

Thushantha Indrajit DE SILVA
Wellcome Trust Intermediate Clinical Fellow
Vaccines and Immunity Theme
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, UK

Vijaykrishna DHANASEKARAN
Associate Professor
Microbiology
Monash University, Australia

Ann Regina FALSEY
Professor of Medicine
Infectious Disease
University of Rochester, USA

William A. FISCHER II
Assistant Professor
Division of Pulmonary and Critical Care Medicine,
Department of Medicine
The University of North Carolina at Chapel Hill School of Medicine, USA

Annette FOX
Immunologist, Senior Research Scientist
WHO Influenza Centre
Doherty Institute, Australia

Sarah Catherine GILBERT
Professor
Jenner Institute
University of Oxford, UK

SESSION SPEAKERS

Larisa GUBAREVA
Lead of the Molecular Epidemiology Team
Influenza Division
Centers for Disease Control and Prevention, USA

Sander HERFST
Assistant Professor and Workgroup Leader
Viroscience
ErasmusMC Rotterdam, The Netherlands

David Shu-Cheong HUI
Professor
Medicine & Therapeutics
The Chinese University of Hong Kong, Hong Kong

Ivan Fan Ngai HUNG
Clinical Professor
Medicine
The University of Hong Kong, Hong Kong

Aeron Christopher HURT
Associate Professor and Senior Principal Research Scientist
WHO Collaborating Centre for Reference and Research on Influenza
Peter Doherty Institute, Australia

Michael Grundle ISON
Medical Director
Infectious Diseases
Northwestern University, USA

Angela Danielle IULIANO
Infectious Diseases Epidemiologist
Influenza Division
Centers for Disease Control and Prevention, USA

Lance CORDNER JENNINGS
CHAIR, ISIRV, Associate Professor
Pathology Department
University of Otago, New Zealand

Chengyu JIANG
Professor, Executive Vice Dean
School of Basic Medicine
Peking Union Medical College and Chinese Academy of Medical Sciences,
China

Katherine KEDZIERSKA
Professor and Laboratory Head
Microbiology and Immunology
University of Melbourne, Australia

Insik KONG
Director,
Division of TB, HIV & AIDS Control, Center for Disease Prevention
Korea Centers for Disease Control and Prevention,
Ministry of Health and Welfare, Republic of Korea

Florian KRAMMER
Professor
Microbiology
Icahn School of Medicine at Mount Sinai, USA

Adam James KUCHARSKI
Associate Professor
Infectious Disease Epidemiology
London School of Hygiene & Tropical Medicine, UK

Thijs KUIKEN
Professor of Comparative Pathology
Viroscience
Erasmus University Medical Centre,
The Netherlands

Deepali KUMAR
Professor of Medicine
Transplant Infectious Diseases
University Health Network, Canada

Jeff KWONG
Professor, Epidemiologist
Populations and Public Health
ICES, Canada

Seema Sailesh LAKDAWALA
Assistant Professor
Microbiology and Molecular Genetics
University of Pittsburgh, USA

Ryan Andrew LANGLOIS
Assistant Professor
Microbiology and Immunology
University of Minnesota, USA

SESSION SPEAKERS



Nelson LEE
Professor
Medicine, Infectious Diseases
University of Alberta, Canada

Vernon LEE
Director
Communicable Diseases Division
Ministry of Health, Singapore

Xiaofeng LIANG
Vice President and Secretary general
Chinese Preventive Medicine Association,China

Anice LOWEN
Associate Professor
Microbiology and Immunology
Emory University School of Medicine, USA

Sebastian MAURER-STROH
Deputy Executive Director (Research), Programme Director Human Infectious Diseases Bioinformatics Institute (BII)
*A*STAR, Singapore*



Andrew MEHLE
Associate Professor
Medical Microbiology & Immunology
University of Wisconsin Madison, USA

Donald K MILTON
Professor
Maryland Institute for Applied Environmental Health
University of Maryland School of Public Health, USA

Robert MOSS
Research Fellow
Melbourne School of Population and Global Health
The University of Melbourne, Australia

Martha Irene NELSON
Staff Scientist
Fogarty International Center
National Institutes of Health, USA

Marta Coelho NUNES
Associate Professor
Vaccine Preventable Diseases Unit
University of the Witwatersrand, South Africa

Albert OSTERHAUS
Founding Director, Professor
RIZ
TiHO, Hannover, Germany

Colin Ross PARRISH
Baker Institute, Microbiology and Immunology
Cornell University, USA

Andrew Tobias PAVIA
Professor and Chief
Division of Pediatric Infectious Diseases
University of Utah, USA

Richard Gordon PEBODY
Consultant Medical Epidemiologist
Immunisation Division
Public Health England, UK

Mario Andrés PIZZORNO
Post-doctoral researcher at CIRI and co-founder of Signia Therapeutics
VirPath Laboratory
Centre International de Recherche en Infectiologie (CIRI), France



Richard Karl PLEMPER
Professor
Institute for Biomedical Sciences
Georgia State University, USA

Barbara A RATH
Co-founder & Chair
Infectious Diseases & Vaccines
Vienna Vaccine Safety Initiative, Germany and USA

Carrie REED
Epidemiologist
Influenza Division
Centers for Disease Control and Prevention, USA

SESSION SPEAKERS

Pejman ROHANI
Georgia Athletic Association Professor
University of Georgia, USA

Ted Milburn ROSS
Director
Center for Vaccines and Immunology
University of Georgia, USA

Colin Andrew RUSSELL
Professor
Medical Microbiology
AMC, University of Amsterdam, The Netherlands

Andrea J SANT
Professor
David H. Smith Center for Vaccine Biology and Immunology
University of Rochester Medical Center, USA

Stacey Lynne SCHULTZ-CHERRY
Professor
Infectious Diseases
St. Jude Children's Research Hospital, USA

Martin SCHWEMMLE
Professor
Institute of Virology
Medical Center - University of Freiburg, Germany

Malcolm G SEMPLE (Calum SEMPLE)
Professor
Child Health & Outbreak Medicine
University Of Liverpool, UK

SENG Heng MD, FETP, MPH
Director of Disease Surveillance Bureau
Communicable Disease Control
Ministry of Health, Cambodia

Jeffrey Louis SHAMAN
Professor
Environmental Health Sciences
Columbia University, USA

Nahoko SHINDO
Professor, Medical officer in charge of Expert Networks
Infectious Hazard Management
World Health Organization, Switzerland

Yuelong SHU
Dean
School of Public Health (Shenzhen)
Sun Yat-sen University,China

Danuta M SKOWRONSKI
Physician Epidemiologist
Influenza and Emerging Respiratory Pathogens
British Columbia Centre for Disease Control, Canada

Padmini SRIKANTIAH
Senior Program Officer
Pneumonia, Global Health
Bill & Melinda Gates Foundation, USA

Sheena SULLIVAN
Head of Epidemiology and Associate Professor Epidemiology
WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

Paul Anantharajah TAMBYAH
Professor
Medicine
National University of Singapore, Singapore

Paul GLYNDWR THOMAS
Member
Immunology
St. Jude Children's Research Hospital, USA

Andrew THOMPSON
Staff Scientist
Molecular Medicine
Scripps Research Institute, USA

Mark Gregory THOMPSON
Epidemiologist
Influenza Division
US Centers for Disease Control and Prevention, USA

SESSION SPEAKERS

Stephen Mark TOMPKINS
Professor
Center for Vaccines and Immunology
University of Georgia, USA

Tim UYEKI
Chief Medical Officer
Influenza Division
Centers for Disease Control and Prevention, USA

Kristien VAN REETH
Professor
Laboratory of Virology
Faculty of Veterinary Medicine, Ghent University, Belgium

Jonathan Nguyen VAN TAM
Deputy Chief Medical Officer, Professor
Department of Health and Social Care, UK

Dayan WANG
Dayan WANG
Director
Chinese National Influenza Center
National Institute for Viral Disease Control and Prevention,China

Steven Anthony WEBB
Senior Staff Specialist, Professor
Intensive Care
Royal Perth Hospital, Australia

Patrick C WILSON
Professor
Medicine / Rheumatology
University of Chicago, USA

Christopher W WOODS
Professor
Medicine and Pathology
Duke University, USA

Hui-Ling YEN
School of Public Health
The University of Hong Kong, Hong Kong

Barnaby Edward YOUNG
Consultant
Infectious Diseases
National Centre for Infectious Diseases, Singapore

Hongjie YU
Professor
School of Public Health
Fudan University,China

Maria ZAMBON
Professor, Virologist,
UK National Microbiology Focal Point
Public Health England, UK

Nanshan ZHONG
Professor of Respiratory Medicine, Senior Principal Investigator of Guangzhou Medical University; Academician of Chinese Academy of Engineering; Director of the National Clinical Research Center for Respiratory Diseases
Respiratory Medicine
The First Affiliated Hospital of Guangzhou Medical University; The National Clinical Research Center for Respiratory Diseases,China

Hassan ZARAKET
Assistant Professor
Experimental Pathology, Immunology, and Microbiology
Faculty of Medicine, American University of Beirut, Lebanon



Maria Huachen ZHU
Tenured Associate Professor
School of Public Health
The University of Hong Kong, Hong Kong

Lei ZHOU
Senior Researcher, Chief of Branch
Branch for Emerging Infectious Disease
Public Health Emergency Center in Chinese Center for Disease Control and Prevention,
China

SPONSORED LUNCH SYMPOSIUM

SANOFI PASTEUR

Sanofi Pasteur Lunch Symposium

Date : **Thursday, 29 August 2019**
Time : **12:00pm - 1:30pm**
Venue : **Hall 406CX, Level 4**
Title : **Beyond Acute Respiratory Disease: How to Demonstrate the Full Public Health Impact of Influenza and its Prevention**
Chair : **Robert Booy**
/Senior Professorial Fellow at Australia's National Centre for Immunisation Research and Surveillance; Professor, The University of Sydney, Australia/

AGENDA

12:00pm	**Lunch Distribution**
12:15pm	**Changing the paradigm: the domino effect of influenza - beyond the respiratory disease** **Robert Booy** */Senior Professorial Fellow at Australia's National Centre for Immunisation Research and Surveillance; Professor, The University of Sydney, Australia/*
	Cardiovascular complications of influenza **Charlotte Warren Gash** */Assoc. Prof., London School of Hygiene & Tropical Medicine, UK/*
	Evaluating the impact of influenza vaccines on cardiovascular outcomes - an industry perspective **Rosalind Hollingsworth** */Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA/*

SPONSORED EVENING SYMPOSIUM

Roche

Hoffmann La-Roche Evening Symposium

Date : **Thursday, 29 August 2019**
Time : **6:00pm - 7:30pm**
Venue : **Hall 406CX, Level 4**
Title : **Can we stop flu going viral?**
Chair : **Arnold Monto** */University of Michigan, USA/*

AGENDA

6:00pm	**Tea Reception**
6:30pm	**Chair's welcome and introduction** **Arnold Monto** */University of Michigan, USA/*
	Influenza transmission: insights from the primary care perspective **Hoe Nam Leong** */Rophi Clinic, Mt Elizabeth Novena Hospital, Singapore/*
	Transmission in animal models: what have we learned from the ferret? **Wendy Barclay** */Imperial College, London, UK/*
	Transmission in humans: learnings and limitations **Aeron Hurt** */University of Melbourne, Australia/ Roche Basel, Switzerland/*
	Panel discussion and Q&A **Close** **Arnold Monto** */University of Michigan, USA/*

SPONSORED LUNCH SYMPOSIUM

Seqirus™
A CSL COMPANY

Seqirus Lunch Symposium

Date : **Friday, 30 August 2019**
Time : **12:30pm - 2:00pm**
Venue : **Hall 406CX, Level 4**
Title : **Raising Defenses: Strengthening Influenza Protection**

AGENDA

12:30pm	**Lunch Distribution**
12:45pm	**Identifying the threats: Evaluating the unmet needs in influenza vaccination** **John S. Tam** */Hong Kong/*
12:50pm	**Protecting against an elusive enemy: The challenge of strain mismatch and egg mutagenesis** **Catherine Moore** */United Kingdom/*
1:05pm	**Shielding the vulnerable: Improving effectiveness through adjuvanted vaccines** **Terry Nolan** */Australia/*
1:20pm	**Defending against the threat of a pandemic: How prepared are we?** **Andrew Pavia** */United States/*
1:35pm	**Close** **John S. Tam** */Hong Kong/*

SPONSORED LUNCH SYMPOSIUM

gsk

GSK Lunch Symposium

Date : **Saturday, 31 August 2019**
Time : **12:30pm - 2:00pm**
Venue : **Hall 406CX, Level 4**
Title : **Prevention of Paediatric Influenza: Why and How?**
Chair : **Ab Osterhaus**
/Professor and Founding Director of the Research Center for Emerging Infections and Zoonoses University of Veterinary Medicine, Hannover, Germany/

AGENDA

12:30pm	**Lunch Distribution**
12:45pm	**Welcome and Introduction** **Ab Osterhaus** */Professor and Founding Director of the Research Center for Emerging Infections and Zoonoses University of Veterinary Medicine, Hannover, Germany/*
12:50pm	**Burden of paediatric influenza** **Robert Booy** */Infectious Diseases Paediatrician & Immunisation expert National Centre for Immunisation Research and Surveillance (NCIRS), Sydney/*
1:05pm	**Efficacy and safety of an inactivated influenza vaccine in the paediatric population** **Halima Tahrat** */Senior Medical Manager Influenza Vaccines, GSK Vaccines, USA/*
1:15pm	**Paediatric influenza vaccination: recommendations and implementation** **Ab Osterhaus** */Professor and Founding Director of the Research Center for Emerging Infections and Zoonoses University of Veterinary Medicine, Hannover, Germany/*
1:30pm	**Discussion and Q&A**

GSK invites you to a
Satellite Symposium:

Prevention of paediatric influenza: why and how?

vaccinate for life

Saturday 31st August 2019
12:45 – 13:45
Level 4 Suntec-Room 406 CX
Options X, Singapore

Agenda

Welcome and introduction

- **Burden of paediatric influenza**
- **Efficacy and safety of an inactivated influenza vaccine in the paediatric population**
- **Paediatric influenza vaccination: recommendations and implementation**

Discussion and Q&A

Chair — **Prof Albert Osterhaus**

Expert Panel — **Prof Robert Booy**
Dr Halima Tahrat
Prof Albert Osterhaus

Fluarix Tetra- Southern Hemisphere 2019 Season
Singapore Abbreviated Prescribing Information
ACTIVE INGREDIENT: Fluarix Tetra is an inactivated influenza vaccine (split virion), containing antigens (propagated in embryonated eggs) equivalent to the following types and subtypes: A/Michigan/45/2015 (H1N1)pdm09-like strain (A/Singapore/GP1908/2015, IVR-180); A/Switzerland/8060/2017 (H3N2)-like strain (A/Brisbane/1/2018,NYMC X-311); B/Colorado/06/2017-like (B/Maryland/15/2016, NYMC BX-69A); and B/Phuket/3073/2013-like virus (B/Phuket/3073/2013, wild type). Each 0.5 ml vaccine dose contains 15 µg haemagglutinin of each of the recommended strains. This vaccine complies with the World Health Organization (WHO) recommendation (Southern Hemisphere) for the **2019** season. Each 0.5 ml vaccine dose contains 15µg haemagglutinin of each of the recommended strains. Fluarix Tetra may contain traces of Formaldehyde, Sodium Deoxycholate, Ovalbumin, Gentamicin sulphate and Hydrocortisone. The maximum amount of Ovalbumin that may be present is not more than 0.05 micrograms per dose. **INDICATIONS:** For active immunization of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. The use of Fluarix Tetra should be based on official recommendations. **DOSAGE AND ADMINISTRATION:** Adults and Children from 6 months onwards: 0.5 ml via intramuscular route of injection. For children aged < 9 years, who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks. **CONTRAINDICATIONS:** Hypersensitivity to the active substances or to any of the excipients or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins) formaldehyde, gentamicin sulphate and sodium deoxycholate. Immunization should be postponed in patients with febrile illness or acute infection. **WARNINGS AND PRECAUTIONS:** It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination. As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient. Fluarix Tetra is not effective against all possible strains of influenza virus. Fluarix Tetra is intended to provide protection against those strains of virus from which the vaccine is prepared and to closely related strains. As with any vaccine, a protective immune response may not be elicited in all vaccinees. **FLUARIX TETRA SHOULD UNDER NO CIRCUMSTANCES BE ADMINISTERED INTRAVASCULARLY.** As with other vaccines administered intramuscularly, Fluarix Tetra should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. **INTERACTIONS:** If Fluarix Tetra is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites. **EFFECTS ON ABILITY TO DRIVE AND USE OF MACHINES:** Fluarix Tetra has no or negligible influence on the ability to drive and use machines. **PREGNANCY AND LACTATION:** Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of inactivated influenza vaccines do not indicate any adverse foetal and maternal outcomes attributable to the vaccine. Fluarix Tetra may be used during breast-feeding.**UNDESIRABLE EFFECTS:** Adverse reactions reported in the different age groups are listed per dose according to the frequency categories: **Very common:** irritability[1], myalgia, injection site pain, fatigue. **Common:** appetite loss[1], drowsiness[1], headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), arthralgia, injection site redness[4], injection site swelling[4], shivering, fever, sweating, injection site induration. Uncommon: dizziness[2], rash[3], injection site hematoma[2], injection site pruritus. **Note:** 1: reported as a solicited symptom in subjects less than 6 years of age. 2: Reported in adult subjects. 3: Reported in subjects 3 years to 17 years of age. 4: Very common in subjects 3 years to 17 years of age. **Post-marketing data:** There has been no post-marketing exposure to Fluarix Tetra. However, as all three of the influenza strains contained in Fluarix are included in Fluarix Tetra, the following adverse events that have been observed for Fluarix during post-marketing surveillance may occur in patients receiving Fluarix Tetra post-approval. **Rare:** Transient lymphadenopathy, allergic reactions (including anaphylactic reactions), neuritis, acute disseminated encephalomyelitis, Guillain-Barré syndrome*, urticaria, pruritus, erythema, angioedoema, influenza-like illness, malaise. *Spontaneous reports of Guillain-Barré syndrome have been received following vaccination with Fluarix; however, a causal association between vaccination and Guillain-Barré syndrome has not been established. **OVERDOSE:** Insufficient data are available.

Please read the full prescribing information prior to administration, available GlaxoSmithKline Pte Ltd. 23 Rochester Park, Singapore 139234 Tel.+65 6232 8338 Fax +65 6291 9737

Full Prescribing Information is available on request. Version abbrev: GDS03/IPI11SI (SH)

For reporting of adverse events please write to: sg.drugsafety@gsk.com.

PM-GBL-FLQ-ADVT-190002 Preparation date: June 2019

For Healthcare Professionals Only. All images used in this material are for illustration purposes only.
GlaxoSmithKline Pte Ltd. 23 Rochester Park, Singapore 139234
© 2019 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies

ORAL PRESENTATION LISTINGS

Date: 29 August 2019, Thursday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 10.30am - 12:00pm			
Clinical Sciences: Clinical Trials - Treatment and Prevention			
10563	Nathan Brendish	Session 1 : Clinical I	The impact of syndromic molecular point-of-care testing for respiratory viruses in adults presenting to hospital with exacerbation of airways disease: further analysis form a randomised controlled trial
Clinical Sciences: Diagnostics and Disease Markers			
10565	Nathan Brendish	Session 1 : Clinical I	Evaluation of the febridx host response point-of-care test to differentiate viral from bacterial aetiology in adults hospitalised with acute respiratory illness during influenza season
Public Health: Vaccine Effectiveness/Impact			
10311	George Okoli	Session 1: Vaccine Efficacy/ Effectiveness (I)	Variations In Seasonal Influenza Vaccine Effectiveness Due To Biological Characteristics: A Systematic Review And Meta-Analysis Of Test-Negative Design Studies
10395	Hung Fu Tseng	Session 1: Vaccine Efficacy/ Effectiveness (I)	Vaccine Effectiveness Against Influenza Hospitalization In The 2018-2019 Season: Comparison Between Cell-Based And Egg-Based Influenza Vaccines
10499	Robertus van Aalst	Session 1: Vaccine Efficacy/ Effectiveness (I)	Relative Vaccine Effectiveness Of High Dose Versus Adjuvanted Influenza Vaccine: A Retrospective Cohort Study
10881	Jeff Kwong	Session 1: Vaccine Efficacy/ Effectiveness (I)	Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Mortality In Older Adults
Virology and Pathogenesis: Virus Pathogenesis & Transmission			
10440	Siwen LIU	Session 1: Virus Pathogenesis & Transmission	Autophagy-mediated restriction of avian influenza virus replication in mammalian cells
10855	Honglei Sun	Session 1: Virus Pathogenesis & Transmission	Haemagglutinin mutation and higher neuraminidase activity enhanced the adaption of H5N6 avian influenza viruses to mammalian hosts
10945	Ian Brown	Session 1: Virus Pathogenesis & Transmission	Assessment Of Zoonotic Transmission Of Swine Influenza A Viruses From Pigs To Naïve Or Vaccinated Ferrets
Time: 2.30pm - 4.00pm			
Clinical Sciences: Diagnostics and Disease Markers			
10750	Larisa Gubareva	Session 2 : Clinical II	Seasonal And Other Influenza Viruses With Reduced Susceptibility To Baloxavir And Pimodivir
10877	Rangaraj Selvarangan	Session 2 : Clinical II	Rapid Molecular Testing For Influenza In Children Improves Patient Management In Acute Care Setting
Co-Infection: Bacterial Co-infections with Influenza			
10904	Edin Mifsud	Session 2: Co-infection	Evaluating The Window Of Susceptibility To Secondary Bacterial Infections Post-Influenza Infection In Ferrets
10912	Win Mar Kyaw	Session 2: Co-infection	Epidemiology Of Influenza-Associated Community-Acquired Pneumonia Admissions: A 7-Year Retrospective Cohort Study In Singapore
Public Health: Vaccine Effectiveness/Impact			
10983	Danuta Skowronski	Session 2: Vaccine Efficacy/ Effectiveness (II)	Viral Genomic Variation And Vaccine Effectiveness Across Consecutive Influenza A(H3N2) Epidemics In Canada, 2016-17 And 2017-18
11047	Esther Kissling	Session 2: Vaccine Efficacy/ Effectiveness (II)	Birth Cohort-Specific Vaccine Effectiveness Against Influenza A(H1N1)Pdm09 In Seasons With Different A(H1N1)Pdm09 Virus Vaccine Components, I-Move Multicentre Primary Care Study, Europe, 2013/14 To 2018/19

ORAL PRESENTATION LISTINGS

Date: 29 August 2019, Thursday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 2.30pm - 4.00pm			
Virology and Pathogenesis: Influenza Glycobiology			
10964	Lauren Byrd-Leotis	Session 3: Influenza Glycobiology	Seasonal H1N1 And Antigenically Drifted H3N2 Influenza Viruses That Have Limited Binding To Sialic Acid Bind To Phosphorylated High Mannose Glycans From The Human Lung
11089	Michael Vahey	Session 3: Influenza Glycobiology	Influenza A Virus Surface Proteins Are Organized To Help Penetrate Host Mucus
Time: 4.30pm - 6.00pm			
Clinical Sciences: Clinical Trials - Treatment and Prevention			
10753	Simon Portsmouth	Session 3 : Clinical III	Emergence Of Viruses With Reduced Susceptibility To Baloxavir Marboxil: Impact On Clinical And Virologic Outcomes In Patients With Influenza At High Risk Of Complications (Capstone-2)
Clinical Sciences: Therapeutics – Antivirals			
10900	Xin Liu	Session 3 : Clinical III	Neuraminidase-Targeted Hapten Immunotherapy To Treat Influenza
Public Health: Surveillance & Forecasting			
10347	Matthew Biggerstaff	Session 3: Surveillance & Forecasting	Flusight: Six Seasons Of Forecasting Influenza In The United States, 2013–14 To 2018–19
11184	Xiu-Feng (Henry) Wan	Session 3: Surveillance & Forecasting	Globalization Complicated Emergence And Spread Of H3N2 Seasonal Influenza A Viruses

Date: 30 August 2019, Friday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 10.30am - 12.30pm			
Clinical Sciences: Clinical Trials - Treatment and Prevention			
11127	Yu-Hsiang Hsieh	Session 4 : Clinical IV	Intravenous Peramivir In Emergency Department High-Risk Patients With Influenza: A Multicenter Randomized Controlled Study
11217	Dennis Kai Ming Ip	Session 4 : Clinical IV	A Randomized Controlled Trial On The Effect Of Fever Suppression By Antipyretics On Influenza
Clinical Sciences: Therapeutics – Antivirals			
10475	Emi Takashita	Session 4 : Clinical IV	Human-To-Human Transmission Of Influenza A(H3N2) Viruses Exhibiting Reduced Susceptibility To Baloxavir Due To A PA I38T Substitution In Japan
11025	Sam Lee	Session 4 : Clinical IV	Development Of A New Class Of Broad Spectrum Influenza PB2 Inhibitors
11286	Yeming Wang	Session 4 : Clinical IV	Pharmacokinetics Of Favipiravir (T-705) In Combination With Oseltamivir For Treatment Of Critically ill Patients With Severe Influenza
Virology and Pathogenesis: NextGen/Universal Vaccines			
10535	Daniel Stadlbauer	Session 4: NextGen/ Universal Vaccines	A Human Broadly Cross-Reactive Anti-Neuraminidase Antibody Protects Against Different Subtypes Of Influenza A And B Viruses In The Mouse Model
10880	Jae-Keun Park	Session 4: NextGen/ Universal Vaccines	Pre-Existing Immunity To The Conserved Hemagglutinin Stalk Of Influenza Virus May Drive Selection For An Escape Mutant Virus In Humans

ORAL PRESENTATION LISTINGS

Date: 30 August 2019, Friday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 10.30am - 12.30pm			
Virology and Pathogenesis: NextGen/Universal Vaccines			
10980	Lidia Oostvogels	Session 4: NextGen/ Universal Vaccines	RNACTIVE©: A Promising mRNA Based Influenza Vaccine
11110	Joseph Eiden	Session 4: NextGen/ Universal Vaccines	Intranasal M2SR (M2-Deficient Single Replication) Influenza Vaccine Induced Protection Against Challenge With A Substantially Drifted H3N2 Virus In A Phase 2 Study
11170	Adam Wheatley	Session 4: NextGen/ Universal Vaccines	Characterising Human Memory B Cells With Cross-Lineage Recognition Of The Influenza B Hemagglutinin Following Seasonal Immunisation
11735	Florian Krammer	Session 4: NextGen/ Universal Vaccines	Immunogenicity Of Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccine Candidates: Interim Results Of A Randomized, Placebo-Controlled, Phase 1 Clinical Trial
Public Health: Pandemic Preparedness			
10375	Min Levine	Session 4: Optimising Vaccine Strategies (I)	Heterologous Prime-Boost Using AS03 Adjuvanted A(H5N1) Pandemic Stockpiled Influenza Vaccines Induces Broader Cross-Clade Antibody Responses Than Homologous Prime-Boost
Public Health: Vaccine Effectiveness/Impact			
10385	Joshua Adam Mott	Session 4: Optimising Vaccine Strategies (I)	Comparison Of Influenza Antibody Titers Among Women Who Were Vaccinated In The 2nd And 3rd Trimesters Of Pregnancies
10390	Huong Mclean	Session 4: Optimising Vaccine Strategies (I)	Serologic Response To Sequential Influenza Vaccination In Older Adults From A Randomized Trial
10561	Surender Khurana	Session 4: Optimising Vaccine Strategies (I)	Repeat Vaccination Reduces Antibody Affinity Maturation Irrespective Of Influenza Vaccine Platform In Humans
10609	Huong Mclean	Session 4: Optimising Vaccine Strategies (I)	Does Strain Change Influence Vaccine Effectiveness Against Influenza A(H3N2)?
11171	Maria Auladell	Session 4: Optimising Vaccine Strategies (I)	Prior Infection Enhances The Magnitude And Breadth Of Anti-H3N2 Antibody Responses To Influenza Vaccination And Reduces The Risk Of Subsequent A/H3N2 Virus Infection
Time: 2.00pm - 4.00pm			
Virology and Pathogenesis: Immune Response to Infection			
10471	Carolien Van De Sandt	Session 5: Immune Response to Infection	Molecular And Functional Dissection Of The Influenza Virus-Specific CD8+ T-Cell Receptor Repertoire During Aging
10490	Hang Xie	Session 5: Immune Response to Infection	Broadened Cross-Reactive Immunity In Ferrets After Repeated Influenza A/H3 Exposures
10528	Julius Wong	Session 5: Immune Response to Infection	Annotation And Recovery Of Ferret-Specific Immunoglobulin Sequences
11035	Suzanna Paterson	Session 5: Immune Response to Infection	Innate-Like Signatures Of Influenza-Specific CD8+ Resident Memory T Cell Responses In The Human Lung
11216	Hyon-Xhi Tan	Session 5: Immune Response to Infection	Subdominance And Diminished TFH Elicitation Constrain Humoral Immunity Against The Influenza Ha-Stem

ORAL PRESENTATION LISTINGS

Date: 30 August 2019, Friday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 2.00pm - 4.00pm			
Public Health: Pharmaco-ecomonics, Cost-Effectiveness Studies			
10332	Pieter De Boer	Session 5: Optimising Vaccine Strategies (II)	Costs And Effects Of Childhood Influenza Vaccination In The Netherlands: Important Risk Of Undesirable Effects
10376	Mu Yue	Session 5: Optimising Vaccine Strategies (II)	Cost-Effective Analysis For Influenza Vaccination Coverage And Timing In Tropical And Subtropical Climate Settings: A Modelling Study
Public Health: Vaccine Effectiveness/Impact			
10749	David Jackson	Session 5: Optimising Vaccine Strategies (II)	Viral Shedding In Recipients Of Live Attenuated Influenza Vaccine In The 2016/17 And 2017/18 Influenza Seasons In The United Kingdom
10811	George Kassianos	Session 5: Optimising Vaccine Strategies (II)	The United Kingdom'S Childhood Influenza Vaccination Programme: Review Of Uptake And Vaccine Effectiveness Over The First Six Seasons
10913	Punam Mangtani	Session 5: Optimising Vaccine Strategies (II)	First Trimester Seasonal Influenza Vaccination And Major Congenital Malformations: A 2010-2016 Uk Retrospective Cohort Study
11195	Mary Anissa Sinnathamby	Session 5: Optimising Vaccine Strategies (II)	Impact Of The Introduction Of The Paediatric Live Attenuated Influenza Vaccine (LAIV) Programme: An Intercountry Comparison Across The United Kingdom And The Republic Of Ireland
Clinical Sciences: Development of Human Disease			
11345	Eduardo Azziz-Baumgartner	Session 5 : Special Populations - Clinical Aspects	Lower Cognition Among Toddlers Who Experience Acute Respiratory Illnesses In Panama And El Salvador
Clinical Sciences: Special Populations			
11300	Melissa K Andrew	Session 5 : Special Populations - Clinical Aspects	Long-Term Care/Nursing Home Admission Following Hospitalization With Influenza And Acute Respiratory Illness: The Role Of Social Vulnerability. A Report From The Canadian Serious Outcomes Surveillance Network.
Clinical Sciences: Therapeutics – Antivirals			
10712	Cornelia Adlhoch	Session 5 : Special Populations - Clinical Aspects	Effect Of Treatment With Neuraminidase Inhibitors On The Risk Of In-Hospital Death Among Influenza Patients Reported From Eu Countries, 2010–2019
11161	Chris Wallick	Session 5 : Special Populations - Clinical Aspects	Treating Influenza With Antivirals Is Associated With A Decreased Burden Of Complications And Health Resource Utilization In High Risk Patients
11163	Chris Wallick	Session 5 : Special Populations - Clinical Aspects	Impact Of Antiviral Therapy On Short- And Long-Term Outcomes Of Patients With Copd Following Influenza Infection
Time: 4.30pm - 6.00pm			
Clinical Sciences: Avian & Zoonotic Influenza - Human Infections			
10853	Ghazi Kayali	Session 6: Avian and Zoonotic Influenza	Incidence And Seroprevalence Of Avian Influenza Viruses Among Egyptian Backyard Poultry Growers: Results From A Prospective Cohort Study
Clinical Sciences: Clinical Trials – Vaccines			
10966	Ruben O. Donis	Session 6: Avian and Zoonotic Influenza	Clinical Evaluation Of Adjuvanted Recombinant Hemagglutinin H7 Vaccine To Highly Pathogenic A(H7N9) Influenza Virus

ORAL PRESENTATION LISTINGS

Date: 30 August 2019, Friday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 4.30pm - 6.00pm			
Virology and Pathogenesis: Cellular & Molecular Virology			
10698	Lin Zhu	Session 6: Cellular and Molecular Virology	Differential Regulation Of Post-Translational Modification (PTM) Status Of Influenza A Viral Ribonucleoproteins (RNPS) During Different Stages Of The Viral Life Cycle
11313	Stephan Ludwig	Session 6: Cellular and Molecular Virology	Dissecting The Mechanism Of Signaling-Induced Nuclear Export Of Influenza Virus vRNPS
Public Health: Disease Burden & Severity			
10547	Rachael Pung	Session 6: Infection Severity	Estimating The Influenza Disease Pyramid In Singapore
11254	Craig Dalton	Session 6: Infection Severity	Burden And Severity Of Influenza-Like Illness In Australia: 10 Years Of Flutracking Online Surveillance

Date: 31 August 2019, Saturday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 10.30am - 12.30pm			
Virology and Pathogenesis: Host-Pathogen Interactions			
10428	Joe Ong	Session 7: Host-Pathogen Interactions	Spatial And Temporal Quantification Of Putative Lung Regenerating Cells During Early Recovery From Influenza Pneumonia.
10591	Thiprampai Thamamon-good	Session 7: Host-Pathogen Interactions	MHC Class II Proteins Mediate Cross-Species Entry Of Bat Influenza Viruses
10740	Ian York	Session 7: Host-Pathogen Interactions	Repeated Seasonal Influenza Vaccination Results In Reduced Protection Against Influenza A(H3N2) Infection In Ferrets Compared To Single Vaccination
11112	Katina Hulme	Session 7: Host-Pathogen Interactions	A History Of Obesity Reduces The Immune Response To Influenza Virus In An NLRP3 Dependent Manner
11138	Kirsty Short	Session 7: Host-Pathogen Interactions	Obesity Increases The Cardiac Complications Of Influenza Virus Infection
Clinical Sciences: Clinical Trials – Vaccines			
10100	Sarah Larteley Lartey Jalloh	Session 7 : Influenza in the Tropics	Live Attenuated Influenza Vaccine Induces Early Tonsillar Follicular T Helper Cell Responses Correlating With Durable Systemic Antibody Responses
11289	Elizabeth Eagling-Vose	Session 7 : Influenza in the Tropics	Development Of A Universal Influenza A T Cell-Based Vaccine
11748	Angus Forster	Session 7 : Influenza in the Tropics	Vaccination With 1/6th Standard Dose Of A Split Inactivated Influenza Vaccine Using A High-Density Micro-Projection Array Patch Induces Comparable Immune Responses To Conventional Full-Dose Intramuscular Injection; Results From A Phase I Randomized Controlled Clinical Trial
11792	Igor Smolenov	Session 7 : Influenza in the Tropics	Prevention Of Influenza During Mismatched Seasons In Older Adults: A Randomized Efficacy Study Of An MF59-Adjuvanted Quadrivalent Influenza Vaccine

ORAL PRESENTATION LISTINGS

Date: 31 August 2019, Saturday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 10.30am - 12.30pm			
Clinical Sciences: Therapeutics – Antivirals			
11211	Josef Järhult	Session 7: Influenza in the Tropics	Resistance Development In Influenza A Viruses Infecting Mallards Exposed To Low Levels Of Peramivir
Time: 2.00pm - 3.30pm			
Clinical Sciences: Diagnostics and Disease Markers			
10943	Delphine Guyon-Gellin	Session 8: Controlled Human Infection Model (CHIM) Challenge Studies	Pre-Existing Np Specific T-Cell Response Correlates With Reduction Of Symptoms In A Human Influenza Challenge Model
Clinical Sciences: Clinical Trials – Study Designs, Clinical Endpoints			
11082	Armen Donabedian	Session 8: Controlled Human Infection Model (CHIM) Challenge Studies	Correlates Of Protection For Better, Faster Influenza Vaccine Development
Virology and Pathogenesis: Viral Replication			
10606	David Bacsik	Session 8: Viral Replication	New Genomic Approaches To Understand The Heterogeneity Of Viral Replication In Single Cells
10843	Thomas Peacock	Session 8: Viral Replication	ANP32 Proteins From Different Mammalian Species Act As Host Range Barriers And Shape Influenza Polymerase Adaptation.
Time: 4.00pm - 5.30pm			
Clinical Sciences: Therapeutics – Immunomodulators, Supportive Care, Others			
11151	Resti Yudhawati Meliana	Session 9 : Critical influenza illness	Potential Therapeutic Role Of Bone Marrow-Derived Mesenchymal Stem Cells In Acute Lung Injury Induced By Highly Pathogenic Avian Influenza Virus A/H5N1
Clinical Sciences: Therapeutics – Antivirals			
11309	Mirella Salvatore	Session 9 : Critical influenza illness	Baloxavir For The Treatment Of Influenza Virus Infection In Hematopoietic Stem Cell Transplant Recipients Who Failed Oseltamivir
Public Health: Disease Burden & Severity			
10362	Mark Thompson	Session 9: Disease Burden, Impact, and Severity	Under-Detection Of Laboratory-Confirmed Influenza-Associated Hospitalizations Among Infants In A Multi-Country Prospective Study
10667	Cheryl Cohen	Session 9: Disease Burden, Impact, and Severity	Community Burden Of Influenza In A Rural And An Urban Setting, South Africa, 2016-2017
10858	Melissa Rolfes	Session 9: Disease Burden, Impact, and Severity	Estimating The Number Of Deaths Due To Influenza — An Alternative To Regression-Based Estimates Of Excess Influenza Mortality
11044	Shikha Garg	Session 9: Disease Burden, Impact, and Severity	The Burden Of In-Hospital And Out-Of-Hospital Deaths Among Patients Hospitalized With Influenza, Flusurv-Net, 2010–2016

ORAL PRESENTATION LISTINGS

Date: 31 August 2019, Saturday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 4.00pm - 5.30pm			
Virology and Pathogenesis: Influenza Evolution & Human Ecology			
10822	Adam Lauring	Session 9: Influenza Evolution & Human Ecology	The Evolutionary Dynamics Of Influenza A And Influenza B Viruses In Naturally Infected Human Hosts
10995	Rubaiyea Farrukee	Session 9: Influenza Evolution & Human Ecology	Predicting Evolutionary Pathways To 'Fit' Oseltamivir Resistant Influenza Viruses

Date: 1 September 2019, Sunday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 8.30am - 10.30am			
Public Health: Epidemiology & Transmission			
11088	Anna Hayman Robertson	Session 10: Imprinting, Sero-epidemiology, Age Profile Differences	Effect Of Maternal Pandemic Vaccination On Seroprevalence Against Influenza In Children At Birth And At 4 Years
Public Health: Human Sero-Epidemiology Studies			
11051	Sook-San Wong	Session 10: Imprinting, Sero-epidemiology, Age Profile Differences	Hemagglutinin And Neuraminidase Antibodies Are Induced In An Age- And Subtype- Dependent Manner After Influenza Virus Infection.
11162	Vivian Leung	Session 10: Imprinting, Sero-epidemiology, Age Profile Differences	Antibody Response And Influenza-Like Illness Among Healthcare Workers After Influenza Vaccination
11206	Steven Riley	Session 10: Imprinting, Sero-epidemiology, Age Profile Differences	Serosolver: An Open Source Tool To Infer Epidemiological And Immunological Dynamics From Serological Data
11349	Sue Huang	Session 10: Imprinting, Sero-epidemiology, Age Profile Differences	Risk Factors And Attack Rates Of Seasonal Influenza Infection: Results Of The SHIVERS Seroepidemiologic Cohort Study
Clinical Sciences: Clinical Trials - Treatment and Prevention			
11718	Hideyuki Ikematsu	Session 10: Non Pharmaceutical Interventions	Single-Dose Baloxavir For The Prevention Of Influenza Among Household Contacts: A Randomized, Double-Blinded, Placebo Controlled Post-Exposure Prophylaxis Study (Blockstone)
11756	Jeffrey Baker	Session 10: Non Pharmaceutical Interventions	Single-Dose Baloxavir Is Well Tolerated And Effective For Treatment Of Influenza In Otherwise Healthy Children Aged 1 To < 12 Years: A Randomized, Double-Blinded, Active-Controlled Study (Ministone-2)
Clinical Sciences: Therapeutics – Antivirals			
10812	Takeki Uehara	Session 10: Non Pharmaceutical Interventions	Reduced Susceptibility Viruses To Baloxavir Marboxil: Prognosis Factors Of The Emergence And Impact On Clinical And Virologic Outcomes In Pediatric Patients In Japan
11754	David Oldach	Session 10: Non Pharmaceutical Interventions	A Global, Randomised, Double-Blind, Placebo-Controlled Study Evaluating Safety And Efficacy Of Vis410 In Combination With Oseltamivir Versus Oseltamivir Alone In Hospitalized Adults With Influenza A Requiring Oxygen

ORAL PRESENTATION LISTINGS

Date: 1 September 2019, Sunday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 8.30am - 10.30am			
Public Health: Non-Pharmaceutical Interventions – Public health aspects			
10466	Faruque Ahmed	Session 10: Non Pharmaceutical Interventions	Access To Telework, Paid Leave Benefits, And Work Attendance In Adults With Medically-Attended Acute Respiratory Illness (Ari)
10910	Sheikh Taslim Ali	Session 10: Non Pharmaceutical Interventions	Quantifying The Effects Of School Closures On Mitigation Of Influenza Epidemics In Hong Kong
Virology and Pathogenesis: Non-Human Influenza Viruses			
10108	Nigel Temperton	Session 10: Non-Human Influenza Viruses	The Bat Influenza H17N10 Can Be Neutralized By Bnmabs And Its Na Facilitates Viral Egress
10355	David Swayne	Session 10: Non-Human Influenza Viruses	Low Literacy Program For Safe Slaughter Of Poultry In Developing Countries To Reduce Human Infection With Avian Influenza Virus
11198	Lauren Tindale	Session 10: Non-Human Influenza Viruses	Improving Avian Influenza Surveillance Through Wetland Sampling
11253	Ariful Islam	Session 10: Non-Human Influenza Viruses	Repeated Crow (Corvus Spendens) Mortality Events Linked To H5N1 Influenza Virus Circulation In Live Bird Markets, Bangladesh
Virology and Pathogenesis: Emerging Influenza Viruses			
11794	Guha Asthagiri Arunkumar	Session 10 : Non-Human Influenza Viruses	Characterizing The Functionality Of The Wuhan Spiny Eel Influenza Virus Surface Glycoproteins
Time: 11.00am - 1.00pm			
Virology and Pathogenesis: Emerging Influenza Viruses			
10649	Shirleen Soh	Session 11: Emerging Influenza Viruses	Comprehensive Mapping Of Adaptation Of The Avian Influenza Polymerase Protein Pb2 To Humans
10960	John R. Barnes	Session 11: Emerging Influenza Viruses	Mitigating Pandemic Risk With Influenza A Virus Field Surveillance: Mia (Mobile Influenza Analysis)
11179	Khristine Joy Antigua	Session 11: Emerging Influenza Viruses	Few Substitutions Of H5 Gene Belonging To Clade 2.3.4 Have Altered The Na Gene Preferences Of The Virus Other Than N1
Public Health: Disease Burden & Severity			
10448	Rakesh Kumar	Session 11: Epidemiology and Transmission Dynamics	Preliminary Estimates Of The Incidence Of Influenza-Associated Acute Respiratory Infection Among Adults Aged >60 Years In A Multi-Site Community Cohort In India

ORAL PRESENTATION LISTINGS

Date: 1 September 2019, Sunday

Abstract ID	Name	Presentation Session	Abstract Title
Time: 11.00am - 1.00pm			
Public Health: Epidemiology & Transmission			
10352	Meredith Mcmorrow	Session 11: Epidemiology and Transmission Dynamics	Influenza Virus Transmission From Symptomatic And Asymptomatic Individuals In A Rural And An Urban Setting, South Africa, 2016-2017
10492	Aslesh Ottapura Prabhakaran	Session 11: Epidemiology and Transmission Dynamics	Determinants Of Influenza Transmission In Households In Rural North India
10702	Amanda Perofsky	Session 11: Epidemiology and Transmission Dynamics	Impact Of Influenza Antigenic Evolution On Disease Dynamics In The United States
11001	John Paget	Session 11: Epidemiology and Transmission Dynamics	The Epidemioloogical Signature Of The Influenza B/Victoria And B/Yamagata Lineages In The 21St Century
11200	Dennis Kai Ming Ip	Session 11: Epidemiology and Transmission Dynamics	Effect Of Host Genetic Polymorphism On Transmission Of Influenza Virus Infection In A Household Setting
Clinical Sciences: Clinical Trials - Treatment and Prevention			
10937	Alexandre Le Vert	Session 11: Vaccines	Ovx836, A Novel Universal Influenza A Vaccine Candidate: First Results Of A Phase I Clinical Trial In Humans
11073	Vivek Shinde	Session 11: Vaccines	Induction Of Broadly Cross-Reactive Immune Responses Against A(H3N2) Viruses: Results Of A Phase 2 Trial Of A Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Influenza Vaccine
11095	Tomer Hertz	Session 11: Vaccines	Immune History To Influenza Is A Novel Correlate Of Protection Of Influenza Vaccination
Clinical Sciences: Clinical Trials - Treatment and Prevention			
10324	Sean Tucker	Session 11: Vaccines	Vaccine Induced Mucosal Iga Contributes To Protection Against Influenza Infection In Humans
10944	Marina Stukova	Session 11: Vaccines	First-In-Man Clinical Trials Of Influenza Vectored Vaccines Against Tuberculosis With Intranasal And Sublinqual Routes Of Administration
11083	Vivek Shinde	Session 11: Vaccines	Towards An Improved Wild-Type Sequence Based Hemagglutination Inhibition Assay For The Evaluation Of Influenza Vaccines: Challenges And New Developments.

POSTER PRESENTATION LISTINGS: CLINICAL SCIENCES AND CO-INFECTION

Date: 28 August 2019, Wednesday /Time: 6.30pm - 8.00pm

Time	Abstract ID	Topic	Name	Abstract Title
6:30pm	10743	Clinical Sciences: Clinical Trials-Vaccines	Timo Vesikari, Janine Oberyé	MF59-Adjuvanted Quadrivalent Influenza Vaccine Provides Consistent Benefit upon Revaccination In Young Children
6:35pm	10530	Co-Infection: Viral Coinfections with Influenza	Ekaterina Stepanova	Development of a Bivalent Live Viral Vectored Vaccine against Influenza and Human Metapneumovirus Infections
6:40pm	11263	Clinical Sciences: Clinical Trials-Vaccines	Rebecca Jane Cox	Immune Response After Pandemic And Seasonal Influenza Vaccination In Healthcare Workers
6:45pm	11123	Clinical Sciences: Clinical Trials-Vaccines	Ju Hwan Jeong	Preclinical Evaluation of H5N8 Vaccine Candidate (IDCDC-RG43A) in Mouse and Ferret Models
6:50pm	11013	Co-Infection: Viral Coinfections with Influenza	Jonathan Temte, Maureen Goss	Coinfections with Influenza and other Respiratory Viruses: Oregon Child Absenteeism due to Respiratory Disease Study (ORCHARDS), Wisconsin, USA, 2015-2019
6:55pm	10850	Co-Infection: Bacterial Co-infections with Influenza	Young Ho Byun	Knock out of PB1-F2 for Enhanced Safety of Cold-adapted Live Attenuated Influenza Vaccine
7:00pm	10846	Co-Infection: Viral Coinfections with Influenza	Anastasiia Evsina	Development of a Bivalent Vaccine against Influenza and Human Adenovirus Infections
7:05pm	11307	Co-Infection: Bacterial Co-infections with Influenza	Michael Schotsaert	TIV Vaccination Modulates Host Responses to Influenza Infection that Correlate with Protection against Bacterial Superinfection
7:10pm	11317	Co-Infection: Bacterial Co-infections with Influenza	Miriam Klausberger	Off-Target Effects of Immunity Conferred by Insect Cell-Expressed Influenza HA-VLPs on Secondary Bacterial Infections
7:15pm	10770	Clinical Sciences: Clinical Trials-Treatment and Prevention	Megumi Hara	Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
7:20pm	10354	Clinical Sciences: Clinical Trials-Study Designs, Clinical Endpoints	Michael Ison	Efficacy and Safety of Anti-Influenza A Monoclonal Antibody, CT-P27, in Subjects with Acute Uncomplicated Influenza A Infection: Updated Phase IIB Study Results
7:25pm	11140	Co-Infection: Bacterial Co-infections with Influenza	Liang Li	Antibody Treatment against Angiopoietin-Like 4 (ANGPTL4) Reduces Pulmonary Edema and Injury In Secondary Pneumococcal Pneumonia
7:30pm	11239	Co-Infection: Bacterial Co-infections with Influenza	Irene Lirio	Identifying Influenza and its Co-Infections from MERS-COV Assay-Negative Travelling Patients from the Middle East to the Philippines
7:35pm	10564	Clinical Sciences: Diagnostics and Disease Markers	Nathan Brendish	The Impact on Healthcare Resource Utilization and Cost of Routine Molecular Point-of-Care Testing for Respiratory Viruses in Adults Hospitalised with Acute Respiratory Illness: Further Analysis from a Pragmatic Randomised Controlled Trial (RESPOC)
7:40pm	10536	Clinical Sciences: Clinical Trials-Study Designs, Clinical Endpoints	Nelson Lee	Development of an Ordinal Scale Treatment Endpoint in Adults Hospitalized with Influenza
7:45pm	11292	Clinical Sciences: Therapeutics-Antivirals	Johan Vingerhoets, Lorant Leopold	In Vitro Combination Experiments With Pimodivir And Other Influenza Antiviral Drugs.
7:50pm	11026	Clinical Sciences: Therapeutics-Antivirals	Reiko Saito	Clinical Effectiveness of Baloxavir Marboxil Compared to Oseltamivir - Appearance of Mutated Viruses at Position 38 in PA Protein for Influenza A/H1N1pdm09 And A/H3N2
7:55pm	10718	Clinical Sciences: Therapeutics-Antivirals	Angeliki Melidou	Low Frequency of Reduced Neuraminidase Inhibitor Susceptibility in Twelve EU/EEA Countries, 2008-2018
8:00pm	11183	Co-Infection: Viral Coinfections with Influenza	Sherry Blackmon	Pathogenicity of influenza D virus (IDV) and Influenza A virus (IAV) co-infection in pigs

POSTER PRESENTATION LISTINGS: VIROLOGY AND PATHOGENESIS

Date: 30 August 2019, Friday /Time: 6.10pm - 7.30pm

Time	Abstract ID	Topic	Name	Abstract Title
6:10PM	10827	Virology and Pathogenesis: Virus Pathogenesis & Transmission	Jeremy C. Jones	Fitness And Ferret Transmissibility Of Influenza A And B Viruses Harboring Clinically Significant (I38T/F/M) Baloxavir Marboxil Resistance Substitutions
6:15PM	11046	Virology and Pathogenesis: Influenza Glycobiology	Dirk Eggink	Genetic Diversity And Receptor Specificity Of Highly Pathogenic Avian Influenza H5N1 During Human Infection
6:20PM	11342	Virology and Pathogenesis: NextGen/Universal Vaccines	Deborah Heydenburg Fuller	Universal Influenza DNA Vaccine Induces Broadly Specific Antibody and T Cell Responses In Mice and Nonhuman Primates and Affords Cross-Protection from Influenza A Challenges
6:25PM	10550	Virology and Pathogenesis: NextGen/Universal Vaccines	Ivan Sychev	"Conserved Epitopes of Influenza Virus Neuraminidase as a Target for Universal Influenza Vaccine Design
6:30PM	10515	Virology and Pathogenesis: Immune Response to Infection	Alec Freyn	Human Monoclonal IGA Antibodies Elicited by Seasonal Influenza Virus Vaccination Exhibit Distinct Fc-Effector Activity Dependent on Epitope-Specificity
6:35PM	10668	Virology and Pathogenesis: Immune Response to Infection	Wen-Pin Tzeng	Changes In Cross-Protective Immunity During Maturation Of The Antibody Repertoire Against Influenza
6:40PM	10715	Virology and Pathogenesis: Cellular & Molecular Virology	Samaporn Teeravechyan	Role of PB2 and PA-X in Avian Influenza Virus Replication
6:45PM	11256	Virology and Pathogenesis: Viral Replication	Nilanshu Manocha	EXOSOME: An RNAi Messenger in Stealth
6:50PM	10911	Virology and Pathogenesis: Viral Replication	Lieve Naesens	A Class of Influenza Virus Fusion Inhibitors with Nanomolar Activity and the Same HA Binding Pocket as Arbidol
6:55PM	11177	Virology and Pathogenesis: Viral Replication	Yee-Joo Tan	Characterization Of Three Human-Like Neutralizing H5N6 Monoclonal Antibodies Obtained Using B Cells From Vaccinated Macaques
7:00PM	10555	Virology and Pathogenesis : Non-Human Influenza Viruses	Daniel Perez	Improved Detection of Influenza A Virus in Wild Ducks by Sequencing Directly from Swab Material
7:05PM	11275	Virology and Pathogenesis: Non-Human Influenza Viruses	Diep Nguyen Thi	Active Surveillance For Avian Influenza Virus In Poultry In Vietnam, 2017 – 2018
7:10PM	11201	Virology and Pathogenesis: Viral Replication	Brad Gilbertson	Interaction between Defined Regions of PB1 And NA Gene Segments Drives Cosegregation of these Genes During Influenza Reassortment
7:15PM	10659	Virology and Pathogenesis: Emerging Influenza Viruses	Sukanta Chowdhury	Detection of Highly Pathogenic Avian Influenza A(H5N6) Viruses in Waterfowl in Bangladesh

POSTER PRESENTATION LISTINGS: PUBLIC HEALTH

Date: 31 August 2019, Saturday /Time: 5.30pm - 7.00pm

Time	Abstract ID	Topic	Name	Abstract Title
5:30pm	10411	Public Health: Vaccine Effectiveness/Impact	Wakaba Fukushima	Influenza Vaccine Effectiveness In Young Japanese Children Over Five Seasons
5:33pm	10685	Public Health: Vaccine Effectiveness/Impact	Sigrid Gouma	Comparison Of Human H3N2 Antibody Responses Elicited By Egg-Based, Cell-Based, And Recombinant Protein-Based Influenza Vaccines During The 2017-2018 Season
5:36pm	10701	Public Health: Vaccine Effectiveness/Impact	S Rajaram	Retrospective Evaluation Of Antigenic Similarity Between Egg-Derived Versus Cell-Derived Influenza Vaccine Reference Strains And Circulating Influenza B-Victoria And Yamagata Viruses
5:39pm	10445	Public Health: Vaccine Effectiveness/Impact	Wey Wen Lim	The Identification And Establishment Of New Correlates Of Protection In Randomized-Controlled Trials
5:42pm	11061	Public Health: Epidemiology & Transmission	David Haw	Multi-Annual Models Of Seasonal Flu At High Spatial Resolution
5:45pm	11075	Public Health: Epidemiology & Transmission	Edward Kong Seng Lam	Small And Variable Influenza Epidemics In Australian Cities Suggest That Host Contact Structure May Limit The Effects Of Climate And Antigenic Evolution On Local Influenza Epidemilogy
5:48pm	10999	Public Health: Epidemiology & Transmission	Mahbubur Rahman	Cross Sectional Survey For Assessment Of Aerosolization Of Influenza A Viruses And Potential Transmission Risk For Live Bird Market Workers At The Animal-Human Interface In Bangladesh
5:51pm	10801	Public Health: Human Sero-Epidemiology Studies	Yiu Chung Lau	Variation By Lineage In Antibody Responses To Influenza B Virus Infections
5:54pm	10902	Public Health: Human Sero-Epidemiology Studies	Francesca Mordant	Antibody Titres Elicited By The 2018 Seasonal Inactivated Influenza Vaccine Persist For At Least 6 Months.
5:57pm	11284	Public Health: Non-Pharmaceutical Interventions – Public health aspects	Nancy Hiu Lan Leung	Shedding Of Respiratory Viruses In Human Exhaled Breath And Efficacy Of Face Masks In Reducing Viral Dissemination
6:00pm	10828	Public Health: Disease Burden & Severity	Cecile Viboud	Crowdsourced Genealogy Data Reveals The Mortality Footprints Of The 1918-1919 Influenza Pandemic
6:03pm	10578	Public Health: Disease Burden & Severity	Jessica Y. Wong	Estimation Of The Influenza-Associated Excess Mortality In Real-Time In Hong Kong, 2012-2018
6:06pm	10374	Public Health: Surveillance & Forecasting	Robert Moss	Improving Epidemic Forecasts With Behavioural Insights Gained From Community-Level Surveillance
6:09pm	11337	Public Health: Surveillance & Forecasting	Rafael Medina	Long-Term Influenza Virus Surveillance In The Antarctic Peninsula Reveals The Dynamic Circulation Of Endemic And Introduced Strains
6:12pm	10757	Public Health: Pandemic Preparedness	Michael CW Chan	Risk Assessment on Lung Injury and Transmission Potential of Influenza Viruses Using In VITRO And Ex VIVO Models of Human Respiratory Tract
6:15pm	11237	Public Health: Pandemic Preparedness	Steven Riley	Potential Public Health Benefits From Reduced Delay In The Production Of Pandemic Influenza Vaccine
6:18pm	10672	Public Health: Pandemic Preparedness	Bin Zhou	From The Field To A Vaccine Candidate: A Proof Of Concept Study For Advancing Influenza Pandemic Preparedness

POSTER DISPLAY

Date: 28 August 2019, Wednesday / Time: 6.30pm - 8.00pm

Abstract ID	Name	Abstract Title
Clinical Sciences: Avian & Zoonotic Influenza-Human Infections		
10796	Yi-Mo Deng	The First Human Case Of Zoonotic Influenza Swine H3N2 Variant In Australia And Its Association With Local Swine Influenza Viruses
11090	Anup Halappanavar	H1N1 Encephalitis – An Unusual Presentation
11142	Mai Le	Prevalence Of Antibodies Against Avian Influenza A(H5N1) And A(H7N9) On Live Poultry Market Workers In Hanoi, 2017.
Clinical Sciences: Clinical Trials-Study Designs, Clinical Endpoints		
11084	Tanima Sinha	Controlled Human Infection Model (CHIM) Design For Influezna Vaccine Development
11236	Roman Fleishhackl	Determining An Optimal Endpoint For Severe Influenza Requiring Hospitalization: A Literature Review Of Categorically Analyzed Ordinal Scales As Endpoints In Clinical Trials Across All Therapy Areas
11243	Nicolas Noulin	Human Viral Challenge Model With A/Perth/16/2009: A Systematic Analysis From Five Clinical Studies
11257	Roman Fleishhackl	Real-World Journey Through The Hospital Recovery Scale (Hrs): US Medicare Population
Clinical Sciences: Clinical Trials-Treatment and Prevention		
10489	Frank Albano	Afluria Quadrivalent Influenza Vaccine For Adults And Paediatric Use
10739	Nusrat Homaira	A Pilot Randomised Controlled Study To Evaluate The Impact Of Text Message Reminder On Influenza Vaccine Uptake In Children With Chronic Lung Disease: Feasibility Study
10756	Chisako Sato	The Safety, Pharmacokinetics, And Clinical And Virological Outcomes Of Baloxavir Marboxil 2% Granules For Pediatric Patients Weighing Less Than 20 Kg With Influenza In Japan
11299	Klaus Kuhlbusch	CENTERSTONE: A Global Phase IIIb, Randomised, Double-Blind, Placebo-Controlled Clinical Efficacy Study Of Baloxavir Marboxil For The Reduction Of Direct Transmission Of Influenza From Otherwise Healthy Patients To Household Contacts
Clinical Sciences: Clinical Trials-Vaccines		
10099	Sarah Larteley Lartey Jalloh	Live Attenuated Influenza Vaccine (LAIV) Induces Functional Neutalizing And Neuraminidase Inhibiting Antibody Responses After Immunization In Children And Adults
10473	Daphne Sawlwin	Modification Of The Vaccine Manufacturing Process Improves The Pyrogenicity Profile Of Inactivated Influenza Vaccines In Young Children
10537	Giuseppe Palladino	Vaccination With Adjuvanted Vaccine Induced Higher Strain Cross-Reactive Antibody Response Than Non-Adjuvanted Vaccine
10719	Marten Heeringa	Microneutralization Assay Titers As Estimates Of Protective Effectiveness Against Influenza Infection In Children
10742	Bruce Essink	MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine (aQIV) Is Non-Inferior To The Licensed MF59-Adjuvanted Trivalent Vaccine (aTIV) And Well-Tolerated In Elderly Adults
10745	Pornthep Chanthavanich	Antibody Responses Against Heterologous H5N1 Strains For An MF59-Adjuvanted Cell Culture-Derived H5N1 (aH5N1c) Influenza Vaccine In Healthy Pediatric Subjects
10747	Esther Van Twuijver	Immunogenicity, Lot-To-Lot Consistency, And Safety Of An MF59-Adjuvanted Cell Culture-Derived H5N1 (aH5N1c) Influenza Vaccine In Healthy Adults
10748	Mathew Hohenboken	Antibody Responses Against Heterologous H5N1 Strains For An MF59-Adjuvanted Cell Culture-Derived H5N1 (aH5N1c) Influenza Vaccine In Adults And The Elderly
10972	Carol Weiss	Neutralizing Antibody Responses To Licensed Egg-Derived, Cell-Derived And Recombinant Seasonal Influenza Vaccines In US Department Of Defense Healthcare Beneficiaries
10982	Danuta Skowronski	Antibody Response To 2018-19 Influenza B/Victoria-Lineage Vaccine In Children Originally Primed To 2008-09 B/Yamagata-Lineage Vaccine: Longitudinal Assessment Of Potential Lineage-Specific Imprinting
10993	Sapna Sadarangani	Evaluation Of Metabolic Predictors Of Influenza Vaccine Immune Response In Singapore's Elderly Population: The Dynamic Trial

POSTER DISPLAY

Date: 28 August 2019, Wednesday / Time: 6.30pm - 8.00pm

Abstract ID	Name	Abstract Title
Clinical Sciences: Clinical Trials-Vaccines		
11008	Athena Py Li	Enhanced Annual Influenza Vaccination Strategies Generate Higher Quality Immune Responses In Older Adults
11070	Rebecca Jane Cox	Adjuvanted H5N1 Vaccine Elicits Rapid And Multifaceted Humoral Immune Responses In Human
11092	Lora Thomas	Safety Of Influenza Vaccine In Adult Hematopoietic Stem Cell Transplant Recipients
11108	Rebecca Jane Cox	Seasonal Influenza Vaccination Induces Cross-Reactive Antibodies Against A/H3N2 Viruses
11116	Ruben Donis	Rationally Designed Heterologous Prime And Boost Vaccination Strategy For Induction Of Cross-Protective Immunity Using Stockpiled H5 Influenza Virus Vaccines
11352	Thushan De Silva	Induction Of Peripheral Follicular Helper T-Cells Following Live Attenuated Influenza Vaccine
Clinical Sciences: Development of Human Disease		
11017	Alison Han	Long-Term Hemagglutination And Neuraminidase Antibody Titers After Influenza Challenge
11287	Yeming Wang	Incidence And Outcome Of Acute Kidney Injury In Hospitalized A(H7N9) Patients: A National Retrospective Multicenter Study
Clinical Sciences: Diagnostics and Disease Markers		
10326	James Karichu	Cost-Effectiveness And Budget Impact Of Molecular Point-Of-Care Nucleic Acid Amplification Testing For The Diagnosis Of Influenza In Japan
10539	Hiroshige Mikamo	Clinical Evaluation Of COBAS® Influenza A/B In Japanese Patients With Influenza Like Illness
10575	Yoke Lee Low	Evaluation Of Genediaò Multi Influenza Antigen Rapid Test Kit
10683	Helena Jirincova	Towards A Universal Influenza A RT-qPCR Detection
10773	Kin On Kwok	Alternate Measures Of Infection Based On Serological Outcomes To Multiple Influenza Strains
10924	Rattiya Wannawong	Clinical Risk Score To Diagnose Influenza Infection In Kamphaeng Phet, Thailand
11012	Maureen Goss	Inter-Nostril Variation In Detection Of Influenza By Rapid Influenza Detection Tests
11024	Kelvin To	Use Of Saliva In The Detection Of Influenza Viruses At The Accident And Emergency Department During An Influenza Epidemic
11042	Hidekazu Osada	Detection Of Influenza A Viruses Associated With Reduced Susceptibility To Cap-Dependent Endonuclease Inhibitor By Using The Cycleavepcrtm Method
11099	Kristin G-I Mohn	Effect Of A New Point-Of-Care Test (POCT) For Influenza On Clinical Outcomes In Hospitalised Patients With Severe Influenza Disease.
11109	Nicolas Noulin	Development And Validation Of Algorithm'S Prognostic For Influenza Contagiousness
11315	Paulina Parra Castro	Development And Estimation Of Diagnostic Accuracy Of A Real-Time Multiplex RT-PCR Assay For The Detection Of Influenza And Porcine Reproductive And Respiratory Syndrome Viruses In Swine
11344	Rafael Medina	Obesity, Diabetes, Chronic Cardiovascular Disease And Early Increased Expression Of Il-6, Il-8 And Il-10 Are Associated With Increased Severity During Influenza A Virus Infection
11348	Keiko Mitamura	Clinical Evaluation Of Rapid Molecular Test For Influenza, Id Now Influenza A&B 2 In Comparison With Currently Available Tests
11763	Darunee Buddhari	Performance Of Quickvue Influenza A+B Rapid Test To Detect Influenza Infection During Year 2012-2019 In Kamphaeng Phet, Thailand
Clinical Sciences: Special Populations		
10334	Helena Jiirincova	Influenza As A Cause Of Sudden Death - The Experience From The National Reference Laboratory For Influenza, Czech Republic
10394	Mary Patricia Nowalk	Hospitalization Of High Functioning Adults For Respiratory Illness Is Associated With Changes In Mental Status

POSTER DISPLAY

Date: 28 August 2019, Wednesday / Time: 6.30pm - 8.00pm

Abstract ID	Name	Abstract Title
Clinical Sciences: Special Populations		
10511	Richard Zimmerman	Frailty And Immune Response To Inactivated Influenza Vaccine In Older Adults
10864	Antonia Ho	Epidemiology Of Hospitalised Adults With Seasonal Influenza Infection And Risk Factors For Severe Outcome In Glasgow, Scotland
10873	Mary Checovich	Respiratory Virus Surveillance In Long-Term Care Facilities
10975	Devika Chawla	Oseltamivir Treatment Patterns Among Immunocompromised Patients In U.S. Insurance Claims Data During The 2017-18 Influenza Season
10977	Devika Chawla	Oseltamivir Treatment Patterns During Pregnancy In U.S. Insurance Claims Data (2015-2018)
11003	H. Keipp Talbot	Prematurity Associated With Maternal Influenza Hospitalization
11085	Raquel Guiomar	Influenza A(H3) Hospital Outbreak In Portugal During 2017/2018 Season. NGS - A Tool For Investigation.
11114	Lilach Friedman	Obesity Is Associated With A Decrease In Anti-Influenza IgG And An Increase In Anti-Influenza IgA Antibody Responses
11182	Jyoti Jethani	Viral Respiratory Infections In Adults Following Hematopoetic Stem Cell Transplant (HSCT) at a Tertiary Care Hospital In India
Clinical Sciences: Therapeutics-Antivirals		
10139	Iaryna Iosyk	Yeasts Ribonucleic Acid Efficiency In A Treatment Of Patients With Acute Respiratory Infectiousyeasts Ribonucleic Acid Efficiency In A Treatment Of Patients With Acute Respiratory Infectious
10510	Masatoki Sato	Clinical And Virological Efficacy Of Baloxavir Marboxil In Children With Influenza A
10613	Hyo Jin Kim	Antiviral Activities Of Mulberry (Morus Alba) Juice And Its Gallic Acid Against Influenza Viruses
10794	So-Jung Shim	A Systematic Review Of The Uptake And Effectiveness Of Oseltamivir In Treatment Of Influenza Illness In Patients With Chronic Cardio-Pulmonary Disease
10830	Stefan Pöhlmann	Defective Interfering Particles (DIPS): Development Of Production Systems and Identification of Determinants Of Antiviral Activity
10889	Natalia Breslav	The Facts Of Influenza Antivirals Susceptibility Surveillance In Russia
10940	João Trigueiro-Louro	Victoria And Yamagata: Exploiting Lineage-Specificity Of Influenza B Virus Neuraminidase Inhibitor Natural Susceptibility And Selective Pressure Strenght At Resistance-Associated Sites.
10959	Daniel Keebler	Limited Use Of Antivirals For Treatment Of Influenza In Germany, 2014-2018: Analysis of The Ims-Eu Electronic Medical Records Database
10978	Amanda Oliver	Aqueous Zanamivir Global Compassionate Use Program – 2009-2019
11057	Raquel Guiomar	Antiviral Susceptibility Of Influenza A Viruses During 2018/19 Season, Portugal
11101	Dagmara Bialy	Defining Functional Resistance Of Avian Influenza Viruses To Neuraminidase Inhibitor Drugs
11152	Felix Zhiqiang Zheng	Contribution Of Antibody-Dependent Cellular Cytotoxicity To The Antiviral Function Of The Vestigial Esterase-Targeting Monoclonal Antibody 9F4 Against H5N6 Infections In Vivo
11175	Su Hui Catherine Teo	Structural Studies On The Interaction Between A H5NX Neutralizing Monoclonal Antibody And H5N6 Hemagglutinin
11760	Les Tari	Efficacy Of CB-012, A Novel Antiviral Fc-Conjugate, Against Influenza A (H1N1) In A Lethal Mouse Model Of Severe Combined Immunodeficiency (SCID)
Clinical Sciences: Therapeutics-Immunomodulators, Supportive Care, Others		
10938	Stephan Ludwig	Antiviral Potential Of Ifnα Subtypes Against Influenza Infection In A Human Lung Explant Model
11141	Guha Asthagiri Arunkumar	Characterization Of Broadly Cross-Reactive Neutralizing Antibodies Against The Influenza B Virus Hemagglutinin And Their Mechanism Of Protection In Mice

POSTER DISPLAY

Date: 28 August 2019, Wednesday / Time: 6.30pm - 8.00pm

Abstract ID	Name	Abstract Title
Co-Infection: Bacterial Co-infections with Influenza		
10336	Yulia Desheva	Experimental Mucosal Vaccine Against Influenza And Pneumococcal Infections
10901	Chris Ka Pun Mok	Establishment Of Avian Influenza Virus/Acinetobacter Baumannii Co-Infection Model In Mice
10957	Daniel Keebler	Increased Burden Of Care Among Patients Hospitalized With Influenza And Co-Infected With Pneumonia In The United States, 2009-2018: Analysis Of The Premier Healthcare Database
11086	Augustina Kwakyewaa Arjarquah	Occurrence Of Influenza And Bacterial Co-Infections In Upper-Torso Cancer Patients Undergoing Radiotherapy In Ghana.
11136	Bishnu Prasad Upadhyay	Bacterial Co-Infection With Influenza Among The Hospitalized Patients With Severe Acute Respiratory Infection
11264	Norosoa Razanajatovo	The Prevalence Of Influenza-Associated Co-Infections In Children Under 5 Years With Acute Respiratory Infections In Madagascar, 2018.
Co-Infection: Viral Coinfections with Influenza		
10695	Elizabeth Kassens	Coinfections Of Influenza And Other Respiratory Viruses In Florida Surveillance Specimens January 2014 – February 2019
11076	Raquel Guiomar	Influenza And Other Respiratory Viruses, 2015-2018, Portugal
11153	Sumit Dutt Bhardwaj	Investigation Of Pneumonia Outbreak Among Under Five Years Children In A Tribal Area Of Maharashtra, India
11166	Vina Lea Arguelles	Viral Co-Infections With Influenza Among Severe Acute Respiratory Infection (SARI) Cases In The Philippines, 2016–2017
11762	Alisha Sapkota	Molecular Characteristics And Seasonality Of Respiratory Viruses Co-Infection Among Influenza Positive Cases In Nepal

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Cellular & Molecular Virology		
10715	Samaporn Teer-avechyan	Role Of PB2 And PA-X In Avian Influenza Virus Replication
Virology and Pathogenesis: Emerging Influenza Viruses		
10659	Sukanta Chowdhury	Detection Of Highly Pathogenic Avian Influenza A(H5N6) Viruses In Waterfowl In Bangladesh
Virology and Pathogenesis: Immune Response to Infection		
10515	Alec Freyn	Human Monoclonal IGA Antibodies Elicited By Seasonal Influenza Virus Vaccination Exhibit Distinct Fc-Effector Activity Dependent On Epitope-Specificity
10668	Wen-Pin Tzeng	Changes In Cross-Protective Immunity During Maturation Of The Antibody Repertoire Against Influenza
Virology and Pathogenesis: Influenza Glycobiology		
11046	Dirk Eggink	Genetic Diversity And Receptor Specificity Of Highly Pathogenic Avian Influenza H5N1 During Human Infection
11326	Jorge Levican-Asenjo	The Role In Antigenicity And Viral Fitness Of n-glycosylations Near The Receptor Binding Site.

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: NextGen/Universal Vaccines		
10550	Ivan Sychev	Conserved Epitopes Of Influenza Virus Neuraminidase As A Target For Universal Influenza Vaccine Design
11342	Adebimpe Obadan	Universal Influenza Dna Vaccine Induces Broadly Specific Antibody And T Cell Responses In Mice And Nonhuman Primates And Affords Cross-Protection From Influenza A Challenges
Virology and Pathogenesis : Non-Human Influenza Viruses		
10555	Daniel Perez	Improved Detection Of Influenza A Virus In Wild Ducks By Sequencing Directly From Swab Material.
Virology and Pathogenesis: Virus Pathogenesis & Transmission		
10827	Jeremy C. Jones	Fitness And Ferret Transmissibility Of Influenza A And B Viruses Harboring Clinically Significant (I38T/F/M) Baloxavir Marboxil Resistance Substitutions
Virology and Pathogenesis : Viral Replication		
10911	Lieve Naesens	A Class Of Influenza Virus Fusion Inhibitors With Nanomolar Activity And The Same HA Binding Pocket As Arbidol
11177	Yee-Joo Tan	Characterization Of Three Human-Like Neutralizing H5N6 Monoclonal Antibodies Obtained Using B Cells From Vaccinated Macaques
11201	Brad Gilbertson	Interaction Between Defined Regions Of PB1 And NA Gene Segments Drives Cosegregation Of These Genes During Influenza Reassortment
11256	Nilanshu Manocha	Exosome: An Rnai Messenger In Stealth
Virology and Pathogenesis: Cellular & Molecular Virology /6:00pm - 7:30pm/		
10396	Pin Chen	Exploration Of M Splicing Variants In Influenza A Viruses
10418	Michiyo Kataoka	Three-Dimensional Ultrastructural Analysis Of Cells From Lung Autopsy Case Of A/H1N-1pdm09 Influenza Virus Infection
10422	Huibin Lv	Preventing An Antigenically Disruptive Mutation In EGG-Based H3N2 Seasonal Influenza Vaccines By Mutational Incompatibility
10431	Erica Dawson	Fluchip-8G Characterization Of Seasonal And Non-Seasonal Influenza
10432	Erica Dawson	Correlation Between Vaxarray HA And NA Multiplexed Immunoassays And Immunogenicity In Mice
10464	Yingxia Wen	Reference Antigen-Free And Antibody-Free LTD-IDMS Assay For Influenza Pandemic Vaccine In Vitro Potency Determination
10467	Galina Landgraf	Expression Of Type I And II Interferon In The Lungs Of Immune Mice After Viral - Bacterial Infection
10504	Jinhee Kim	Identification Of A Novel Host Factor: TMPRSS9 Is Required For Replication Of Influenza A Virus
10658	Yuri Furusawa	Stabilization Of Foreign Gene Insertion Into The Influenza Virus Genome
10687	Han Byul Jung	Effect Of Proline Mutagenesis On Fusion Proteins Of Enveloped RNA Viruses
10708	Chi Ong	Method For Determining Percentage Split Virion By Nanosight
10727	Heba Al Khatib	Intra-Host And Intra-Population Sequence Diversity Of pH1N1 And Associated Clinical Outcomes
10730	Christine H. T. Bui	Replication COMPETENCE And Tropism Of Influenza B Viruses In Human Airway Organoids
10733	Naranzul Tsedenbal	Influenza Like Illness And Severe Acute Respiratory Infection Surveillances In Mongolia In 2018/19 Influenza Season
10755	Jesse Leigh Bodle	Development Of An Enzyme Linked Immunoassay For The Quantitation Of Influenza Hemagglutinin
10763	Sonja Chua	Establishment Of A Yeast-Based System To Study Influenza Proteins

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Cellular & Molecular Virology		
10766	Yang Pan	Effects Of Codon Usage And CpG Frequency In Influenza Virus Expressing GFP
10785	Kosuke Takada	A Humanized Mdck Cell Line For The Efficient Isolation And Propagation Of Human Influenza Viruses
10818	Lauren Parker	Improvement Of Live Attenuated Influenza Vaccine Strain Selection By Employment Of Site-Directed Mutagenesis
10841	Kamonthip Rungro-jcharoenkit	Development Of An Adjuvant Nanosphere For Delivery Of Influenza Virus Proteins
10844	Manon Laporte	Comprehensive Analysis Of Protease Recognition And Fusion Characteristics Of The Four Seasonal Influenza Virus Hemagglutinins
10897	Piyawan Chinnawirotpisan	Molecular Characterization And Phylogenetic Analysis Of Influenza Viruses Circulating In Thailand Between 2009 And 2018.
10976	Danuta M Skowronski	Genotypic Characterization Of Influenza A Viruses Collected By The Canadian Sentinel Practitioner Surveillance Network During The 2018-19 BIMODAL A(H1N1)PDM09 And A(H3N2) Epidemic
10997	Sho Miyamoto	VRNA-VRNA Interactions In Influenza A Virus HA VRNA Packaging
11020	Irina Baranovskaya	Stable Hairpin Secondary Structure In NS Gene RNA Enhances Expression Of NS1 In Influenza Infected Cells
11065	Mariia Sergeeva	Increasing The Susceptibility Of HEK293FT Cell Line To Influenza Infection By CRISPR-CAS9 Mediated Knockout Of Particular Genes
11098	Alla Mironenko	Influenza Virus Replication In A549 Cells In The Presence Of Antiviral Agent Amizon (Enisamium Iodide)
11245	Noriko Shimasaki	Development Of An Alternative Potency Assay To Measure The HA Content Of Two Influeza B Virus In Quadrivalent Influenza Vaccine In Japan.
11251	Orienka Hellferscee	Detection Of Victoria Lineage Influenza B Viruses With Δ162-163 Deletions In The Hemagglutinin (HA), South Africa, 2018
11308	Bimalesh Jha	Overview Of Seasonal Flu Inf (A/H3)Infection In Nepal
11310	Dave Chapman	Defective Interfering Vrna Are Not A Majority Population In Live Attenuated Influenza Vaccine And Appear To Not Drive Vaccine Effectiveness
11737	Natalia Kolosova	NGS Investigation Of A(H1N1)Pdm09 HA-D222G/N Polymorphism Associated With Influenza Cases In Russia In 2017-2019
11773	Wei Zhao	Heterologous Prime-Boost Regimens With Ad5 And NDV Vectors Elicit Stronger Immune Responses To Ebola Virus Than Homologous Regimens In Mice
Virology and Pathogenesis: Emerging Influenza Viruses		
10360	Xiaoyan Li	First Case Of Human Infection With A Novel Triple-Reassortant H1N1Virus In Northern China
10420	Vijaykrishna Dhanasekaran	Emergence Of Influenza A/H7N4 Virus In Cambodia
10554	Daniel Perez	Pathology Of Clade 2.3.4.4 H5N2 Hpaiv In Experimentally Infected Commercial Broad Breasted White Turkeys
10558	Daniel Perez	Flexibility In Vitro Of Amino Acid 226 In The Receptor-Binding Site Of An H9 Subtype Influenza A Virus And Its Effect In Vivo On Virus Replication, Tropism, And Transmission.
10596	Daniel Perez	Evidence Of A Fixed Internal Gene Constellation In Influenza A Viruses Isolated From Wild Birds In Argentina (2006-2016).
10656	Momoko Nakayama	A Nobel H7N3 Reassortant That Has Adapted To Ducks
10669	Ada Yan	In Vitro Growth Kinetics Traits That Differ Between Human And Avian Influenza Strains
10681	Kwang-Min Yu	Compairison The Pathogenicity Of Recemt H5N6 And H5N8 Viruses Isolated During The Winter Season 2016-2017 In South Korea

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
		Virology and Pathogenesis: Emerging Influenza Viruses
10717	Kim Mi-Seon	Pathogenesis Of Influenza C Virus In Mice And Ferrets
10731	Christine H. T. Bui	Risk Assessment Of The Tropism And Pathogenesis Of Canine Influenza A/H3N2 Viruses In The Human Respiratory Tract
		Virology and Pathogenesis: Emerging Influenza Viruses
10781	Yipeng Sun	Canine Influenza Virus A(H3N2) Clade With Antigenic Variation,China, 2016-2018.
10878	Kevin Kuchinski	Genomic Surveillance Of Avian Influenza Viruses In Wetlands Sediment From Wild Bird Habitats
10949	Ian Brown	Monitoring Changes In Avian Influenza: Relevance For Human Health
10953	Susan Sloan	VIS410, A Broad-Spectrum, Anti-Influenza A Monoclonal Antibody Neutralizes Baloxavir-Resistant Influenza A Virus In Vitro
11059	Agnes Theresia Soelih Estoepangestie	An Influenza A/H5N1 Reassortant Isolated From Apparently Healthy Chicken At A Live-Poultry Market In East Java, Indonesia
11060	Aleksandra Agafonova	The Growth Evaluation Of Trivalent Or Quadrivalent Live Attenuated Influenza Vaccine In Vitro
11071	Krisnoadi Rahardjo	Isolation And Identification Of Avian Influenza Viruses From Asymptomatic Ducks In East Java, Indonesia During 2016 – 2019
11078	Arindita Niatazya Novianti	Avian Influenza A/H9N2 Reassortant Isolated From Sick Chickens At Live-Poultry Markets In East Java, Indonesia
11121	Julie Mcauley	Can We Predict The Severity Of Inflammatory Disease By Newly Emerging Influenza Viruses Encoding The PB1-F2 Virulence Protein?
11199	Rima Ratnanggana Prasetya	Isolation Of Avian Influenza A(H4N6) Viruses From Ducks At A Live-Poultry Market In East Java, Indonesia
11288	Erasmus Kotey	Presence Of Influenza A H9N2 Viruses Among Poultry In Ghana
11709	Suh-Chin Wu	Recombinant Hemagglutinin Produced From Chinese Hamster Ovary (CHO) Stable Cell Clones And A PELC/CpG Combination Adjuvant For H7N9 Subunit Vaccine Development
11710	Tsai-Chuan Weng	Development Of A Suspended Mdck Cell Line For Influenza Vaccine Production
		Virology and Pathogenesis: Host-Pathogen Interactions
10327	Dileep Kumar Verma	Study Of Host Lipid Rafts In Influenza A Virus (IAV) Host Binding And Endocytosis With Subsequent Identification Of Hemagglutinin Interacting Host Raft Proteins.
10358	Paula Lopez Monteagudo	Analyses Of Recombinant Influenza Viruses Reveal Distinct Immune Antagonistic Profiles Induced By Human Versus Avian NS1 Proteins In Primary Human Systems
10458	Bobo Mok	Influenza NS1 Protein Epigenetically Upregulates MicroRNA-146A To Suppress Antiviral Responses And Promotes Viral Infection
10474	Sheng-Yu Huang	Novel Role For MIR-1290 In Host Species Specificity Of Influenza A Virus
10551	Sebastian Beck	The Importin-a7 Interactome As A Platform To Study Molecular Mechanisms Of Influenza A Virus Host Adaptation And Pathogenesis
10557	Daniel Perez	Plasticity Of Amino Acid Residue 145 Near The Receptor Binding Site Of H3 Swine Influenza A Viruses And Its Impact On Receptor Binding And Antibody Recognition.
10723	Su-Jin Park	Highly Pathogenic Avian Influenza H5N8 Reassortant Viruses Could Alter Virulence In Mammalian Models
10764	Baik L. Seong	Degradation Of Interferon Signaling Factor DDX3 By PB1-F2 As A Basis For Virulence Of 1918 Pandemic Influenza
10807	Emma Job	Antibodies Directed Towards Influenza Neuraminidase Restrict Influenza Virus Replication In Primary Human Bronchial Epithelial Cells

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Host-Pathogen Interactions		
10820	Shivaprakash Gangappa	Impact Of Virus Subtype And Age On Influenza A Virus-Induced Oxidative Stress-Specific Gene Expression In The Lungs
10839	Sarah Londrigan	IFITM3 And Type I Interferons Are Important For The Control Of Influenza A Virus Replication In Murine Macrophages
10840	Augustin Twabela	Characterization Of H5N8 Highly Pathogenic Avian Influenza Viruses Isolated In The Democratic Republic Of Congo In 2017
10849	Zhimin Jiang	Induction Of PGRN By Influenza Virus Inhibits The Antiviral Immune Responses Through Downregulation Of Type I Interferons Signaling
10886	Chenxi Wang	Naturally Loss Of Threonine 37 Phosphorylation On M1 Protein Enhances The Inter-Species Infectivity Of H9N2 Avian Influenza Virus In Mammals
10888	Michiko Ujie	Long-Term Cultured Human Lung Adenocarcinoma A549 Cells Show Enhanced Susceptibility To Human Influenza a Viruses
10891	Man Chun Cheung	Alveolar Regeneration Upon Highly Pathogenic Influenza A/ H5N1 Virus Induced Acute Lung Injury
10892	Kah Man Lai	Attenuating Influenza A Virus Infection By Heparin Binding EGF-Like Growth Factor
10926	Shruti Mishra	Influenza A Virus Nucleoprotein And Host Cellular Nucleolin Interaction In Virus Replication
11027	Katina Hulme	Hyperglycaemia Induces Epithelial-Endothelial Barrier Damage During Influenza A Infection
11039	Ming-Shou Hsieh	The Positive Charge Of Arg-201 On Hemagglutinin Is Required For H6N1 Avian Influenza Virus To Bind With Host Cell
11041	Yun-Sang Tang	Mapping The Nuclear Localization Signal On Influenza C Virus Nucleoprotein
11077	Beth Thielen	Single Cell Sequencing Identifies Variability In Host Response Among Different Genera Of Influenza Viruses
11132	Julie Mcauley	Host Innate Factors Regulating Inflammatory Disease Resulting From Influenza Infection: A Critical Role Is Played At The Cell-Surface.
11135	Alyson Kelvin	Host Influenza History Dictates Vaccine Responses Suggesting A Memory B Cell Mechanism
11158	Sumit Chanda	Integrative Multiomics Analysis Of Influenza A Virus Restriction Mechanisms Identifies TBC1D5 As A Driver Of Viral Autophagosomal Degradation
11159	Slim Fourati	Inflammatory Monocyte Maturation Predicts The Severity Of Symptoms Following Influenza Infection
11261	Sanjesh Saini	Upr Redefined In Influenza Virus Replication
11276	Pierre Bessiere	Deciphering The Interaction Between The Host, The Gut Microbiota And The Virus, Following An Infection With An H5N9 Highly Pathogenic Influenza Virus In Ducks
11312	Ericka Kirkpatrick	Defining The Epitopes Of Human Broadly-Reactive Anti-Influenza Virus Neuraminidase Monoclonal Antibodies
11327	Megan Dunagan	Functions Of Host Shut-Off Proteins Of Influenza A Virus
11729	Wen Su	From Birds To Pigs: Molecular Determinants Associated With The Transmission Potential Of Eurasian Avian-Like Swine Influenza Viruses In Pigs
11785	Sebastian Beck	ANP32B But Not ANP32A Promotes Influenza A Virus Replication And Pathogenicity In Mice
Virology and Pathogenesis: Immune Response to Infection		
10377	Irina Kiseleva	Could Trivalent Laiv Protect Against Both Genetic Lineages Of Influenza B Virus?
10410	Tatiana Kotomina	Recombinant Live Attenuated Influenza Vaccine Viruses Carrying CD8 T-Cell Epitopes Of Respiratory Syncytial Virus Protect Mice Against Both Infections Without Inflammatory Disease
10427	Sun Woo Yoon	Immunological Profile In Pregnant Ferrets Infected With Influenza Virus
10443	Honglian Liu	The Function Of Mammalian Argonaute 2 In Influenza A Virus Infection

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Immune Response to Infection		
10662	Eun-Young Jang	Improvement Of Influenza Virus Neutralizing Antibody Assay Using Pseudoviruses Expressing HA And NA
10670	George Carnell	Exploiting Lentiviral Pseudotypes For The Detection Of Neuraminidase Inhibiting Antibodies.
10709	Chi Ong	Use Of A Biological Assay To Mitigate Vaccine Pyrogenicity
10729	Mark Sangster	H7-Reactive Memory B Cell Expansion By Adjuvanted Inactivated H7N9 Influenza Virus Vaccination
10754	Anders Madsen	Influenza B Virus Infection In Humans Induces Broadly Cross-Reactive And Protective Neuraminidase-Reactive Antibodies
10787	Xuemin Chen	A Novel Influenza Specific Antibody-Dependent Cell-Mediated Cytotoxicity Assay
10803	Emanuele Montomoli	Serological Assays For Detection Of Antibody Levels Against Seasonal Influenza Viruses And Correlates Of Protection
10887	Moe Okuda	Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize An Epitope In Antigenic Site A Of Influenza A(H5) Virus HA Detected Between 2015 And 2018
10893	Sophie Valkenburg	Assessing Antibody Function In Responses To Twice-Annual Vaccination Due To 2014/2015 H3N2 Antigenic Mismatch In Hong Kong.
10947	Kaori Sano	HA-Stalk Reactive Secretory IgA Antibodies Exhibit Anti-Viral Activity By Steric Hindrance Of Viral HA And NA
10948	Catherine Thompson	Neuraminidase Antibody Responses To A(H1N1)Pdm09 Pandemic Vaccine In Uk Children
10987	Shuai Liu	Gene Regulation And Antiviral Activity Of Il-36 In Response To Influenza Virus Infection.
11022	Victoria Matyushenko	Functional Activity Of M2e-Specific Antibodies Induced By Live Attenuated Influenza Vaccine (LAIV) Carrying Four M2e Tandem Repeats Embedded In The Hemagglutinin Molecule
11030	Peter Kasson	Assessing Mechanisms Of Antibody Neutralization: Heterogeneity Among Broadly Neutralizing Antibodies
11048	Jie-Long He	Evaluating Protein Yield And Immuno-Efficacy For The Recombinant HA Of H6 Avian Influenza Produced From A Novel Secretory Bi-Cistronic Baculovirus Expression System
11069	Swan Tan	Influenza Vaccine Immunity Is Modulated By Human-Like Hemagglutinin (HA) T Cell Epitopes
11097	Adolfo Garcia-Sastre	Impact Of Pre-Existing Specific Influenza Antibodies As A Determinant Of Disease Severity And Clinical Outcome On Influenza Virus-Infected Patients
11100	Weiping Cao	Novel Approaches For Studying Cell-Mediated Immune Responses To Influenza Vaccination In Humans
11139	Kenrie Pui Yan Hui	The Immunomodulatory Effects Of Fak In Highly Pathogenic Avian Influenza A/H5N1 Virus Infection
11197	Chisha Sikazwe	Nasal Cytokine Profiles Of Patients Hospitalised With Rhinovirus Species C Associated Respiratory Wheeze Differ In Children With And Without Pre-Existing Asthma
11235	Kayoko Sato	Different Innate Immune Responses By Infection With Various Influenza Viruses In Macrophages.
11304	Angela Choi	Infection-Permissive Immunity Against Influenza Virus Provided By Vaccination Prevents Loss Of Alveolar Macrophages And Modulates Virus-Induced Cross-Reactive Immune Responses During Subsequent Influenza Infections.
11711	Ranawaka Apm Perera	Hemagglutinin Head And Stalk Binding Antibody Responses Following The 2009 Pandemic Influenza Infection In Ethnic Chinese.
11744	Kirill Vasiliev	Mucosal Immunization With The Influenza A Virus Encoding Truncated NS1 Protein Protects Mice From Heterologous Challenge
11788	Wei Zhao	The Cross-Reaction Between Seasonal Influenza Vaccine And H7N9 Virus In Mice
11789	Erik J. Stemmy	Ceirs Reagents And Resources To Advance Influenza Research And Discovery

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Influenza Evolution & Human Ecology		
10412	Guang-Wu Chen	Neuraminidase Of H1N1pdm Viruses Exhibited Mixed Genetic Makeup In Taiwan In 2015-2016 Season
10438	Seiya Yamayoshi	The Antigenic Change In The Hemagglutinin Of A(H7N9) Influenza Virus
10481	Hongquan Wan	Study Of Amino Acid Mutation At Neuraminidase Residue 267 Of A(H3N2) Influenza Viruses
10531	Yasuhara Atsuhiro	Antigenic Drift Originating From Changes To The Lateral Surface Of The Neuraminidase Head Of Influenza A Virus.
10532	Chiharu Kawakami	Genetic And Antigenic Characterisation Of Influenza A(H3N2) Viruses Isolated In Yokohama During The 2016/17 And 2017/18 Influenza Seasons
10728	Simon De Jong	The Circulation And Origins Of Seasonal Influenza Viruses In Singapore
10738	Yipu Lin	Receptor Binding Characteristics Of Human A(H3N2) Influenza Variants Circulating Since 2013
10762	Haogao Gu	Dinucleotide Evolutionary Dynamics In Influenza A Virus
10824	D. Colllins Owuor	Countrywide Transmission Patterns Of Influenza A(H1N1)Pdm09 In Kenya 2009-2016 Identified Through Whole-Genome Sequencing
10825	Liudmyla Leibenko	Genetic Characteristic Of The Hemagglutinin Of Human Influenza Viruses Type A Isolated In 2017-2018 Season In Ukraine
10826	Nídia Trovão	Reconstructing The Antigenic Evolution Of Influenza A Viruses In Multiple Hosts
10831	Catherine Macken	Predicting Coevolving Pairs Of Sites In Influenza Virus HA Protein.
10854	D. Colllins Owuor	Utility Of Whole-Genome Sequence Analysis In Tracking The Transmission Of A(H3N2) Virus Circulating In Coastal Kenya
10861	Catherine Smith	Antigenic And Genetic Trajectory Of Influenza A(H1N1)Pdm09 Viruses Since 2009
10872	Katarina Braun	Stochastic Transmission Bottlenecks Constrain Adaptation Of H7N9 Influenza Viruses To Mammalian Hosts
10927	Edyth Parker	A Unified Genotyping Nomenclature For The Internal Genes Of Influenza A Viruses
10933	Björn Koel	Within-Host Virus Evolution In Sequentially Sampled Influenza-Positive Patients
10939	Rebecca Garten Kondor	Comparative Evolution And Phylogeography Of Influenza B/Victoria Lineage Viruses With Double And Triple Amino Acid Deletions In Hemagglutinin
10946	Gaelle Simon	Evolution Of A/H1N1 2009 Pandemic Influenza Virus In Pigs In France From 2010 To 2018: Divergence Of A Swine-Specific Lineage, Reassortment Events And Bi-Directional Transmissions With Humans
10951	Louise Moncla	H5N1 Within-Host Diversity In Humans And Domestic Ducks In Cambodia
10989	Sean Hsiang-Yu Yuan	Short-Sighted Evolution Of Influenza Cellular Receptor Binding In Human Populations
10996	Saira Hussain	Identification Of Amino Acid Substitutions In Neuraminidase Of Currently Circulating A(H3N2) Viruses Resulting In Reduced Sialidase Activity
11015	Jonathan Temte	Using Whole-Genome Sequencing To Investigate The Within-Season Genetic Diversity Of Influenza A(H3N2) Viruses In A School-Associated Community In Wisconsin, Usa, 2017-2018
11033	René Vigeveno	Evolution Of The Polymerase Complex Of Seasonal Influenza A Viruses
11052	Aldise Mareta Nastri	Evolution Of Avian Influenza A(H5N1) Viruses Isolated From Poultry In East Java, Indonesia
11113	Eric A. F. Simões	Independent Introductions Of Clade 2.3.2 H5N1 Avian Influenza In Rural Villages In West Java, Indonesia 2013-2014.
11128	Noriko Kishida	Characterization Of Influenza A(H1N1)Pdm09 Variants Selected With Human Antisera Collected In The 2017/18 Season

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Influenza Evolution & Human Ecology		
11178	Xiu-Feng (Henry) Wan	Quantifying Antigenicity Of Influenza A(H1N1) Virus Using Mutations And Variations In Glycosylation Of Hemagglutinin
11187	Yao-Tsun Li	Population Dynamics Of H5N1 Viruses In China And The Emergence Of Novel H5NX Viruses
11192	Bruno Lina	Ha – Na Epistasis Contributed To The Emergence Of The Seasonal Oseltamivir-Resistant Influenza A (H1N1) Virus (2006-2007).
11193	Muzaffar Ali	Serologic Evidence Of Avian Influenza A (H9N2) Virus Infection Among Poultry Workers, Domestic Animals And Migratory Waterfowl In Pakistan
11212	Ramandeep Kaur Virk	Evolutionary Mechanisms Contributing To Elevated Influenza B Activity In Singapore From 2016–2018
11267	Chrysanti Murad	Phylogeny Of Influenza A (H1N1pdm09 And H3N2) Viruses In Bandung District Between 2008 And 2011
Virology and Pathogenesis: Influenza Glycobiology		
10131	Irina Alymova	A Novel Inhibitor Of N-Linked Glycosylation, NGI-1, Exhibits Anti-Viral Activity Against Influenza A And B
10664	Myung Guk Han	Receptor Preference Of H5 Avian Influenza Viruses To Both A-2,3 And A-2,6 Sialic Acids
11174	Xiu-Feng (Henry) Wan	Decoding Glycan Substructures Specific For Influenza Cell And Host Tropisms Using Systems Biology Approaches
11185	Jennifer Mck-imm-Breschkin	Selection Of A Novel, But Unfit Influenza A(H1N1)pdm09 I106M Neuraminidase Mutant After Passaging In A Difluoro Sialic Acid Inhibitor
11269	Wang-Chou Sung	Proteomic Characterization Of Influenza H7N9 Virus Cultivated In MDCK Cell
Virology and Pathogenesis: NextGen/Universal Vaccines		
10097	Anitha Jagadesh	Immunogenic Response Of A Novel VLP Designed Using The Influenza Neuraminidase (N1, N2), Hemagglutinin (H1) And Matrix (M) Proteins
10176	Irina Isakova-Sivak	Immunogenicity And Protective Efficacy Of Universal Live Attenuated Influenza Vaccine Candidates Expressing Chimeric Hemagglutinins And Wild-Type Nucleoproteins In A Ferret Model
10330	Vladimir Berezin	Saponin-Containing Nanoparticles As An Efficient Adjuvant/Delivery Systems For Influenza Vaccine Mucosal Immunization
10382	Yoshita Bhide	Cross-Protective Potential And Protection-Relevant Immune Mechanisms Of Whole Inactivated Influenza Virus Vaccines Are Determined By Adjuvants And Route Of Immunization
10408	Xiaoyan Li	Protection Against Hmpv Conveyed By Influenza Virus Vectors Carrying Multiple Epitope Antigens Of HMPV In The NS Protein
10425	Wei Wang	Induction Of Neutralizing Stem Antibodies By Immunization With Influenza A Hemagglutinins From The Strains Sensitive To Neutralizing Antibodies And Identification Of Virus Resistance Mutations Against A Stem Monoclonal Antibody
10461	Siu-Ying (Phoebe) Lau	Generation And Characterization Of DelNS1 Influenza A And B Viruses: A Strategy For Optimizing Live Attenuated Influenza Vaccines
10484	Nicholas Wu	Influenza H3N2 Viruses Have A Low Genetic Barrier To Resistance To Broadly Neutralizing Hemagglutinin Stem-Binding Antibodies
10508	Daria Mezhenskaia	Live Attenuated Influenza Vaccines Expressing Four M2e Tandem Repeats Within The Hemagglutinin Molecule Protect Mice Against Divergent Influenza Viruses
10509	Yu-Chieh Cheng	Improvement Of Influenza Virus-Like Particle Production From A New Baculovirus Design
10533	Hsiao-Han Tsai	Single-Dose Nanoparticle-Based M2e Peptide Vaccine Induces Cross-Protective Immunity Against Influenza A Viruses
10534	Wan-Ting Liao	A Sting-Activating Polymeric Nanoparticle Enhances Humoral And Cellular Immunity Against Influenza A Virus

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
		Virology and Pathogenesis: NextGen/Universal Vaccines
10655	Saurabh Bhargava	Development & Characterization Of An Aerodynamic System For Pulmonary Delivery Of Influenza Vaccine
10680	Se Mi Kim	Generation Of Avian Influenza A Diva Vaccines With Chimeric Hemagglutinin Recombinant Viruses
10688	Jeong Suk An	Stability And Immunogenicity Of Influenza Virus Hemagglutinin Monomers
10703	Surender Khurana	Antibody Dependent Enhancement Of Influenza Disease Promoted By Increased Virus Fusion Kinetics: Implications For Safety And Efficacy Of Next Generation Influenza Vaccines And Therapeutic Antibodies
10704	Hana Golding	As03 Adjuvant Promotes H5N1 Antibody Diversity And Affinity Maturation: Improved Cross-Clade Neutralization, Higher Neuraminidase Inhibition, But Limited Cross-Subtype Activity
10706	Surender Khurana	Immune-Focused HA1 Influenza Vaccines Provide Long Lasting Cross-Protective Immunity
10732	Suh-Chin Wu	Highly Immunogenic Influenza Virus-Like Particles Containing B-Cell-Activating Factor (BAFF) For Multi-Subtype Vaccine Development
10759	Suh-Chin Wu	Glycan-Masking Hemagglutinin Antigens From Stable Cho Cell Clones For H5N1 Avian Influenza Vaccine Development
10760	Li-Meng Yan	Induction Of Heterologous Protection By Combined Use Of Sequential Influenza Vaccination Strategy In Balb/c Mouse
10761	Yohan Jang	A Step Toward A Universal Influenza Vaccine: Pan-Influenza A Protection By Single Immunization With X-31 Cold-Adapted Live Attenuated Vaccine
10765	Yucheol Cheong	A Green Technology For Vaccines: Catechin As A Novel Inactivating Agent With Built-In Adjuvant For Influenza Vaccine
10772	Chek Meng Poh	Multiplex, Direct Screening Of CD8 T Cell Cytotoxicity Reveals Discrepancy Against Ifng Expression
10777	Jongkwan Lim	Harnessing An RNA-Mediated Chaperone (Chaperna) For Self-Assembly Of Ferritin-Based Nanoparticle Influenza Vaccine
10791	Mani Bhargava	Development And Characterization Of Oral Combination Vaccine Against Hepatitis B And Influenza
10879	Jae-Keun Park	A Cocktail Influenza Vaccine Broadly Protects Mice And Ferrets Against Multiple Subtypes Of Influenza A Virus Challenge
10934	Alexandre Le Vert	OVX836, A Novel Universal Influenza A Vaccine Candidate, Provides CD8-Mediated Protective Efficacy In Mice
10936	Alexandre Le Vert	OVX836, A Novel Universal Influenza A Vaccine Candidate, Protects Ferrets Against Viral Challenge
10981	John Ngunjiri	Optimized NS1-Truncated Live Vaccines Provide Robust Protection From Highly Pathogenic Avian Influenza Virus Infection
10984	Wonil Chae	Universal Monoclonal Antibody Based Influenza Hemagglutinin Quantitative Enzyme-Linked Immunosorbent Assay.
11007	Nita Patel	Broadly Neutralizing Influenza A (H3N2) Monoclonal Antibodies Against Hemagglutinin Receptor Binding Site And Vestigial Esterase Domain And Induction Of Competitive Antibody Responses In A Phase 2 Trial In Older Adults
11019	John Ngunjiri	Systematic Development Of Next-Generation NS1-Truncated Live Attenuated Influenza Vaccines By Targeting Viral Subpopulations With Enhanced Interferon-Inducing Capacity
11058	Lynda Coughlan	A Single Shot Of An Adenoviral Vectored Influenza Vaccine Provides Protection Against Heterosubtypic Lethal Influenza Virus Challenge In Mice
11126	Bo Ryoung Park	Enhanced Cross Protective Efficacy Of Recombinant Live Influenza H3N2 Virus Expressing Conserved M2 Extracellular Domain In A Chimeric Hemagglutinin Conjugate

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
		Virology and Pathogenesis: NextGen/Universal Vaccines
11129	Keith Kulowiec	Practical Implementation Of Cell Isolated Candidate Vaccine Viruses For Large Scale, Cell-Based Influenza Vaccine Manufacture
11134	Leo Poon	Lung-Resident Memory CD8 T Cells Require The Help Of Non-Resident CD8 T Cells To Provide Effective Anti-Influenza Immunity
11146	Maireid Brigid Bull	Investigation Of T Cell Immune Pressure On The Influenza Genome Within A Universal Vaccination Model
11168	Hannah G Kelly	Augmented Germinal Center Formation Underpins Enhanced Immunogenicity Of Self-Assembling Protein Nanoparticle Vaccines For Influenza
11204	Kristien Van Reeth	Exploring Different Heterologous Prime-Boost Vaccination Regimens With H1N1 Influenza Viruses Of Swine
11255	Jiho Lee	Evaluation Of Chimeric Virus-Like Particle Vaccines Displaying Dual Inter- And Intra- Clade HA Protein Of Highly Pathogenic H5 Subtype Avian Influenza Virus.
11266	Jei-Hyun Jeong	A Heat-Killed Lactic-Acid Bacteriasupplemented In The Inactivated HPAI Vaccine Provides Early Onset Of Protection Against Lethal HPAI Challenge
11271	Sunhak Lee	Evaluation And Screening Of 4 Adjuvant Candidates For Enhancing Immunogenicity Of Microneedle Vaccination Against Influenza Virus In Mice.
11282	Meagan Mcmahon	Correctly Folded, But Not Functional, Influenza Virus Neuraminidase Is Required To Produce Protective Antibodies In Mice
11330	Victor Huber	Evaluation Of The Safety And Efficacy Of A Chimeric Influenza Virus Ha Antigen As The Candidate Vaccine In Swine Model Systems
11339	Mirella Salvatore	Intranasal Administration Of Multi-Antigen Idlv Protect From Homologous And Heterosubtypic Influenza Challenge
11779	Maureen Mcgargill	Autoreactive Potential Of Universal Influenza Vaccines
11817	Kavishna Ranmali	Targeting The “Universal” Influenza A Vaccine Candidate M2e To Clec9A-Expressing Dendritic Cells
		Virology and Pathogenesis: Non-Human Influenza Viruses
10320	Nailya Klivleyeva	Monitoring Of Influenza A Virus Circulating In Swine Population In The Northern And Western Regions Of Kazakhstan In 2018
10344	Vasily Marchenko	Highly Pathogenic Avian Influenza Virus In Russia, 2016-2018.
10417	Marina Gulyaeva	Pathogenicity Of HPAI H5N8 Virus, First Isolated In The Russian Federation, For Chicken.
10480	Denys Muzyka	Ukraine Is The Unique Region For Surveillance And Research Of Ecology Of Emergence H5, H7, H9 Subtypes Of Avian Influenza In Eurasia
10525	Xinyu Toh	Isolation And Characterisation Of Equine Influenza Virus (H3N8) From An Equine Influenza Outbreak In Malaysia In 2015
10526	Taoqi Huangfu	Isolation And Characterisation Of Avian Influenza Virus (H9N5) From A Migratory Common Redshank In Singapore In 2015
10527	Yifan Wang	Molecular Characterisation Of Canine Influenza Virus (H3N2) From A Canine Influenza Outbreak In Singapore In 2018
10779	Yelizaveta Khan	Prevalence Of Influenza A/H3 Virus In Wild Bird Populations In Different Regions Of Kazakhstan In 2004-2017
10899	Ryota Tsunekuni	Improving Avian Paramyxovirus Vector Vaccine Against HPAI
11143	Marcus Tong	Chicken And Duck Endothelial Cells Display A Markedly Different Innate Immune Response To Viral Challenge
11224	Deok Hwan Kim	Evaluation Of Lactobacillus Addition In HPAI Vaccine As An Adjuvant In Ducks.

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
		Virology and Pathogenesis: Non-Human Influenza Viruses
11272	Gyeongbeom Heo	Isolation And Characterization Of Low-Pathogenic H7N5 Avian Influenza Virus From Wild Duck In South Korea
11324	Susan Detmer	Human Seasonal pdmh1N1 Infection In Pigs
		Virology and Pathogenesis: Viral Replication
10264	Deborah Fuller	Computationally Designed Mini-Proteins Broadly Bind And Neutralize Diverse Influenza A Strains And Afford Potent And Durable Protection In Mice And Ferrets
10351	Ian Wilson	Structure-Assisted Design Of Antivirals Against Influenza Virus Hemagglutinin
10497	Xavier Saelens	Bispecific Fcg Receptor Engaging Single Domain Antibodies Protect Against Influenza A
10639	João Trigueiro-Louro	Unlocking The Antiviral Target Potential Of Influenza A Virus NS1 Protein
10640	João Trigueiro-Louro	PB1-HA Functional Compatibility Contributes To Genome Segregation Patterns And To The Overall Viral Fitness In A(H1N1)PDM09 Vaccine Seeds
10710	Tomoko Kuwahara	Biological Significance Of Neuraminidase Of Egg-Adapted Influenza A(H3N2) Virus Without Amino Acid Substitutions In The Antigenic Sites Of Its Hemagglutinin
10758	Denise Iok Teng Kuok	Treatment Of Highly Pathogenic Avian Influenza A/H5N1 Virus Infection With Mesenchymal Stromal Cell-Derived Exosomes
10774	Kevin Ciminski	Genome Packaging Of Influenza A Viruses Is Regulated By An Interplay Of VRNA Packaging Sequences And NP Acetylation.
10780	Yixin Chen	Enhanced Reactivity Of A Neutralizing Antibody Against Influenza B Virus Redesigned Using Rational Sequence- And Structure-Based Approach
10792	Milan Kožíšek	DNA-Linked Inhibitor Antibody Assay (DIANA) As A New Method For Screening Influenza Neuraminidase And Polymerase Inhibitors
10804	Tao Deng	Identification Of A Type-Specific Promoter Element That Differentiates Between Influenza A And B Viruses
10896	Yutaro Yamagata	Generation Of A Purely Clonal DI Virus
10903	Edin Mifsud	Combination Therapy With Nitazoxanide And Oseltamivir Reduces The Impact Of Influenza Virus Infection In Vitro And In Vivo.
10973	Voon Ong	Preclinical Efficacy, Pharmacokinetics, And Safety Of CB-012, A Novel Antiviral Fc-Conjugate Against Influenza
10974	Jeffrey Locke	Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity In Cytopathic Effect (CPE) And Viral Growth Inhibition Assays Against Influenza A And B Strains
10979	James Levin	Efficacy Of CB-012, A Novel Antiviral Fc-Conjugate, In Lethal Mouse Models Of Oseltamivir-Sensitive And -Resistant Influenza A H1N1 And H3N2 Isolates.
11055	Sushant Bhat	A Restriction Digestion And Ligation Independent Technique For Cloning Influenza Gene Segments Into PHW2000
11094	Simon Döhrmann	Fc-Mediated Effector Function Contributes To Potency Of Novel Antiviral Fc-Conjugate CB-012
11154	Keiichi Taniguchi	Inhibitory Effect Of Baloxavir Acid On Replication Of Avian And Swine Influenza A Viruses Harboring Distinct Variants Of PA Gene In Vitro
11164	Lorena Brown	A Novel Concept For The Design Of Antiviral Drugs For Influenza
11202	Charley Mackenzie-Kludas	Resistance Studies On A Novel Influenza Antiviral With A Dual Mode Of Action
11223	Takashi Hashimoto	Competitive Fitness Of The Influenza Viruses With PA/I38T Substitution In Primary Human Airway Epithelium Cells
11301	Chengjun Li	Low Polymerase Activity Attributed To PA Drives The Acquisition Of The PB2 E627K Mutation Of H7N9 Avian Influenza Virus In Mammals

POSTER DISPLAY

Date: 30 August 2019, Friday / Time: 6.00pm - 7.30pm

Abstract ID	Name	Abstract Title
Virology and Pathogenesis: Viral Replication		
11338	Hazem Hamza	The Broad Antiviral Potential Of Mek Inhibitor PD0184264 In Preclinical Studies Against Influenza Viruses Compare To Standard Of Care
11774	Christof Hepp	Fish And Single-Molecule Localization Microscopy As A Tool To Study Influenza Virus Transcription And Replication
Virology and Pathogenesis: Virus Pathogenesis & Transmission		
10424	Charles Russell	A Stabilized HA Protein Increases A/H1N1(2009) Pathogenesis In Mice By Dampening Type I Interferon Responses In Dendritic Cells
10483	Eric Bortz	Nanopore Sequencing Of Novel Avian Influenza Viruses In Wild Birds And Poultry In Ukraine: Localized Reassortment With HPAIV Strains From Migratory Birds
10663	Eun-Ji Choi	Multiple Amino Acid Substitutions Of Hemmagglutinin Are Determinants That Enhanced Virulence In H3N2 Mouse-Adapted Virus
10842	Kosuke Soda	Clade 2.3.4.4 H5 Highly Pathogenic Avian Influenza Viruses Showed Various Pathogenicity In Domestic Ducks
10857	Rebecca Frise	Baloxavir Reduces Respiratory Droplet Transmission Of Influenza A Virus In Ferrets
10905	Leo Lee	Baloxavir Reduces Transmission Of Influenza Virus By Direct Contact In Ferrets
10915	Kiyoko Iwatsuki-Horimoto	The Marmoset As An Animal Model Of Influenza
10942	Caroline Walters	Model For Comparising The Transmissibility Of Influenza Using Data From Ferret Experiments
11034	Jie Zhou	The Mechanisms Of Hemagglutinin Adaptation In The Emergence Of The 1968 H3N2 Pandemic Virus
11063	Soo Jeong Kye	Pathogenicity Of Clade 2.3.4.4B H5N6 Highly Pathogenic Avian Influenza In South Korea
11079	Debby Van Riel	Viral Factors Important For The Neurotropism Of Influenza A Viruses
11106	Wendy Barclay	Favipiravir-Resistant Virus Shows Potential For Transmission
11133	Xiaojun Wang	Fundamental Contribution And Host Range Determination Of ANP32A And ANP32B In Influenza A Virus Polymerase Activity
11155	Masatoshi Okamatsu	H6 Chicken Influenza Virus Recognizes Sulfated ALPHA2,3 Sialylated Glycans As The Receptors
11156	Kenrie Py Hui	Human Airway Organoids As A Platform For Influenza Pandemic Risk Assessment
11305	Jasmin Kutter	Phenotypic Characterization Of The Airborne Transmissibility Of Avian And Human Influenza A H2N2 Viruses
11733	Ana Vazquez-Pagan	Primary Cell Co-Cultures Will Change Our Understanding Of Influenza Virus Cell Biology

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Disease Burden & Severity		
10446	Gideon Emukule	The Epidemiology And Burden Of Influenza B/Victoria And B/Yamagata Lineages In Kenya, 2012 – 2016
10570	David Muscatello	Influenza-Associated Effect On Implementation Of An Emergency Department Length Of Stay Policy In A State Health System, New South Wales, Australia
10586	Giorgi Chakhunashvili	Overview Of Severe Acute Respiratory Infections In The Country Of Georgia, 2017-19
10657	Duy Nghia Ngu	Burden Of Influenza-Associated Severe Acute Respiratory Infections In Vietnam, 2014-2016
10675	Mike Jackson	Comparative Epidemiology Of Influenza And Respiratory Syncytial Virus Across Five Seasons – Washington State, 2011/12 – 2015/16
10726	Xin Wang	Global Burden Of Respiratory Infections Associated With Seasonal Influenza In Young Children In 2015 And 2018: A Systematic Review And Modelling Study
10771	Burnaa Alexander	Influenza Epidemiology And Burden Of Disease In Mongolia, 2013/2014 To 2017/2018
10810	Clotilde El Guerche-Séblain	Influenza-Related Mortality For Hospitalized Patients With And Without Comorbidities In Brazil And Mexico
10813	Allyn Bandell	Influenza B-Associated Pediatric Mortality In The Us Between 2010 And 2018
10814	Elena Burtseva	Etiology Of Pneumonia In Patients With Severe Acute Respiratory Infection, Moscow Experience, 2013-2019
10837	Vivian Leung	Estimating The Burden Of Disease To Inform Vaccination Policy In Australia
10847	Silke Buda	Estimation Of Influenza And RSV Attributable Medically Attended Acute Respiratory Illness In Germany, 2010/11-2017/18
10921	Siri Helene Hauge	Children Hospitalized With Influenza In Norway, 2008-16.
10956	Liselotte Van Asten	How Much Sari In Intensive Care Units Is Attributable To Common Respiratory Viruses?
10958	Fahmida Chowdhury	Influenza Illnesses Among Patients Hospitalized In Bangladesh Cardiology Units, 2018
11000	Katelijn Vandemaele	Seasonal Influenza Epidemic Severity Assessments Using The WHO PISA Guidance
11004	John Paget	Mapping The Global Burden Of Influenza And RSV: The Bird Project
11029	Pui Li Wong	Influenza In Older Patients Is Associated With Increased Healthcare Utilization
11049	Cissy Kartasasmita	Influenza Disease Burden And Cost Estimates In Indonesia
11102	Eric A. F. Simoes	Community Mortality Due To Influenza In Melghat, India
11125	Daouda Coulibaly	The Use Of Health Services By Populations Facing Acute Respiratory Infection In Cote D'Ivoire From 2016 To 2017
11144	Qian Xiong	RSV-Associated Respiratory Hospitalization In Hong Kong, 1998-2015
11186	Sibongile Walaza	Health And Economic Burden Of Influenza-Associated Illness In South Africa, 2013-2015
11213	Ahmad Izuanuddin Ismail	Influenza Surveillance In Hospitalized Patients With Acute Respiratory Symptoms In 2 Klang Valley Hospitals In Malaysia, 2018-2019
11232	Julia Fitzner	Moving From Influenza Burden Estimates Into Policy: A Tool To Support Decision Makers
11268	Joelinotahiana Rabarison	Economic Burden Of Seasonal Influenza-Associated Severe Acute Respiratory Illness Hospitalizations In Madagascar, 2016.
11270	Joelinotahiana Rabarison	Assessing The Severity Of Seasonal Influenza In Madagascar Through Surveillance And Death Certificates Collection In Antananarivo, Madagascar.
11280	Ellen Fragaszy	Effect Of Socio-Economic Status On Influenza Risk In English Households
11290	Mahesh Moorthy	Dynamics Of Seasonal Influenza At A Tertiary Care Hospital In South India

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Disease Burden & Severity		
11294	Maarten Van Wijhe	The Mortality Impact Of The 1918 Influenza Pandemic In Greenland
11322	Maarten Van Wijhe	Loose Ends In The Epidemiology Of The 1918 Pandemic: Explaining The Extreme Mortality Risk In Young Adults
11329	Angela Gentile	Influenza Infections Factors: Active Epidemiological Surveillance In A Pediatric Hospital 2000-2018
11331	Angela Gentile	2018 Influenza Season In Argentina: Multicenter Study
11353	Darmaa Badarch	The Impact Respiratory Syncytial Virus And Influenza Viruses On Hospitalization In Mongolia From 2017 To 2019
11713	Binay Thapa	The Burden Of Influenza-Associated Respiratory Hospitalizations In Bhutan, 2015- 2016
Public Health: Epidemiology & Transmission		
10244	Li Wei Ang	Epidemiology Of Influenza B Virus In Singapore, 2011-2017
10257	Rukshan Ahamed Mohamed Rafeek	Prevalence Of Influenza And Co-Infection With Other Viral Pathogens In A Selected Sample Of Children With Acute Respiratory Tract Infections In Sri Lanka
10321	Dennis Kabantiyok	Seroprevalence Of Swine Influenza A Virus In Live Pig Market, Kafanchan Southern Kaduna
10343	Svetlana Svyatchenko	Fatal Seasonal Influenza Cases In Russia In 2015-2019
10415	Gulyaim Tagayeva	Results Of Sentinel Epidemiological Surveillance Of Severe Acute Respiratory Infections (SARI) In Ust-Kamenogorsk, Kazakhstan During Seasons 2016/2017 – 2017/2018
10416	Ainash Baizhanova	Influenza In Taraz, Zhambyl Region, Republic Of Kazakhstan During Epidemiological Seasons 2013-2018.
10441	Meiramgul Smagulova	Epidemiological Surveillance Of Acute Respiratory Infections In The Intensive Care Units, Kazakhstan, 2017-2019.
10569	David Muscatello	Redefining Influenza Seasonality And Aligning Each Country's Immunisation Policy To The Influenza Vaccine Manufacturing Cycle
10579	Yoke Lee Low	Epidemiological Studies Of Influenza Infection Among Children In Malaysia
10716	S M Murshid Hasan	Quail Rearing Practices In Households And The Potential For Transmission Of Avian Influenza Viruses From Quails To Humans, Dhaka, Bangladesh
10734	Jingyi Xiao	Occurrence Of Influenza Viral Rna On Surfaces In University Campus
10735	Jingyi Xiao	Contamination Of Influenza Virus On Hands And Objects Of Laboratory-Confirmed Influenza Patients
10737	Khishigmunkh Chimedregzen	Influenza-Like Illness Surveillance In Khovd, Orkhon, Darkhan, And Dornod Provinces In Mongolia From 2016 To 2019
10784	Constantina Boikos	Evaluation Of Influenza Case Definitions In A Primary Care Database For Use In Real World Evidence Research
10789	Constantina Boikos	Strengthening Pediatric Influenza Vaccination Offering And Acceptance: Findings From The Pediatric Influenza Vaccination Optimization Trial (PIVOT)
10808	Clarence Tam	Age–Specific Burden Of Influenza Hospitalization In Infants And Young Children In Singapore, 2005-2015
10809	Vittoria Offeddu	Acceptance And Feasibility Of School-Based Seasonal Influenza Vaccination In Singapore
10816	Adamu Tayachew Mekonnen	Influenza Surveillance And Out Break Investigation In Ethiopia, 2016: Establishing And Maintining Strong Laboratory Surveillance Can Help Timely Detect Unusual Influenza Activity
10829	Nídia Trovão	The Evolutionary Dynamics Of Influenza A Viruses Circulating In Mallards In Duck Hunting Preserves In Maryland, USA
10836	Prabda Praphasiri	Underlying Cardiopulmonary Conditions As A Risk Factor For Influenza And Respiratory Syncytial Virus Infection Among Community-Dwelling Adults Aged ≥65 Years In Thailand: Findings From A Two-Year Prospective Cohort Study

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
		Public Health: Epidemiology & Transmission
10838	Abu Muhammad Zubair Akhtar	Risk Factors For Hospitalization Among Individuals With Influenza In Bangladesh, 2007-2017
10874	Min Whui Fong	Presence Of Influenza Virus On Touch-Surfaces In Primary Schools And Kindergartens
10876	Carlos Grijalva	Influenza Transmission In Households: Preliminary Results From The Influenza Transmission Evaluation Study (FluTES)
10907	Lin Yang	Is Frailty A Risk Factor Of Influenza-Like Illness? A Prospective Community Cohort Study Of Older People In Hong Kong
10909	Sheikh Taslim Ali	Characterising The Role Of Absolute Humidity On Influenza Transmission And Seasonality In A Subtropical City, Hong Kong
10919	Sheikh Taslim Ali	Meteorological Drivers Of Respiratory Syncytial Virus Infections In Singapore
10922	Lefei Han	The Impact Of Indoor Environmental Factors On Influenza-Like Illness In The Community-Dwelling Older Population Of Hong Kong
10954	Olav Hungnes	Nothing Second-Rate About Influenza B
10955	H. Edward Davidson	Assessing Factors Influencing Influenza Vaccine Choice In U.S. Nursing Homes
10994	Ramesh Kumar	Setting Up A Network Of Laboratories To Estimate The Burden Of Real Time Polymerase Chain Reaction (RT-PCR) Confirmed Influenza Among Older Adults In The Community In A Limited Resource Setting
11006	Cornelia Adlhoch	Highly Pathogenic Avian Influenza In Europe, Seasons 2017-18 And 2018-19
11036	Woo Joo Kim	A Varied Genetic Match Rates Of Circulating Influenza B Viruses Compared To The Vaccine Strains During The 2014-2016 Seasons In Republic Of Korea
11067	Md. Zakiul Hassan	Optimal Time To Vaccinate Against Influenza And Treat Severe Respiratory Illness Empiricically With Antivirals In Bangladesh, 2008-2017
11119	Aubree Gordon	Influenza Associated With Subsequent Viral And Bacterial Pneumonia Among Nicaraguan Children: A Nested Matched Case-Control Study
11120	Daouda Coulibaly	Influenza Seasonal And Intensity Thresholds Estimation In Cote D'Ivoire.
11148	Kathryn Anderson	Seasonality Of Influenza Viruses In South And Southeast Asia: Implications For The Timing Of Seasonal Vaccines
11149	Qian Xiong	Hemagglutination-Inhibition Antibody Titers And Protection Against Influenza Virus Infection: A Systematic Review And Meta-Analysis
11194	Djatnika Setiabudi	Epidemiology Of Influenza Virus Infection Among Influenza-Like-Illness Patients In The Out-Patient Setting
11219	Taro Kamigaki	Incidences And Transmission Of Influenza A And B In A Cohort Population, Ulaanbaatar, Mongolia, 2013-2017
11222	Ausraful Islam	Survey For Avian Influenza Among Crows In Bangladesh
11230	Ausraful Islam	Mobile Poultry Vendors In Bangladesh: Practices And Movement Patterns
11234	Eunice Shiu	Detection Of Airborne Influenza Virus In Pediatric Wards
11238	Agustiningsih Agustiningsih	The Evolution Of Influenza A/H3N2 Virus Across Indonesian Archipelago, 2008-2017
11248	Sibongile Walaza	Influenza Was Not Associated With Respiratory Healthcare-Associated Infections In Children Hospitalised In A Paediatric Hospital In South Africa, 2016-2017
11278	Nancy H. L. Leung	Incidence Of Influenza Virus And Respiratory Syncytial Virus Infections In Older Adults In Eastern China: Findings From The China Ageing Respiratory Infections Study (CARES)
11285	Burtseva Elena	Influenza Infection In Hospitalized Patients: Global Influenza Hospital Surveillance Network (GIHSN) Protocol, Moscow Site, 2012-2018

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Epidemiology & Transmission		
11316	Jacqueline Nolting	Understanding The Social Issues Influencing Risk Perception Of Zoonotic Influenza A Virus Transmission At Swine Exhibitions
11340	Jacob Bueno De Mesquita	Estimating The Airborne Infectious Dose From Influenza Transmission Observed In A Human Transmission Trial With A Controlled Environment
11357	P. Jacob Bueno De Mesquita	Comparison Of Symptomatology And Influenza A Viral Shedding In Respiratory Droplets Produced By Experimentally Infected Volunteers And Naturally Infected Community Cases
11717	Maggie Wang	The Role Of Latitudes In Mediating The Association Between Influenza Activity And Meteorological Factors In 45 Japanese Prefectures
11723	Catherine Moore	Does Routine Whole Genome Sequencing Of Influenza Viruses For Surveillance Purposes Improve The Detection Of Chains Of Transmission In The Community? Experience From An Outbreak Of Influenza In A Welsh Prison Population During Late 2018/19 Season Circulation Of H3N2 Virus In Wales.
11740	Julian Wei-Tze Tang	The Use Of Nebulisers Should Be Reconsidered As An Aerosol-Generating Procedure (AGP)
11775	Isha Berry	Live Poultry Exposure In Urban Bangladesh: Evaluating Poultry Purchasing And Contact Patterns To Identify Avenues For Avian Influenza Transmission At The Human-Poultry Interface
11782	Kazi Munisul Islam	Laboratory-Confirmed Influenza Among Family Caregivers In District Hospitals In Bangladesh 2015-2017
Public Health: Human Sero-Epidemiology Studies		
10329	Zifeng Yang	Is IgM Serological Diagnosis Suitable For Detection Of Respiratory Viruses In Children And Adults?
10767	Claudia Trombetta	Influenza D Virus: A Potential Threat For Humans?
11064	Raquel Guiomar	Influenza Trivalent Vaccine Induced Immune Response And Waning Immunity During The 2017/2018 Influenza Season
11708	Maria Smith	Humoral Immunity To Natural Infection In Colombian Indigenous Populations
Public Health: Non-Pharmaceutical Interventions-Public Health Aspects		
10478	Amra Uzicanin	Pre-Emptive School Closures (PSC) As A Pandemic Countermeasure In The United States: When, Where, And For How Long?
10540	Maureen Tham	Effectiveness Of An Independent, Online Educational Program For Australian Healthcare Professionals On Seasonal Influenza Immunisation Strategies In Older Adults In 2018
10541	Harsha Shetty	Effectiveness Of Risk Minimisation Activities For Afluria Quad Through An Online Survey - A Quantitative Research Study
10682	Yonat Shemer Avni	A Multifaceted Intervention To Overcome The Flu Season
10741	Maria Sundaram	Effect Of Provider Recommendations To Combat Low Vaccination, Low Vaccine Trust And Low Perceived Influenza Risk In US Young Adults
10815	Faruque Ahmed	Feasibility Of Social Distancing Practices In Primary And Secondary Schools In The United States To Reduce Influenza Transmission During A Pandemic
10821	Amra Uzicanin	Potential Demand For Facemasks In General Population During A Severe Influenza Pandemic, United States
11074	Nadia Rimi	Pilot Experiments To Estimate Respirable Aerosols Produced During Poultry Slaughtering And Defeathering
Public Health: Non-Pharmaceutical Interventions-Public Health Aspects		
11150	Anita Patel	A National Strategy To Address The Gap In Respiratory Protective Devices During An Influenza Pandemic
11247	Dennis Km Ip	Health Promotion Programme Targeting Early School-Age Children For Influenza Prevention In Hong Kong
11265	Yujin Kim	Applying Surface-Remaining-Disinfectant To Better Biosecurity In Poultry Facility

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Pandemic Preparedness		
10333	Seth Ferrey	Strategic Investment For Global Influenza Preparedness
10453	Nicole Zviedrite	Interpandemic Experience With Reactive School Closures Over Seven Influenza Seasons – United States, 2011–2018
10462	Nga Ha	Influenza Vaccination Introduction Program For Health Care Workers In Vietnam
10700	Angela Branche	A Phase I Study To Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine
10823	Emily Hanlin	Leveraging One Health: Protecting Delaware's Residents And Economy From Influenza
10845	Silke Buda	Assessing Severity In The Unusual 2017/18 Influenza Epidemic In Germany Using PISA Indicators
10908	Win Mar Kyaw	A Multi-Pronged Strategy To Increase Influenza Vaccination Uptake By An Acute Tertiary Care Hospital In Singapore
10914	Tu Tran Anh	Severe Viral Pneumonia Surveillance To Identify Novel Influenza Viruses Including Influenza A/H7N9, Northern Region Of Vietnam, 2013 – 2018
10929	Sheena Sullivan	Prioritizing Influenza Vaccine Allocation During A Pandemic – A Review Of Pandemic Plans
10998	Gina Samaan	Implementation Of The Pandemic Influenza Preparedness (PIP) Framework Partnership Contribution, 2018
11028	Sheena Sullivan	Ethics Framework For Prioritising Scarce Pandemic Influenza Vaccine
11032	Joel Southgate	Accurate Influenza Classification From Short-Read Data Improves Robustness Of Bioinformatics Pipelines For Routine Surveillance And Pandemic Preparedness
11147	Anita Patel	Medfinder: A System To Help Find Antiviral Drugs During A Pandemic
11321	Katelijn Vandemaele	WHO Pandemic Influenza Special Studies: Preparing For The New Pandemic
11343	Chuong Huynh	HHS Biomedical Advanced Research And Development Authority International Influenza Vaccine Manufacturing Capacity Building Program
11358	Chwan-Chuen King	Integrated Influenza Surveillance System, Real-Time Epidemiological And Glycan-Array Data Analyses, Serological Surveillance Among High-Risk Populations Plus Machine-Learning Approaches Can Minimize Pandemic Threat – Taiwan's Experiences
11758	Todd Davis	Detection And Characterization Of Swine-Origin Influenza A(H1N1)PDM09 Viruses In Humans Following Zoonotic Transmisson
11790	Ellen Fragaszy	Review Of The National Pandemic Flu Service Treatment Algorithm On Community Cases: Results From The Flu Watch Study
Public Health: Pharmaco-ecomonics, Cost-Effectiveness Studies		
10388	Chalinthorn Sinthu-wattanawibool	The Cost Per Episode Of Influenza-Like Illness In Infants And Children In Thailand, 2011-2016
10405	Joaquin Mould-Quevedo	The Economic Advantages Of A Cell-Based Quadrivalent Influenza Vaccine In The Adult Population In Europe. The Cost-Effectiveness Evidence In United Kingdom And Spain
10421	Mu Yue	Optimal Design Of Population-Level Financial Incentives Of Influenza Vaccination For Elderly
10500	Robertus Van Aalst	Economic Assessment Of A High Dose Versus An Adjuvanted Influenza Vaccine: An Evaluation Of Hospitalization Costs Based On A Cohort Study
10684	Matthew Biggerstaff	The Economic Burden Of Influenza In The United States Since 2009
10790	Constantina Boikos	Influenza Vaccine Programs With The Cell-Based Quadrivalent Influenza Vaccine Are Highly Effective In Canada
10988	Juan Yang	Evaluating The Potential Health And Economic Impact Of Free Influenza Vaccination In The Elderly In Mainland China

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Surveillance & Forecasting		
10325	Jan Kyncl	Surveillance Of Severe Influenza In The Czech Republic During 2015-16, 2016-17 And 2017-18 Influenza Seasons
10328	Man Zhang	The Application Of CUSUM Model And Serfling Regression Model In Early Detecting Of Onset Of Seasonal Influenza
10379	Alicia Budd	Influenza Surveillance Enhancements: Improving Influenza Surveillance To Answer Questions About Disease Impact
10442	Zhibin Peng	Evaluation Of The Application Of Moving Epidemic Method On Making Influenza Epidemic Thresholds In The 7 Climate Zones In China Mainland
10457	Heui Man Kim	Characterization Of Influenza B Victoria Lineage Viruses In Recent Two Seasons In South Korea
10496	Anne Teirlinck	Current Practices For Respiratory Syncytial Virus Surveillance Across The EU/EEA Member States, 2017
10501	Sonja Olsen	Seasonal Influenza Activity In The World Health Organization European Region, 2010 To 2018
10552	Laura Van Poelvoorde	Use Of Whole Genome Sequencing To Improve The Influenza Surveillance In Belgium During The 2016-2017 Pilot Season
10562	Christy Wilson	BioFire Syndromic Trends: A Worldwide, Online Network Tracking Respiratory Disease In Real-Time
10679	Christine Wadey	First International Workshop On Preparation Of Influenza Candidate Vaccine Viruses By Reassortment
10690	Annabel Soh	Impact Of Seasonal Influenza On Polyclinic Attendances In Singapore, 2012-2017
10714	Changmin Kang	Phylogenetic Diversity Of Swine H1N2 Influenza A Virus In Korea
10721	Lenee Blanton	A Comparison Of Influenza A(H3N2) And A(H1N1)PDM09-Associated Pediatric Deaths In The United States, 2010-2011 To 2017-2018 Season
10744	Ledor Igboh	Influenza Surveillance In 18 African Countries Who Are Members Of The Anise Network, 2011-2017.
10768	Xiangjun Du	Evolution-Informed Ahead-Of-Season Influenza Incidence Forecasting For The US
10776	Andrey Komissarov	Influenza A(H3N2) Antigenic Profile In Russia In 2017-2018 And 2018-2019 Epidemic Seasons
10783	Varsha Potdar	Magnitude Of Respiratory Viruses Among Ari And Sari Cases: Multi-Site Study From India
10802	Angeliki Melidou	Genetic And Antigenic Characteristics Of Circulating Influenza A Viruses, WHO European Region, 2018/19
10885	Han Sol Lee	Significant Detection Of Influenza C Viruses Among Patients With Influenza-Like Illness From October 2018 To February 2019, Republic Of Korea.
10930	Julia Fitzner	Guiding Countries On Threshold Setting For Surveillance Data
10968	Rakeiya Mcknight	Evaluation Of A High-Throughput Nucleic Acid Extraction Platform To Improve Influenza Surveillance Testing Workflow And Efficiency
10970	Lynnette Brammer	Over-Representation Of Influenza A(H1N1)PDM09 And Influenza B Viruses Among Influenza-Associated Pediatric Deaths
11010	Spencer James	Measuring Influenza And RSV Hospitalizations: A Novel Methodology Developed For The Burden Of Influenza And RSV Disease (BIRD) Consortium Using Administrative Clinical Records And The Global Burden Of Disease Study
11011	Emily Temte	Use Of An Influenza-Like Illness School Absenteeism Monitoring System To Identify Seasonal Influenza Outbreaks In The Community: Experience From An Ongoing Study In Wisconsin, United States
11014	Emily Temte	Adequacy Of Study Participant- Vs. Research Staff-Collected Respiratory Specimens For Detection Of Influenza Viruses By RT-PCR
11043	Larysa Radchenko	Influenza Sentinel Surveillance In Ukraine And Characteristics Of Isolates During The Seasons 2017/18 And 2018/19

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Surveillance & Forecasting		
11054	Bruno Lina	Developments Of The Global Influenza Hospital Sureveillance Network To Support Better Monitoring Of Influenza Virus Genetic Evolutions: The GIHSN- SEVVIR Network.
11062	Lenee Blanton	A Comparison Of Influenza-Associated Pediatric Deaths In Children 0-4 Years And 5-17 Years In The United States, 2010-2011 To 2017-2018 Season
11066	Andrey Komissarov	In Silico Antigenic Variants Prediction For Influenza Virus Using Convolutional Neural Network
11080	Md. Habibullah Fahad	Community-Based Early Warning System (CEWS) Using Mobile Phone SMS Service To Report Illnesses And Deaths
11093	Haowei Wang	Forecasting Influenza Incidence As An Ordinal Variable Using Machine Learning Method: Booted Regression Tree
11096	Kseniya Komissarova	Analysis Of Genetic Variability Of Respiratory Syncytial Viruses Group A In Saint-Petersburg In 2016-2018 Years
11124	Kanyarat Jarudilokkul	Establishment Of Influenza Surveillance System And Epidemiology Of Influenzasubtypes In Bangkok Private Hospitals, September 1, 2016 – December 31, 2017.
11180	Heidi Peck	Characterisation Of Influenza Viruses Circulating In Australia During A High Inter-Seasonal Period In 2018-9
11191	Hind Bouguerra	Influenza Epidemic Threshold Using The Moving Epidemic Method In Tunisia, 2009-2018
11203	Eric Ho-Yin Lau	Monitoring H5, H7, H9 Avian Influenza Virus Activity At Live Poultry Markets Via Environmental Samples
11205	Nicki Boddington	Rapid Testing In Secondary Care And Influenza Surveillance In England: Any Impact?
11208	Kai Ming Dennis Ip	Using Smartphone Application-Based Platform To Improve The Surveillance Performance For Influenza-Like-Illness In Hong Kong
11229	Thomas Connor	Implementing A National, Close To Real-Time, Surveillance System Using Whole Genome Sequencing Enables The Identification Of In-Season Regional Genetic Variation Of Influenza
11233	Tomás Vega Rachael Pung	Multiple Wave Algorithm For Influenza Epidemic Timing And Thresholds Settings
11241	Naphtali Odongo Aspen Hammond	FluNet And FluID - A Review
11244	Andrey Komissarov	Genetic Characterization Of Influenza A And B Viruses In Russia In 2018-2019 Epidemic Season
11274	Ana Rita Goncalves Cabecinhas	Hospital-Based Surveillance Of Influenza In Switzerland – A Pilot Study
11314	Thomas J. Stark	CDC Influenza Next-Generation Sequencing Surveillance System And Analytics
11318	Martin Avaro	Circulation Of Influenza B Lineages In Argentina, 1990-2019.
11319	Martin Avaro	Temporal Circulation And Genetic Characterization Of Influenza A Viruses In Argentina 2017-2019
11332	Jennifer Laplante	Whole Genome Influenza Surveillance In The US Enhanced With National Influenza Reference Centers In Cooperation With The CDC
11336	Elena Burtseva	Hospitalizations Due To Influenza In Moscow During 2012-2019.
11347	David Smith	Notification Of Serologically Diagnosed Influenza Cases Enhances The Monitoring Of The Age-Related Incidence And Impact Of Influenza
11356	Paul Simusika	Using The Moving Epidemic Methods(MEM) To Determine The Epidemic Threshold For Influenza, Zambia,2013/2014 To 2017/2018
11706	Kazuya Nakamura	Improved Accuracy Of Antigenic Characterization Of Recent Influenza A/H3N2 Isolates By Modified Focus Reduction Assay
11742	Masaki Imai	Genetic And Antigenic Analyses Of Influenza B Viruses Isolated In Japan During The 2017–2018 And 2018–2019 Influenza Seasons

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Vaccine Effectiveness/Impact		
10132	Shuangsheng Wu	Vaccine Effectiveness Of 2017/18 Trivalent Seasonal Influenza Vaccine In Preventing Laboratory-Confirmed Influenza In Outpatient Settings: A Test-Negative Case-Control Study In Beijing, China
10136	Peng Yang	Influenza Vaccine Effectiveness In Preventing Influenza Illness Among Children During School-Based Outbreaks In The 2016–2017 Season In Beijing, China
10241	Larisa Rudenko	Progress On The Development And The Promotion Of The LAIV For Influenza Prophylaxis In LMIC
10260	Satoko Ohfuji	Effectiveness Of Maternal Influenza Vaccination To Protect Their Infants Against Influenza: Prospective Cohort Study In Japan
10261	Satoko Ohfuji	Safety Of Influenza Vaccination In Pregnant Women In Terms Of Adverse Birth Outcomes: Prospective Cohort Study In Japan
10312	George Okoli	Influence Of Study Characteristics On Seasonal Influenza Vaccine Effectiveness Estimates: A Systematic Review And Meta-Analysis Of Test-Negative Design Studies
10335	Balasubramani G.K.	Influenza Vaccine Effectiveness And Factors Associated With Outcomes In Hospitalized Adult Patients With Chronic Lung Disease
10380	Thoa Thi Minh Nguyen	Acceptability Of Seasonal Influenza Vaccines Among Health Care Workers In Vietnam In 2017
10393	Brendan Flannery	2017-18 Clade-Specific Vaccine Effectiveness Against A(H3N2) Viruses In The United States, US Flu VE Network
10406	Joaquin Mould-Quevedo	Real World Outcomes Of Adjuvanted Trivalent Influenza Vaccine Compared To Fluzone-HD And Egg-Based Quadrivalent And Trivalent Vaccines Among The US Elderly During 2016-2018 Flu Seasons Using Claims Data
10407	Joaquin Mould-Quevedo	Hospitalization Encounters Following Vaccination With Adjuvanted Trivalent Influenza Vaccine Compared To Fluzone-HD And Egg-Based Quadrivalent And Trivalent Vaccines Among The Us Elderly Using Claims Data
10414	Michal Mandelboim	The Israeli Winter Of 2018-19: Unique Influenza Viruses
10419	Tetsuo Kase	Immunogenicity Of Candidate Influenza A(H3N2) Vaccine Virus Strains In Japan
10465	Carmen Arriola Velezmoro	Influenza Vaccine Effectiveness Against Hospitalizations In South America During 2013–2017: Are Two Doses Essential For Young Children? Do Older Adults Receive Protection From Current And Prior Vaccination?
10470	Hannah Segaloff	Influenza Vaccine Effectiveness In The Inpatient Setting; Evaluation Of Potential Bias In The Test Negative Design By Use Of Alternate Control Groups
10512	Lu Lu	An FDA-Approved Anti-Parasitic As An Adjuvant Of Seasonal Influenza Vaccine
10520	Maureen Goss	Assessing Parental Attitudes Toward Influenza Vaccination
10542	Huiying Chua	Vaccine Effectiveness In Partially And Fully Vaccinated Children In Hong Kong
10584	Hanne-Dorthe Emborg	The Victoria CLADE 1A Vaccine Strain Provides Protection In Subsequent Influenza Seasons Despite Lineage Mismatch
10674	Genming Zhao	Influenza Illness And Hospitalizations Averted By Influenza Vaccination In Children Aged 6 Months-59 Months In Suzhou, China, 2011-2016
10676	Jason Lee	Efficacy And Effectiveness Of High-Dose Influenza Vaccine For Older Adults By Circulating Strain And Antigenic Match: A Systematic Review And Meta-Analysis
10746	Joon Young Song	Impact Of Repeated Influenza Vaccination On The Vaccine Effectiveness Among The Elderly In The Country With High Annual Vaccine Uptake Rates During A/H3N2 Epidemic
10786	Sharmi Thor	Avian Influenza A(H7N9) Immunization Provides Broad Cross-Protection Against Heterologous Virus Challenge In Ferrets
10805	Niloufar Kavian	Parallel Assessment Of Enhanced Seasonal Influenza Vaccines In Mice Finds An Ad-Vantage For FluAd For Antibody And Cellular Responses

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Vaccine Effectiveness/Impact		
10832	Emily T. Martin	Influenza Vaccine Effectiveness Against A(H3N2) Hospitalization In The 2016-2017 And 2017-2018 Seasons: Results From The U.S. Haiven Study
10834	Ben Cowling	The Effect Of Influenza Vaccination History On Changes In Hemagglutination Inhibition Titers Following Receipt Of The 2015/16 Influenza Vaccine In Older Adults In Hong Kong
10848	Monika Kuliese	Seasonal Influenza Vaccine Effectiveness In Patients With Underlying Medical Conditions And Aged 65+ Between 2015-2018 In Lithuania
10882	Jeff Kwong	Evaluating The Impact Of Statin Use On Influenza Infection And Influenza Vaccine Effectiveness In Older Adults
10884	Ben Cowling	Psychological Determinants Of Seasonal Influenza Vaccination Uptake Among Healthcare Workers
10895	Rob Moss	Best Use Of A Limited Vaccine Supply In A Pandemic: What Does "Best" Actually Mean?
10906	Huiying Chua	Influenza Vaccine Effectiveness: Addressing Misclassification Bias In The Test-Negative Study Design
10925	Siri Helene Hauge	Strong Increase In Influenza Vaccine Coverage In Norway, 2014-2018
10969	Xing Li	Assessment Of H7N9 Vaccine Immunity Against Highly Pathogenic A(H7N9) Infection In Ferret Model
10971	Danuta M Skowronski	Vaccine Effectiveness Against The 2018-19 Bimodal Epidemic Of Influenza A (H1N1)PDM09 And A(H3N2) In Canada
10985	Wey Wen Lim	Identifying And Establishing Immune Correlates Of Protection For Next Generation Influenza Vaccines – A Review Of Epidemiological Methods
11040	Barnaby Young	A Retrospective Test-Negative Design Case Control Study Of Severe Influenza Among Vaccine Recipients In Singapore
11050	Gaston De Serres	Relative Vaccine Efficacy: Translation Into Absolute Vaccine Efficacy To Inform Incremental Population Benefit And Public Health Recommendations
11056	Rebecca Jane Cox	Neuraminidase Antibody Responses After Pandemic And Seasonal Vaccination: A Five-Year Study
11072	Joan Puig-Barbera	Influenza Vaccine Effectiveness In ≥60 Years Old Hospitalized Patients From The Valencia Region Of Spain In The 2018/2019 Season. Preliminary Results.
11111	Ruthiran Kugathasan	The Consequences Of Egg Adaptation In The H3N2 Component To The Immunogenicity Of Live Attenuated Influenza Vaccine
11118	Arseniy Khvorov	Evaluation Of The Use Of Administrative Data In Test-Negative Vaccine Effectiveness Studies
11145	Chareeya Thanee	Knowledge, Attitudes, And Practices Toward Influenza Vaccination Among Guardians Of Young Thai Children
11160	Huiying Chua	Influence Of Repeated Vaccination On Influenza Vaccine Effectiveness Estimation
11176	Woo Joo Kim	Estimates Of Seasonal Influenza Vaccine Effectiveness In Preventing Laboratory-Confirmed Influenza In The Hospital-Based Influenza Morbidity And Mortality Surveillance, South Korea: 2018-2019 Season
11210	Brenda Westerhuis	Comparison Of Results Obtained With HAI, Protein Micro Array, And ADCC From Influenza Vaccine Studies.
11218	Kylie Ainslie	Model-Based Comparison Of Annual And Biannual Childhood Vaccination Strategies
11221	Dennis Kai Ming Ip	Comparison Of Side Effect Profiles Of Inactivated And Live Attenuated Seasonal Influenza Vaccines In Primary School Children Of Hong Kong
11226	Nicki Boddington	Influenza Vaccine Effectiveness Against Hospitalisation Due To Influenza In Children In England: A Comparison Of Methods
11249	Iceu Dimas Kulsum	Acceptability And Determinant Of Influenza Vaccination Among Health Care Workers

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Vaccine Effectiveness/Impact		
11258	Sonja Olsen	Improved Sharing Of Influenza-Positive Samples In The Who European Region To Better Inform Vaccine Strain Selection
11311	Oliver Dibben	Defining A Mechanism For H1N1 Live Attenuated Influenza Vaccine Effectiveness
11325	Melissa Andrew	Influenza Burden Of Disease And 2017/18 End-Of-Season Influenza Vaccine Effectiveness Estimates For Preventing Influenza-Associated Hospitalization Among Canadian Adults: An Update From The Cirn Serious Outcomes Surveillance (SOS) Network
11725	Hui Chen	Passage Adaptation Correlates With The Reduced Efficacy Of The Influenza Vaccine
11767	Ming-Chu Cheng	rVP3-Adjuvanted Virus-Like Particles Vaccine Efficacy Against Taiwan HPAI H5N2 In Chicken
11787	Michael I. Hauser	AS03 And MF59 Adjuvants In Pandemic Influenza A (H1N1) PDM09 Vaccines: A Systematic Review And Indirect Comparison Meta-Analysis
11791	Benjamin Cowling	The Causal Interpretation Of "Overall" Vaccine Effectiveness In Test-Negative Studies
Public Health: Disease Burden & Severity / 5.45pm - 6.45pm /		
10578	Jessica Y. Wong	Estimation Of The Influenza-Associated Excess Mortality In Real-Time In Hong Kong, 2012-2018
10828	Cecile Viboud	Crowdsourced Genealogy Data Reveals The Mortality Footprints Of The 1918-1919 Influenza Pandemic
Public Health: Epidemiology & Transmission / 5.45pm - 6.45pm /		
10999	Mahbubur Rahman	Cross Sectional Survey For Assessment Of Aerosolization Of Influenza A Viruses And Potential Transmission Risk For Live Bird Market Workers At The Animal-Human Interface In Bangladesh
11061	David Haw	Multi-Annual Models Of Seasonal Flu At High Spatial Resolution
11075	Edward Kong Seng Lam	Small And Variable Influenza Epidemics In Australian Cities Suggest That Host Contact Structure May Limit The Effects Of Climate And Antigenic Evolution On Local Influenza Epidemiology
Public Health: Human Sero-Epidemiology Studies / 5.45pm - 6.45pm /		
10801	Yiu Chung Lau	Variation By Lineage In Antibody Responses To Influenza B Virus Infections
10902	Francesca Mordant	Antibody Titres Elicited By The 2018 Seasonal Inactivated Influenza Vaccine Persist For At Least 6 Months.
Public Health: Non-Pharmaceutical Interventions – Public Health Aspects / 5.45pm - 6.45pm /		
11284	Nancy Hiu Lan Leung	Shedding Of Respiratory Viruses In Human Exhaled Breath And Efficacy Of Face Masks In Reducing Viral Dissemination
Public Health: Pandemic Preparedness / 5.45pm - 6.45pm /		
10672	Bin Zhou	From The Field To A Vaccine Candidate: A Proof Of Concept Study For Advancing Influenza Pandemic Preparedness
10757	Michael Cw Chan	Risk Assessment On Lung Injury And Transmission Potential Of Influenza Viruses Using In Vitro And Ex Vivo Models Of Human Respiratory Tract
Public Health: Surveillance & Forecasting / 5.45pm - 6.45pm /		
10374	Robert Moss	Improving Epidemic Forecasts With Behavioural Insights Gained From Community-Level Surveillance
11337	Catalina Pardo-Roa	Long-Term Influenza Virus Surveillance In The Antarctic Peninsula Reveals The Dynamic Circulation Of Endemic And Introduced Strains

POSTER DISPLAY

Date: 31 August 2019, Saturday / Time: 5.30pm - 7.00pm

Abstract ID	Name	Abstract Title
Public Health: Vaccine Effectiveness/Impact / 5.45pm - 6.45pm /		
10411	Wakaba Fukushima	Influenza Vaccine Effectiveness In Young Japanese Children Over Five Seasons
10445	Wey Wen Lim	The Identification And Establishment Of New Correlates Of Protection In Randomized-Controlled Trials
10685	Sigrid Gouma	Comparison Of Human H3N2 Antibody Responses Elicited By Egg-Based, Cell-Based, And Recombinant Protein-Based Influenza Vaccines During The 2017-2018 Season
10701	S Rajaram	Retrospective Evaluation Of Antigenic Similarity Between Egg-Derived Versus Cell-Derived Influenza Vaccine Reference Strains And Circulating Influenza B-Victoria And Yamagata Viruses
Clinical Sciences: Clinical Trials-Study Designs, Clinical Endpoints / 6.45pm - 7.30pm /		
10354	Michael Ison	Efficacy And Safety Of Anti-Influenza A Monoclonal Antibody, CT-P27, In Subjects With Acute Uncomplicated Influenza A Infection: Updated Phase Iib Study Results
10536	Nelson Lee	Development Of An Ordinal Scale Treatment Endpoint In Adults Hospitalized With Influenza
Clinical Sciences: Clinical Trials-Treatment and Prevention / 6.45pm - 7.30pm /		
10770	Megumi Hara	Immunogenicity Of Quadrivalent Influenza Vaccine For Patients With Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
Clinical Sciences: Clinical Trials-Vaccines / 6.45pm - 7.30pm /		
10743	Timo Vesikari	MF59-Adjuvanted Quadrivalent Influenza Vaccine Provides Consistent Benefit Upon Revaccination In Young Children
11123	Ju Hwan Jeong	Preclinical Evaluation Of H5N8 Vaccine Candidate (IDCDC-RG43A) In Mouse And Ferret Models.
11263	Rebecca Jane Cox	Immune Response After Pandemic And Seasonal Influenza Vaccination In Healthcare Workers
Clinical Sciences: Diagnostics and Disease Markers / 6.45pm - 7.30pm /		
10564	Nathan Brendish	The Impact On Healthcare Resource Utilization And Cost Of Routine Molecular Point-Of-Care Testing For Respiratory Viruses In Adults Hospitalised With Acute Respiratory Illness: Further Analysis From A Pragmatic Randomised Controlled Trial (RESPOC)
Clinical Sciences: Therapeutics-Antivirals / 6.45pm - 7.30pm /		
10718	Angeliki Melidou	Low Frequency Of Reduced Neuraminidase Inhibitor Susceptibility In Twelve EU/EEA Countries, 2008-2018
11026	Reiko Saito	Clinical Effectiveness Of Baloxavir Marboxil Compared To Oseltamivir - Appearance Of Mutated Viruses At Position 38 In PA Protein For Influenza A/H1N1pdm09 And A/H3N2
11292	Johan Vingerhoets	In Vitro Combination Experiments With Pimodivir And Other Influenza Antiviral Drugs.
Co-Infection: Bacterial Co-infections with Influenza / 6.45pm - 7.30pm /		
10850	Young Ho Byun	Knock Out Of PB1-F2 For Enhanced Safety Of Cold-Adapted Live Attenuated Influenza Vaccine
11307	Michael Schotsaert	TIV Vaccination Modulates Host Responses To Influenza Infection That Correlate With Protection Against Bacterial Superinfection
11317	Miriam Klausberger	Off-Target Effects Of Immunity Conferred By Insect Cell-Expressed Influenza HA-VLPS On Secondary Bacterial Infections
Co-Infection: Viral Coinfections with Influenza / 6.45pm - 7.30pm /		
10530	Ekaterina Stepanova	Development Of A Bivalent Live Viral Vectored Vaccine Against Influenza And Human Metapneumovirus Infections
10846	Anastasiia Evsina	Development Of A Bivalent Vaccine Against Influenza And Human Adenovirus Infections.
11013	Jonathan Temte	Coinfections With Influenza And Other Respiratory Viruses: Oregon Child Absenteeism Due To Respiratory Disease Study (Orchards), Wisconsin, USA, 2015-2019

SPONSOR AND EXHIBITOR LISTINGS

F.HOFFMANN LA-ROCHE

Booth: C5
Website: www.roche.com

PLATINUM SUPPORTER

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. All trademarks used or mentioned in this release are protected by law.

SANOFI PASTEUR

Booth: B5
Website: www.sanofipasteur.com/en/

PLATINUM SUPPORTER

For over a century, Sanofi Pasteur has been committed to protect life through vaccination. We believe in a world where no one suffers or dies from a vaccine-preventable disease. Our vaccines help protect as many as half a billion lives every year against life-threatening infectious diseases at every stage of life. With our 15,000 employees worldwide, we seek to extend the protective power of vaccination to new infectious diseases while continuously improving existing vaccines to enhance health and well-being.

Sanofi Pasteur is the world's largest manufacturer of influenza vaccines. In 2018, we completed a production of around 200 million doses of seasonal influenza vaccine, for both Southern and Northern hemispheres, i.e. approximately 40% of influenza vaccines distributed worldwide. Sanofi Pasteur produces vaccines against seasonal influenza on five sites: Swiftwater (Pennsylvania, USA), Pearl River (Connecticut, USA), Val de Reuil (France), Ocoyoacac (Mexico) and Shenzhen (China).

SEQIRUS

Booth: A5
Website: www.seqirus.com www.csl.com

PLATINUM SUPPORTER

Seqirus has public health protection at its core, which reflects the promise of our parent company CSL Limited (ASX-:CSL), founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic in 1918 and we have been committed to the fight against influenza ever since. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, manufactures influenza vaccines using both egg-based and cell-based technologies and has a globally integrated supply chain. It has a rich R&D pipeline, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.

GSK

Website: www.gsk.com

GOLD SUPPORTER

GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

GSK is the world's leading vaccine company, with a portfolio that helps protect people throughout life and an innovative pipeline of 16 vaccines in development. Our vaccines help prevent illnesses such as hepatitis A and B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, pneumococcal disease, influenza, shingles and meningitis. At GSK, more than 17,000 people worldwide deliver around two million vaccines per day to people in 158 countries.

SPONSOR AND EXHIBITOR LISTINGS

JANSSEN PHARMACEUTICALS

Website: www.janssen.com

BRONZE SUPPORTER

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
We are Janssen. We collaborate with the world for the health of everyone in it.

From viral hepatitis and human immunodeficiency virus (HIV) to respiratory syncytial virus (RSV) and influenza, the teams of people working in Infectious Diseases & Vaccines at Janssen have one mission. They work every day with the goal to discover and develop novel therapeutics and vaccines to prevent, treat and cure infectious diseases worldwide.

SABIN VACCINE INSTITUTE: The Influenzer Initiative

Booth: B1
Website: www.sabin.org

BRONZE SUPPORTER

The Influenzer Initiative is building a movement to accelerate development of a universal influenza vaccine. The Initiative is a program of the Sabin Vaccine Institute, a non-profit seeking a future free from vaccine-preventable diseases. We believe in the power of vaccines to change the world.

VIROCLINICS BIOSCIENCES

Booth: B4
Website: www.viroclinics.com

BRONZE SUPPORTER

Viroclinics operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services.

OTHER EXHIBITORS

APACI

Booth: B3
Website: www.apaci.asia

APACI - Asia Pacific Alliance for the Control of Influenza: Reducing the burden of influenza in the Asia Pacific Region - by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities.

CEIRS

Booth: A1
Website: www.niaidceirs.org

The Centers of Excellence for Influenza Research and Surveillance (CEIRS) is an integrated network of centers funded by the National Institute of Allergy and Infectious diseases (NIAID). The CEIRS program was designed to foster innovative and collaborative research on the influenza virus.

ESWI

Booth: C1
Website: eswi.org

The European Scientific Working group on Influenza (ESWI) is a network of independent influenza experts and organizations of public health officials, healthcare professionals, at-risk patients and the elderly. Together, we aim to reduce the burden of influenza in Europe.

GISAID Initiative

Booth: A4
Website: gisaid.org

GISAID is known for successfully enabling the rapid sharing of influenza virus data through a unique sharing mechanism, recognized for its importance to global health security. GISAID's publicly-accessible EpiFlu™ database, hosted by Germany, provides the most complete collection of genetic sequences of influenza viruses and related clinical and epidemiological data.

hVIVO Services Limited

Booth: B2
Website: hvivo.com

Industry-leading clinical development services business supporting product development for antivirals, vaccines and respiratory therapeutics. A pioneer of human disease challenge models in FLU, RSV and HRV having inoculated over 2500 volunteers. hVIVO has expanded the concept into product development for respiratory/airways disease (asthma, COPD, cough) and in wider patient populations.

OTHER EXHIBITORS

InDevR Inc
Booth: A2
Website: indevr.com

InDevR is a global leader in progressive new analytical technologies that enable accelerated development and manufacturing of vaccines and other biotherapeutics. For more information about the company and products, please visit our website or call +1 303-402-9100.

ISIRV
Booth: A3
Website: www.isirv.org

ISIRV, the International Society for Influenza and other Respiratory Virus diseases, is an international, independent scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. It fulfils its mission through the exchange and dissemination of information, facilitating the interaction of scientists and of public health specialists, and the promotion of international collaborative efforts against these diseases. It achieves this mainly through the organisation of scientific meetings, primarily the OPTIONS series.

Viroclinics biosciences
Viroclinics Xplore
Your Preferred Virology Contract Research Organization

EARLY STAGE AND (PRE)CLINICAL TEST SERVICES FOR VACCINES, ANTIVIRALS AND DIAGNOSTICS DEVELOPMENT
Visit www.viroclinics.com for more information

EXHIBITION FLOORPLAN



Exhibitor Name	Booth Number
APACI	B3
CEIRS	A1
ESWI	C1
GISAID Initiative	A4
F.Hoffmann La-Roche	C5
hVIVO Services Limited	B2
inDevR, Inc	A2
ISIRV	A3
Sabin Vaccine Institute	B1
Sanofi Pasteur	B5
Seqirus	A5
Viroclinics Biosciences	B4

isirv DIARY 2020

SAVE THE DATE 11-13 MAY 2020

5th INTERNATIONAL SYMPOSIUM ON NEGLECTED INFLUENZA VIRUSES – 11-13 MAY 2020 COLUMBUS, OHIO, USA

Join us in the glorious spring for the next meeting in the NIV group series, to be held in Columbus, Ohio's capital city. Named one of the New York Times top 50 places to visit in 2019, Columbus is one of the nation's fastest growing cities and is home to The Ohio State University. We welcome you to come enjoy all central Ohio has to offer!

Following the success of the 4th NIV symposium in Brighton, UK, last year, this meeting will retain the format and will explore the latest data on surveillance and disease investigation, virus transmission and control, clinical and experimental virology, and emerging issues and new developments related to swine, equine, canine and other non-human/non-avian influenza viruses.

12th INTERNATIONAL RESPIRATORY SYNCYTIAL VIRUS SYMPOSIUM – 9-12 SEPTEMBER 2020 BELFAST, NORTHERN IRELAND

RSV2020 is currently in the planning stage and this time will be hosted at the ICC (the Waterfront) in Belfast, Northern Ireland, an award-winning venue in the heart of the city.

Following RSV2018 held in Asheville, NC, USA, which received excellent feedback, RSV2020 promises to deliver an equally impressive programme of similar format. This is the premier conference for RSV and will be of significant benefit to RSV researchers/scientists and clinicians. You will have a warm welcome in Belfast – see you there!

SAVE THE DATE 9-12 SEPTEMBER 2020

FOR UPDATES ON ALL ISIRV EVENTS,
VISIT OUR WEBSITE www.isirv.org
TO JOIN OUR MAILING LIST,
WRITE TO contact@isirv.org

isirv
International Society for Influenza and other Respiratory Virus Diseases

SANOFI PASTEUR

Supporting you to protect your patients against influenza

We are here to support you in protecting your high-risk patients from the serious impact of influenza. That's why, since launching our first influenza vaccine over fifty years ago,[1] we have provided you with products and services that allow you to inform and vaccinate more patients.

Now, with VaxigripTetra®, our innovative quadrivalent influenza vaccine, you can give broader protection to your patients.*

*Compared with trivalent influenza vaccines

1. Ministère d'Etat Chargé des Affaires Sociales. Visa Vaxigrip®, vaccin contre la grippe. Visa: 1968.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

VaxigripTetra® Summary of Product Characteristics and Singapore Abbreviated product information available upon request at the booth.

© 2019. SANOFI PASTEUR S.A. au capital de 317 299 248 € - RCS Lyon B 349 505 370 - SAGLB.VAXIQ.18.11.1457(1) - (06/19).

XOFLUZA®

Roche



TREATING THE FLU CAN BE AS EASY AS

1 2.3

DOSE **DAYS TO RELIEF**

A single dose of XOFLUZA®

- Shortens flu symptoms to just 2.3 days[1]
- Treats influenza at its source by stopping viral replication[1]
- As safe and well tolerated as placebo in clinical trials[1]

Visit the Roche congress booth to find out more about XOFLUZA

Suntec Singapore
Level 4
Exhibition Hall

Booth C5

Xofluza® (baloxavir marboxil) – Abbreviated Prescribing Information

Before prescribing Xofluza, please consult the full local prescribing information.

THERAPEUTIC INDICATIONS: Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 12 and above who have been symptomatic for no more than 48 hours. **POSOLOGY AND METHOD OF ADMINISTRATION**: The recommended dose of Xofluza is an oral dose of 40 mg in patients with body weight of 40 kg to <80 kg; oral dose of 80 mg in patients with body weight of ≥80 kg. **CONTRAINDICATIONS**: Xofluza is contraindicated in patients with a known hypersensitivity to baloxavir marboxil or any of the excipients. **USE IN SPECIAL POPULATIONS**: No effects on fertility were observed in animal studies performed with baloxavir marboxil. Xofluza should be avoided during pregnancy unless the potential benefit justifies the potential risk to the fetus. The safety and efficacy of Xofluza in pediatric patients (<12 years of age) and geriatric patients have not been established. The safety and efficacy of Xofluza in patients with renal impairment or severe hepatic impairment has not been studied. A change in dose is not required for patients with renal impairment, or mild to moderate hepatic impairment. **UNDESIRABLE EFFECTS**: The overall safety profile of Xofluza is based on data from 1318 subjects in 14 clinical trials receiving Xofluza. No adverse reactions have been identified based on pooled data from 2 placebo-controlled clinical studies in adult and adolescent patients, in which a total of 910 patients have received Xofluza.

SAFETY REPORTING FOR POTENTIAL UNDESIRABLE EFFECTS: Please report any adverse events to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550. This will enable Roche to better understand the safety of Xofluza and to provide appropriate information to Health Authorities, Healthcare Providers and patients.

Roche Singapore Pte Ltd, 1 Kim Seng Promenade #15-07/11, Great World City West Tower, Singapore 237994

PR/XOFL/1907/0002

xofluza® (baloxavir marboxil)